学术周报 · IF≥10 或专科旗舰刊
神经内科领域文献阅读汇编
2026年第46周 (2026-11-13) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Neurology | 19 | IF 8.9 |
| Stroke | 6 | IF 11.1 |
| Cell | 5 | IF 45.1 |
| Science advances | 4 | IF 13.9 |
| Circulation | 4 | IF 41.3 |
| Nature communications | 4 | IF 18.1 |
| European heart journal | 3 | IF 45.3 |
| Ophthalmology | 2 | IF 10.9 |
| Neurology and therapy | 2 | IF 4.7 |
| Pharmacological research | 2 | IF 12.2 |
1脑血管病与卒中 (32篇)
临床研究 (27篇)
Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis.
Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0-12.0) and 14.0 days (interquartile range, 10.0-20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33-5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33-4.48]), female sex (HR, 1.78 [95% CI, 1.00-3.16]), and age (HR per year, 1.04 [95% CI, 1.00-1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64-4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76-3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20-3.01]), and age (HR per year, 1.06 [95% CI, 1.03-1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02329327.
中文摘要:与常规治疗相比,Andexanet可减少急性因子Xa抑制剂相关脑出血患者的血肿扩大,但伴随血栓事件风险。本研究汇总接受Andexanet治疗的试验参与者数据以确定血栓事件的基线预测因素。对ANNEXA-I和ANNEXA-4试验中接受Andexanet治疗的成人患者进行二次分析,这些患者患有急性危及生命的出血且正在使用因子Xa抑制剂。采用分层Cox比例风险模型考察基线变量与动脉或所有血栓事件及死亡率的关联。使用以动脉事件为时间依赖协变量的分层Cox回归模型,在调整临床协变量后考察动脉事件与死亡率的关联。741名参与者(平均年龄78.5岁,男性占54.5%)中,593人(80.0%)患有颅内出血,109人(14.7%)患有胃肠道出血。77名(10.4%)参与者发生≥1次血栓事件,147名(19.8%)死亡。动脉和静脉血栓栓塞事件在随机分组后分别中位发生3.5天(四分位距2.0-12.0)和14.0天(四分位距10.0-20.0)。未发现基线因素与所有血栓事件相关。动脉血栓事件与既往心肌梗死(风险比2.64,95%置信区间1.33-5.26)、高剂量资格(风险比2.44,95%置信区间1.33-4.48)、女性性别(风险比1.78,95%置信区间1.00-3.16)和年龄(每年风险比1.04,95%置信区间1.00-1.08)相关。死亡率与动脉血栓事件(风险比2.68,95%置信区间1.64-4.36)、既往充血性心力衰竭(风险比2.53,95%置信区间1.76-3.63)、脑出血或脑室内出血(风险比1.90,95%置信区间1.20-3.01)和年龄(每年风险比1.06,95%置信区间1.03-1.08)相关。随机分组后启动抗凝治疗与血栓事件减少相关。在接受Andexanet治疗的因子Xa抑制剂相关出血中,基线因素与动脉血栓事件相关,可用于指导治疗决策。启动抗凝治疗可减少血栓事件的发生。
CT perfusion (CTP) hemodynamic thresholds may overestimate the ischemic core (ghost core) in early presenters. We hypothesized that a metabolic model, defining the core by decreased cerebral metabolic rate of oxygen and penumbra by increased oxygen extraction fraction, estimated from standard CTP, would better predict tissue fate and early neurological outcome. This retrospective single-center study (October 2015 to October 2025) included consecutive thrombectomy-treated patients with anterior-circulation large-vessel occlusion, admission CTP, and 48±12-hour diffusion-weighted imaging. Predefined relative cerebral metabolic rate of oxygen and oxygen extraction fraction thresholds (metabolic model) were compared with relative cerebral blood flow ≤30% and time-to-maximum (Tmax) ≥6 seconds (hemodynamic model) against diffusion-weighted imaging. Each imaging model (core and penumbra volumes) was added to clinical covariates predicting 48-hour lesion volume (linear regression) and 24-hour and discharge National Institutes of Health Stroke Scale (ANCOVA), tested by nested F-tests; imaging models were compared by paired bootstrap of cross-validated R2. Of 3011 thrombectomy patients, 227 were included (median age, 70 years; 46% male; median onset-to-CTP, 108 minutes; 162 recanalized). Relative cerebral metabolic rate of oxygen ≤30% reduced core overestimation versus relative cerebral blood flow ≤30% (bias, +2.6 versus +20.0 mL; dice, 0.20 versus 0.18; both P<0.001; reproduced in temporal validation), but >10-mL underestimation was more frequent (17% versus 6%). Relative cerebral blood flow error decreased with onset-to-recanalization delay (ρ=-0.30), unlike relative cerebral metabolic rate of oxygen (ρ=0.01). In 65 nonrecanalized patients, relative oxygen extraction fraction ≥125% outperformed time-to-maximum on bias (+14.3 versus +19.3 mL; P<0.001) and dice (P=0.002), but not absolute error (P=0.24). The metabolic model better explained 48-hour lesion volume (cross-validated R2, 0.32 versus 0.22; P=0.002). Only the metabolic model improved 24-hour (P=0.004) and discharge (P=0.009) National Institutes of Health Stroke Scale score prediction over clinical covariates, outperforming the hemodynamic model at discharge (P=0.04) but not at 24 hours (P=0.21). A CTP-derived metabolic model reduced ghost-core misclassification, particularly in early presenters, and better explained 48-hour lesion volume than hemodynamic thresholds, with modest added value for early neurological outcome. Positron emission tomography and external validation are warranted.
中文摘要:CT灌注血流动力学阈值可能在早期就诊者中高估缺血核心(幽灵核心)。我们假设一个代谢模型,通过降低的脑氧代谢率和增加的氧摄取分数来定义核心和半暗带,并从标准CT灌注中估算,将能更好地预测组织结局和早期神经功能结果。这项回顾性单中心研究(2015年10月至2025年10月)纳入了连续接受血栓切除术的前循环大血管闭塞患者,包括入院时的CT灌注检查和发病后48±12小时的扩散加权成像。我们将预定义的相对脑氧代谢率和氧摄取分数阈值(代谢模型)与相对脑血流量≤30%及时间至最大峰值≥6秒(血流动力学模型)进行对比,并以扩散加权成像为参照。每个影像模型(核心和半暗带体积)均加入预测48小时病灶体积(线性回归)及24小时和出院时美国国立卫生研究院卒中量表评分(协方差分析)的临床协变量中,并通过嵌套F检验进行测试;影像模型通过交叉验证R2的配对自助法进行比较。在3011名血栓切除术患者中,纳入227例(中位年龄70岁,男性占46%,发病至CT灌注中位时间108分钟,162例再通)。与相对脑血流量≤30%相比,相对脑氧代谢率≤30%减少了核心高估(偏差分别为+2.6和+20.0 mL;Dice系数分别为0.20和0.18;均P<0.001;在时间验证中复现),但低估超过10mL的情况更常见(17%对6%)。相对脑血流量误差随发病至再通延迟而降低(ρ=-0.30),而相对脑氧代谢率则不然(ρ=0.01)。在65例未再通患者中,相对氧摄取分数≥125%在偏差(+14.3对+19.3 mL;P<0.001)和Dice系数(P=0.002)上优于时间至最大峰值,但在绝对误差上无优势(P=0.24)。代谢模型更好地解释了48小时病灶体积(交叉验证R2为0.32对0.22;P=0.002)。仅代谢模型在预测24小时(P=0.004)和出院时(P=0.009)美国国立卫生研究院卒中量表评分方面优于临床协变量,在出院时优于血流动力学模型(P=0.04),但在24小时时无优势(P=0.21)。CT灌注衍生的代谢模型减少了幽灵核心的误分类,特别是在早期就诊者中,并且比血流动力学阈值更好地解释了48小时病灶体积,对早期神经功能结局具有适度的附加价值。需要正电子发射断层扫描和外部验证。
Poststroke spasticity significantly impairs recovery, yet preventive strategies remain limited. This study evaluated the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in reducing the development and severity of spasticity in patients with early subacute stroke, offering a possible early intervention. In this double-blind, randomized, sham-controlled trial, 70 patients with early subacute stroke (7-30 days) were randomized to receive 3 sessions of low-frequency (1 Hz, 1000 pulses at 90% resting motor threshold) rTMS over contralesional primary motor cortex (n=35) or sham stimulation (n=35), alongside standard care. The primary outcome was upper-limb spasticity assessed using the modified Modified Ashworth Scale. Secondary outcomes included handgrip strength, muscle power assessed by the Medical Research Council scale, pain assessed by the Visual Analogue Scale, modified Rankin Scale, and Stroke Impact Scale 3.0. rTMS therapy significantly lowered spasticity scores at 1 and 3 months across all assessed upper-limb joints (P=0.001), improved handgrip strength (P=0.01), and prevented pain (P=0.001). Stroke Impact Scale scores at 1 month showed greater gains in activities of daily living, mobility, hand function, social participation, and recovery in the rTMS group (P=0.001). Functional independence (modified Rankin Scale) was significantly better in the rTMS group (P=0.006) at 3 months. On binary logistic regression, sham stimulation was associated with greater odds of developing spasticity at 1 month (shoulder odds ratio [OR], 8.29 [95% CI, 1.95-35.27], P=0.04; elbow OR, 7.62 [95% CI, 1.69-34.35], P=0.08; wrist OR, 5.18 [95% CI, 1.60-16.78], P=0.06). At 3 months, sham stimulation remained predictive, with higher odds of spasticity at the shoulder (OR, 15.3 [95% CI, 8.26-28.43]), elbow (OR, 13.43 [95% CI, 3.94-45.78]), wrist (OR, 19.9 [95% CI, 4.9-80.96]), and fingers (OR, 26.25 [95% CI, 5.19-132.87], all P=0.001). Minor adverse events like headache and light-headedness were observed in 5 patients. Low-frequency rTMS over contralesional primary motor cortex significantly prevented spasticity, improved motor recovery, reduced pain, improved functional outcomes and quality of life in early subacute stroke, supporting its role as a promising adjunctive therapy in early stroke rehabilitation. URL: https://ctri.nic.in/; Unique identifier: CTRI/2024/01/061225.
中文摘要:卒中后痉挛严重影响康复,但预防策略仍然有限。本研究评估了重复经颅磁刺激在降低早期亚急性期卒中患者痉挛发生率和严重程度方面的有效性,旨在提供一种可能的早期干预措施。在这项双盲、随机、假刺激对照试验中,70名早期亚急性期卒中(发病7至30天)患者被随机分配接受低频(1 Hz,1000脉冲,强度为静息运动阈值的90%)重复经颅磁刺激作用于对侧初级运动皮层(n=35)或假刺激(n=35),同时接受标准护理。主要结局指标是使用改良版改良Ashworth量表评估的上肢痉挛情况。次要结局指标包括握力、通过医学研究委员会量表评估的肌力、通过视觉模拟量表评估的疼痛、改良Rankin量表评分以及卒中影响量表3.0评分。重复经颅磁刺激治疗在1个月和3个月时显著降低了所有评估上肢关节的痉挛评分(P=0.001),改善了握力(P=0.01),并预防了疼痛(P=0.001)。卒中影响量表评分在1个月时显示,重复经颅磁刺激组在日常活动、移动能力、手部功能、社会参与和康复方面获得更大改善(P=0.001)。在3个月时,重复经颅磁刺激组的独立性(改良Rankin量表)显著更好(P=0.006)。二元逻辑回归显示,假刺激与1个月时发生痉挛的更高几率相关(肩部比值比[OR]为8.29 [95%置信区间, 1.95-35.27], P=0.04;肘部OR为7.62 [95%置信区间, 1.69-34.35], P=0.08;腕部OR为5.18 [95%置信区间, 1.60-16.78], P=0.06)。在3个月时,假刺激仍具有预测性,肩部(OR为15.3 [95%置信区间, 8.26-28.43])、肘部(OR为13.43 [95%置信区间, 3.94-45.78])、腕部(OR为19.9 [95%置信区间, 4.9-80.96])和手指(OR为26.25 [95%置信区间, 5.19-132.87], 均P=0.001)发生痉挛的几率更高。5名患者出现了头痛和头晕等轻微不良事件。作用于对侧初级运动皮层的低频重复经颅磁刺激显著预防了痉挛,改善了运动恢复,减轻了疼痛,提高了功能结局和生活质量,支持其作为早期卒中康复中有前景的辅助疗法的地位。URL: https://ctri.nic.in/; 唯一标识符: CTRI/2024/01/061225。
In the Semaglutide Cardiovascular Outcomes Trial (SOUL), oral semaglutide reduced the risk of a first 3-point major adverse cardiovascular event (3-P MACE; including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular [CV] death). Total event analyses, assessing both first and subsequent events, can contribute to a better understanding of the impact of interventions on the total burden of disease; however, the effects of oral semaglutide on subsequent events are unknown. To evaluate the effect of oral semaglutide vs placebo on total 3-P MACE. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries. Participants had type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease. Data were analyzed from December 2024 to August 2025. Once-daily oral semaglutide (maximal dose 14 mg) or placebo, in addition standard of care. Occurrence of total (first and subsequent) 3-P MACE. Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 6860 [71.1%] male) were randomized 1:1. In the oral semaglutide group, fewer first and subsequent 3-P MACE occurred (683 total; 579 first and 104 subsequent events) compared with placebo (791 total; 668 first and 123 subsequent events) (mean ratio, 0.86; 95% CI, 0.76-0.97; P = .01). For the end point of 3-P MACE plus non-CV death, there were 138 fewer total events with oral semaglutide (910 events) compared with placebo (1048 events) (mean ratio, 0.87; 95% CI, 0.79-0.95; P = .004). As previously reported, adverse events led to treatment discontinuation in 749 (15.5%) and 559 (11.6%) participants receiving oral semaglutide and placebo, respectively. Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population. ClinicalTrials.gov Identifier: NCT03914326.
中文摘要:在Semaglutide心血管结局试验(SOUL)中,口服司美格鲁肽降低了首次3点主要不良心血管事件(3-P MACE;包括非致死性心肌梗死、非致死性卒中和心血管死亡)的风险。评估首次和后续事件的总事件分析有助于更好地理解干预措施对疾病总体负担的影响,然而口服司美格鲁肽对后续事件的影响尚不清楚。本研究旨在评估口服司美格鲁肽与安慰剂对3-P MACE总数的影响。这是一项预先指定的二次分析,基于2019年6月至2024年9月在33个国家的444个中心进行的为期双盲、安慰剂对照、事件驱动的3b期SOUL随机临床试验,中位(四分位距)随访时间为49.5(44.0-54.9)个月。参与者患有2型糖尿病和动脉粥样硬化性心血管疾病和/或慢性肾脏病。数据分析时间为2024年12月至2025年8月。每日一次口服司美格鲁肽(最大剂量14 mg)或安慰剂,加上标准护理。主要结局为总(首次和后续)3-P MACE的发生情况。总体而言,9650名参与者(中位年龄66.0岁;男性6860名占71.1%)按1:1随机分组。在口服司美格鲁肽组中,首次和后续的3-P MACE发生较少(共683例;579例首次事件和104例后续事件),而安慰剂组为791例(668例首次事件和123例后续事件)(均值比0.86;95% CI 0.76-0.97;P=.01)。对于3-P MACE加非心血管死亡的终点,口服司美格鲁肽组比安慰剂组少138例总事件(910例对比1048例)(均值比0.87;95% CI 0.79-0.95;P=.004)。如前所述,不良事件导致接受口服司美格鲁肽和安慰剂的参与者分别有749名(15.5%)和559名(11.6%)停药。与安慰剂相比,口服司美格鲁肽降低了首次加后续3-P MACE的风险,突显了其在降低这一高风险人群临床发病率和死亡率总体负担方面的益处。ClinicalTrials.gov标识符:NCT03914326。
To identify the types of cardiovascular disease (CVD) and stroke prevention educational-behavioural programmes for people from culturally and/or linguistically diverse (CALD) backgrounds and investigate their effect on CVD risk factors and disease knowledge. Four electronic databases were searched from inception to September 2023. Mean difference (MD) and standardized MD was calculated using random effects model, and heterogeneity were assessed using the I2 statistic. Studies that were not included in the meta-analysis were narratively described. The Cochrane Risk of Bias tool and Joana Briggs Institute Critical Appraisal checklist were used to assess the quality of the included studies. Sixteen studies originating from USA and UK (4 RCTs and 12 quasi-experimental pre-post studies) with n = 2331 participants (mean age 57.2 years, 50% women) were included. The programmes were multi-component, 15 of which were culturally adapted and 1 was co-designed. Most were delivered face-to-face in groups. In contrast to the results among the pre-post studies, the pooled analysis showed that educational-behavioural programmes may have little to no effect on SBP (MD 1.18 mmHg, 95% CI -2.42 to 4.79) and HbA1c (MD -0.29%, 95% CI -0.89 to 0.32). The results for LDL cholesterol, BMI, physical activity and dietary intake were also mixed except for CVD or stroke knowledge which demonstrated statistically significant improvements after the intervention. The effect of educational-behavioural programmes on CVD risk factors is inconclusive but may improve CVD or stroke knowledge. Co-designing programmes underpinned by behaviour change theories/techniques with stakeholders and target CALD communities may enhance their potential impact. Future studies should use more rigorous study design i.e. RCTs, valid and reliable outcome measures to reduce inherent bias and strengthen the evidence base for the effectiveness of these programmes.
中文摘要:目的:识别针对文化及语言多元背景人群的心血管疾病和卒中预防教育行为干预措施类型,并调查其对心血管疾病危险因素及疾病知识的影响。方法:检索了截至2023年9月的四个电子数据库。采用随机效应模型计算均值差和标准化均值差,使用I2统计量评估异质性,未纳入荟萃分析的研究进行叙述性描述。使用Cochrane偏倚风险评估工具和Joanna Briggs Institute关键质量评价清单评估纳入研究的质量。结果:共纳入16项来自美国和英国的研究(4项随机对照试验和12项类实验前后对照研究),共2331名参与者(平均年龄57.2岁,女性占50%)。这些干预措施多为多成分组成,其中15项经过文化适应,1项为共同设计。大多数通过面对面小组形式实施。与前后对照研究的结果相比,汇总分析显示教育行为干预措施对收缩压(均值差1.18 mmHg,95%置信区间-2.42至4.79)和糖化血红蛋白(均值差-0.29%,95%置信区间-0.89至0.32)的影响可能很小或没有影响。低密度脂蛋白胆固醇、身体活动量和饮食摄入量的结果也不一致,但心血管疾病或卒中知识在干预后显示出统计学上的显著改善。结论:教育行为干预措施对心血管疾病危险因素的效果尚不明确,但可能提高心血管疾病或卒中的相关知识。基于行为改变理论和技术,与利益相关者及目标文化语言多元社区共同设计干预措施可能会增强其潜在影响。未来研究应采用更严格的研究设计,如随机对照试验和有效可靠的结局指标,以减少固有偏倚并加强这些干预措施有效性的证据基础。
Frailty is associated with worse outcomes after coronary artery bypass grafting (CABG). However, the comparative effectiveness of off-pump CABG (OPCAB) versus on-pump CABG (ONCAB) in prefrail and frail patients remains uncertain. This multicenter, randomized, open-label trial enrolled patients ≥60 years of age classified as prefrail or frail, randomized 1:1, between January 2018 and December 2024. The primary outcome was a 30-day composite of death, myocardial infarction, stroke, renal failure, acute respiratory distress syndrome, or reoperation for bleeding. Secondary outcomes included ventilation time, intensive care unit and hospital stay, transfusion requirements, completeness of revascularization, surgical wound infection at 30 days, and neurocognitive function preoperatively and at 1 year. Analyses followed the intention-to-treat principle; relative risks with 95% CIs were estimated. A total of 508 patients were included (OPCAB, n=258; ONCAB, n=250; median age, 68 years [interquartile range, 65.0-73]; 30.5% female). The primary composite outcome occurred in 28 patients receiving OPCAB (10.9%) and 40 patients receiving ONCAB (16.0%; relative risk, 1.47 [95% CI, 0.94-2.31]; P=0.09). Surgical wound infection was more frequent with ONCAB (20 [8.0%] versus 9 [3.5%]; P=0.04). No significant differences were observed in neurocognitive or quality of life outcomes at 1 year. Estimated 1-year survival probabilities were 96.1% and 92.8% in the OPCAB and ONCAB groups, respectively (P=0.099). In prefrail and frail patients undergoing CABG, OPCAB and ONCAB resulted in similar rates of the primary composite outcome. No significant differences between OPCAB and ONCAB were found in neurocognitive outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02338947.
中文摘要:衰弱与冠状动脉旁路移植术(CABG)后不良预后相关。然而,体外循环下CABG(OPCAB)与体外循环外CABG(ONCAB)在预衰弱及衰弱患者中的比较疗效尚不明确。本研究是一项多中心随机开放标签试验,于2018年1月至2024年12月期间招募年龄≥60岁且被分类为预衰弱或衰弱的患者,按1:1比例随机分组。主要终点为30天内死亡、心肌梗死、卒中、肾衰竭、急性呼吸窘迫综合征或因出血再次手术的复合结局。次要终点包括通气时间、重症监护室及住院时长、输血需求、血运重建的完全性、30天时手术切口感染以及术前和1年时的神经认知功能。分析遵循意向性治疗原则,估算相对风险及95%置信区间。共纳入508名患者(OPCAB组n=258;ONCAB组n=250;中位年龄68岁[四分位距65.0-73];女性占30.5%)。接受OPCAB的28名患者(10.9%)和接受ONCAB的40名患者(16.0%)出现主要复合结局(相对风险1.47[95%CI 0.94-2.31];P=0.09)。ONCAB组的手术切口感染发生率更高(20例[8.0%]对比9例[3.5%];P=0.04)。在1年时,神经认知或生活质量方面未观察到显著差异。OPCAB组和ONCAB组的估计1年生存概率分别为96.1%和92.8%(P=0.099)。在进行CABG的预衰弱及衰弱患者中,OPCAB与ONCAB的主要复合结局发生率相似。OPCAB与ONCAB在神经认知结局方面未发现显著差异。
Tyrosine hydroxylase deficiency is a rare, treatable, autosomal recessive disorder of monoamine neurotransmitter biosynthesis that typically presents in infancy or early childhood. Despite potential benefits of presymptomatic treatment with levodopa/carbidopa, prenatal or neonatal diagnosis remains extremely rare. We report 2 preterm neonates from unrelated families, both with known family history of tyrosine hydroxylase deficiency. After early diagnosis, levodopa/carbidopa therapy was initiated during the neonatal period. This proactive approach proved feasible and well tolerated, leading to early normalization of subtle motor abnormalities. These cases highlight the importance of early genetic diagnosis of this rare condition and the feasibility of levodopa/carbidopa treatment in neonates.
中文摘要:酪氨酸羟化酶缺乏症是一种罕见的可治疗性常染色体隐性单胺神经递质生物合成障碍,通常在婴儿期或儿童早期发病。尽管产前或新生儿期使用左旋多巴/卡比多巴进行预防性治疗具有潜在益处,但此类诊断仍极为罕见。我们报告了2例来自不同家庭的早产新生儿病例,两者均有明确的酪氨酸羟化酶缺乏症家族史。在早期确诊后,患儿在新生儿期即开始接受左旋多巴/卡比多巴治疗。这种主动干预策略被证明可行且耐受性良好,促使细微的运动异常早期恢复正常。这些病例强调了对此罕见疾病进行早期基因诊断的重要性,以及新生儿期使用左旋多巴/卡比多巴治疗的可行性。
The rates and factors associated with complete recanalization after cervical artery dissection (CeAD) have not been comprehensively quantified in large cohorts. We sought to determine the 6-month rate of complete recanalization in CeAD, clinical and imaging factors associated with recanalization, and risk of recurrent ischemic stroke based on recanalization status. This was a planned subanalysis of the Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection study, a multicenter retrospective cohort including patients with imaging-confirmed CeAD diagnosed between January 2015 and June 2022 at 63 sites worldwide. For this analysis, we included 1,095 patients with single-vessel CeAD causing stenosis at presentation who had available follow-up vascular imaging at 6 months after CeAD. The primary outcome was complete recanalization within 6 months after CeAD. Clinical and imaging variables, as well as recurrent stroke, were compared between patients with and those without complete recanalization. Factors independently associated with complete recanalization were identified using multivariable logistic regression. Time to complete recanalization was analyzed using an accelerated failure time Weibull model. Among 1,095 included patients (median age 45 years; 46.7% female), 634 (57.9%) achieved complete recanalization by 6 months. In multivariable analysis, each additional year of age was associated with lower odds of complete recanalization (odds ratio [OR] 0.97 per year; 95% CI 0.96-0.98; p < 0.001). Diabetes (OR 0.46; 95% CI 0.27-0.81; p = 0.006), active smoking (OR 0.69; 95% CI 0.50-0.95; p = 0.025), and complete occlusion at presentation (OR 0.44; 95% CI 0.32-0.59; p < 0.001) were independently associated with lower odds of complete recanalization. Complete occlusion at presentation was associated with both longer time to, and lower rates of, complete recanalization. We observed no effect of antithrombotic regimen (antiplatelet therapy vs anticoagulation) on complete recanalization. Incomplete recanalization was associated with a nonsignificant numerically higher proportion of recurrent stroke (5.4% vs 3.5%; p = 0.064). Almost 60% of patients with CeAD achieved complete vessel recanalization by 6 months. Older age, diabetes, smoking, and complete occlusion at presentation were independently associated with incomplete recanalization. Further study is required to determine whether these findings may help guide tailored imaging surveillance and secondary prevention strategies.
中文摘要:颈动脉夹层(CeAD)后完全再通的发生率及相关因素在大型队列中尚未得到全面量化。本研究旨在确定CeAD后6个月完全再通率、与再通相关的临床及影像学因素,以及基于再通状态的复发性缺血性卒中风险。这是抗血栓治疗预防颈动脉夹层卒中的多中心回顾性队列研究的计划亚组分析,该研究纳入2015年1月至2022年6月期间全球63个中心确诊的影像学证实CeAD患者。本分析纳入1,095例表现为狭窄的单血管CeAD患者,且具备CeAD后6个月的随访血管影像资料。主要结局为CeAD后6个月内完全再通。比较完全再通与未完全再通患者的临床及影像学变量和卒中复发情况。采用多变量逻辑回归确定与完全再通独立相关的因素。使用加速失效时间Weibull模型分析完全再通时间。在1,095例纳入患者中(中位年龄45岁,女性占46.7%),634例(57.9%)在6个月内实现完全再通。多变量分析显示,每增加一岁年龄与完全再通几率降低相关(比值比[OR] 0.97/年;95% CI 0.96-0.98;p < 0.001)。糖尿病(OR 0.46;95% CI 0.27-0.81;p = 0.006)、活动性吸烟(OR 0.69;95% CI 0.50-0.95;p = 0.025)和入院时完全闭塞(OR 0.44;95% CI 0.32-0.59;p < 0.001)与完全再通几率降低独立相关。入院时完全闭塞与更长的完全再通时间及更低的完全再通率均相关。我们未观察到抗血栓方案(抗血小板治疗与抗凝)对完全再通有影响。不完全再通患者复发性卒中比例数值上更高但未达统计学显著性(5.4% vs 3.5%;p = 0.064)。近60%的CeAD患者在6个月内实现血管完全再通。高龄、糖尿病、吸烟和入院时完全闭塞与不完全再通独立相关。需要进一步研究以确定这些发现是否有助于指导个体化的影像监测和二级预防策略。
COL4A1 and COL4A2 encode type IV collagen, a principal structural component of basement membranes, and pathogenic variants in these genes cause a multisystem small vessel vasculopathy with prominent cerebrovascular involvement. Despite increasing recognition with the expansion of genetic testing, COL4A1/2-related cerebral small vessel disease remains underrecognized in clinical practice, in part due to its striking phenotypic heterogeneity. Presentations span a broad clinical spectrum-from asymptomatic individuals or incidental imaging findings to recurrent ischemic events, intracerebral hemorrhage, and catastrophic perinatal brain injury-and may occur across the lifespan. In this narrative review, we provide a clinically oriented framework for recognizing and managing COL4A1/2-related cerebral small vessel disease. We integrate underlying molecular mechanisms of type IV collagen dysfunction with vascular pathophysiology, highlighting how impaired basement membrane integrity leads to a dual hemorrhagic-ischemic phenotype. We describe characteristic neuroimaging patterns, including microhemorrhages, white matter hyperintensities, lacunes, and dilated perivascular spaces, and emphasize their anatomic distribution and clinical relevance. Given the systemic nature of the disorder, we also review key extracerebral manifestations-including ocular, renal, and musculoskeletal features-that serve as important diagnostic "red flags." We outline practical considerations for clinical care, including indications for genetic testing, initial diagnostic evaluation, and longitudinal management strategies tailored to neurologists. Particular emphasis is placed on individualized decision-making around antithrombotic therapy, hemorrhage risk mitigation, and surveillance for complications such as intracranial aneurysms. Illustrative multigenerational cases are incorporated to demonstrate genotype-phenotype correlation, incomplete penetrance, and common diagnostic pitfalls. By providing a mechanism-informed and clinically actionable synthesis, this review aims to improve recognition, reduce misdiagnosis, and guide management of COL4A1/2-related cerebral small vessel disease.
中文摘要:COL4A1和COL4A2编码IV型胶原,后者是基底膜的主要结构成分,这些基因的致病性变异会导致一种以脑血管受累为显著特征的多系统小血管病。尽管随着基因检测的普及其认知度不断提高,但在临床实践中COL4A1/2相关脑小血管病仍常被忽视,部分原因在于其表型异质性显著。临床表现涵盖广泛谱系,从无症状个体或偶然发现的影像学改变,到复发性缺血事件、脑出血及灾难性的围产期脑损伤,且可发生于生命周期的任何阶段。本叙事综述为识别和管理COL4A1/2相关脑小血管病提供了以临床为导向的框架。我们整合了IV型胶原功能障碍的潜在分子机制与血管病理生理学,强调了基底膜完整性受损如何导致出血缺血双重表型。我们描述了特征性的神经影像学模式,包括微出血、白质高信号、腔隙性梗死和扩张的血管周围间隙,并强调其解剖分布及临床意义。鉴于该疾病的系统性特征,我们还回顾了关键的脑外表现,包括眼部、肾脏和肌肉骨骼特征,这些是重要的诊断警示信号。我们概述了临床护理的实际考量,包括基因检测指征、初始诊断评估以及针对神经科医生的纵向管理策略。特别强调了围绕抗血栓治疗、出血风险减轻以及颅内动脉瘤等并发症监测的个体化决策。文中结合了多代病例以展示基因型与表型的相关性、不完全外显率及常见诊断陷阱。通过提供基于机制且具临床可操作性的综合论述,本综述旨在提高对该病的识别率,减少误诊,并指导COL4A1/2相关脑小血管病的管理。
The 11th edition of the International Classification of Diseases (ICD-11) incorporates a tissue-based definition of stroke and may alter estimates of incidence and outcomes. We assessed whether transitioning from a time-based to a tissue-based definition introduces age-dependent changes in stroke incidence and post-stroke survival. The Normandy Stroke Study is a population-based study using multiple overlapping sources to identify stroke cases in Caen-Normandy-Metropole, France. Events occurring between May 15, 2017, and December 31, 2022, were classified using time-based (symptoms ≥24 hours) and tissue-based definitions (symptoms ≥24 hours or <24 hours with neuroimaging evidence of ischemic injury). Among 3,826 first-ever strokes meeting the tissue-based definition, median (IQR) age was 76 (64-85) years, and 1,932 (50.5%) were female. The age-standardized incidence rate of stroke (95% CI) was 161 (156-166) per 100,000 person-years (ESP2013), including 132 (128-137) for ischemic or undetermined stroke, 22 (20-24) for intracerebral hemorrhage, and 7 (6-8) for subarachnoid hemorrhage. Three-year mortality was 36.4% (95% CI 34.9-38.0). Compared with the time-based definition, the tissue-based definition increased stroke incidence by 6.5% and reduced 3-year mortality by 3.9%. The impact of the tissue-based definition on stroke incidence was greater at younger ages (all strokes: younger than 55 years = +8.5%; 55 years or older = +6.0%; ischemic stroke: younger than 55 years = +12.5%; 55 years or older = +7.3%). Adoption of a tissue-based definition modestly increased stroke incidence and post-stroke survival, with greater impacts at younger ages. Implementation of ICD-11 may introduce age-related differences in temporal trends, highlighting the importance of consistent definitions in stroke surveillance.
中文摘要:国际疾病分类第11版(ICD-11)纳入了基于组织的卒中定义,可能会改变发病率和预后估计。本研究评估了从基于时间的定义转向基于组织的定义是否会在卒中的发病率和卒中后生存率中引入年龄依赖性变化。诺曼底卒中研究是一项人群基线研究,利用多种重叠来源在法国卡昂-诺曼底大都市区识别卒中病例。2017年5月15日至2022年12月31日期间发生的事件采用基于时间的定义(症状持续≥24小时)和基于组织的定义(症状持续≥24小时或<24小时但有神经影像学缺血损伤证据)进行分类。在符合组织定义的3,826例首次卒中患者中,中位年龄(四分位距)为76岁(64-85岁),女性1,932例(50.5%)。年龄标准化卒中发病率(95%置信区间)为每10万人年161例(156-166例),其中缺血性或未定类型卒中132例(128-137例),脑出血22例(20-24例),蛛网膜下腔出血7例(6-8例)。三年死亡率为36.4%(95%置信区间34.9%-38.0%)。与基于时间的定义相比,基于组织的定义使卒中发病率增加了6.5%,并将三年死亡率降低了3.9%。基于组织的定义对卒中发病率的影响在较年轻年龄组更为显著(所有卒中:小于55岁增加8.5%;大于等于55岁增加6.0%;缺血性卒中:小于55岁增加12.5%;大于等于55岁增加7.3%)。采用基于组织的定义适度增加了卒中发病率和卒中后生存率,且在较年轻年龄组影响更大。ICD-11的实施可能会在时间趋势中引入年龄相关的差异,强调了在卒中监测中使用一致定义的重要性。
The benefit of therapies targeting hematoma expansion (HE) in acute intracerebral hemorrhage (ICH) is highly time dependent and greatest within the first 2 hours after onset. We aimed to develop imaging-based "target expansion criteria" to identify late presenters (2-12 hours from onset/last seen well) who remain at high risk of HE. To achieve this goal, a practical risk score (target expansion score) was developed. We conducted a multicenter, international, retrospective cohort study. To mirror a clinical trial population, we excluded patients with brainstem ICH, anticoagulation, and baseline ICH volume >100 mL. The primary outcome was HE (>33%/6 mL). The following imaging predictors of HE were analyzed: high ultra-early hematoma growth (uHG) (baseline volume/onset to imaging time >10 mL/h), hypodensities on noncontrast CT (NCCT), and spot sign on CT angiography (CTA). The study population was randomly divided into development and validation cohorts, and a weighted score was derived from estimates from multivariable logistic regression. Overall, 492 patients were included: 345 (70.1%) in the development and 147 (29.9%) in the validation cohort. A 4-point score was created, based on independent predictors of HE (high uHG: 1 point, NCCT hypodensities: 1 point, and CTA spot sign: 2 points). The score showed good discrimination in the development and validation cohorts (area under the curve [AUC] 0.77, 95% CI 0.71-0.83, and AUC 0.79, 95% CI 0.71-0.87, respectively). We observed a nonlinear increase in the frequency of HE and mean absolute hematoma growth with higher scores: 9.8% and 0.9 mL (score 0), 17.1% and 3.9 mL (score 1), 48.3% and 11.5 mL (score 2), 70.8% and 13.0 mL (score 3), and 87.5% and 26.9 mL (score 4). These findings were confirmed in the validation cohort. A dichotomized score greater than or equal to 2 predicted HE with 0.61 sensitivity and 0.85 specificity in the development cohort and 0.64 sensitivity with 0.84 specificity in the validation cohort. Imaging-based target expansion criteria, defined as a target expansion score ≥2, identified late-presenting patients with ICH at high risk of HE. These findings might inform future trials targeting HE and increase the pool of eligible patients.
中文摘要:针对急性脑出血血肿扩张的疗法获益具有高度时间依赖性,且在发病后最初2小时内最大。本研究旨在开发基于影像的血肿扩张目标标准,以识别发病或最后一次被看到正常后2至12小时就诊但仍处于高血肿扩张风险中的晚期就诊患者。为实现这一目标,我们开发了一种实用的风险评分(目标扩张评分)。我们开展了一项多中心、国际性的回顾性队列研究。为了模拟临床试验人群,我们排除了脑干出血、使用抗凝药物以及基线脑出血体积大于100毫升的患者。主要结局指标为血肿扩张(超过33%或6毫升)。我们分析了以下血肿扩张的影像预测因素:高超早期血肿生长(基线体积至成像时间间隔内每小时增长超过10毫升)、非增强CT上的低密度影以及CT血管造影上的斑点征。研究人群被随机分为开发队列和验证队列,加权评分源自多变量逻辑回归估计值。共纳入492名患者:345名(70.1%)在开发队列,147名(29.9%)在验证队列。基于血肿扩张的独立预测因素创建了一个4分评分系统(高超早期血肿生长1分、非增强CT低密度影1分、CT血管造影斑点征2分)。该评分在开发队列和验证队列中均显示出良好的区分度(曲线下面积分别为0.77,95%置信区间0.71-0.83,以及0.79,95%置信区间0.71-0.87)。我们观察到血肿扩张频率和平均绝对血肿体积随评分升高呈非线性增加:评分0分为9.8%和0.9毫升,评分1分为17.1%和3.9毫升,评分2分为48.3%和11.5毫升,评分3分为70.8%和13.0毫升,评分4分为87.5%和26.9毫升。这些发现在验证队列中得到确认。二分法评分大于或等于2在开发队列中以0.61的敏感性和0.85的特异性预测血肿扩张,在验证队列中以0.64的敏感性和0.84的特异性预测血肿扩张。基于影像的目标扩张标准定义为目标扩张评分大于或等于2,能够识别出具有高血肿扩张风险的晚期就诊脑出血患者。这些发现可能为针对血肿扩张的未来试验提供信息,并增加合格患者的数量。
Stroke is a major differential diagnosis in patients with acute vertigo/dizziness or imbalance. Current diagnostic algorithms such as head impulse test, gaze-evoked nystagmus, and test of skew are optimized for presentations with spontaneous nystagmus (SPN), traditionally called acute vestibular syndrome (AVS). However, in recent studies, a relevant proportion of patients with stroke-related vertigo/dizziness had no SPN, but rather postural or gait imbalance, a phenotype lately termed acute imbalance syndrome (AIS). We aimed to outline the pathoanatomical differences of stroke-related AIS vs AVS and its clinical implications. Patients with MRI-proven stroke-related acute vertigo/dizziness or imbalance were included in this emergency department (ED) cohort study at LMU Hospital prospectively. Vestibular, ocular motor, and postural signs were documented (including SPN presence/intensity by video oculography, postural imbalance by posturography). Patients were classified as suffering from AIS or AVS based on the presence of SPN. Stroke lesion distribution was depicted in Montreal Neurological Institute space and supplemented by structural disconnectome mapping from the lesion cores. Multivariate lesion symptom-mapping based on support-vector regression and disconnectome mapping was applied for SPN intensity and sway path as surrogate markers for AVS and AIS. Of 75 patients (age: 65.7 ± 13.3 years, 40% female), 58.7% were diagnosed with AIS, 38.7% with AVS, and 2.7% with central positional vertigo. In AIS, the lesion core was located in the anterior cerebellar lobe and deep cerebellar nuclei (superior cerebellar artery/posterior inferior cerebellar artery territory) connecting to the bilateral pontomesencephalic tegmentum through the superior cerebellar peduncle. AVS stroke lesions were mostly located in the posterior cerebellar/flocculonodular lobe (posterior inferior cerebellar artery/anterior inferior cerebellar artery territory) and connected to the ipsilesional vestibular nucleus (VN) and bilateral medial longitudinal fascicle (MLF) through the inferior cerebellar peduncle. SPN intensity correlated with voxels in the cerebellar lobules VI-IX connecting to VN and MLF. Postural sway was associated with a small local cluster in the cerebellar Crus I. AIS accounts for more than half of patients with stroke-related vertigo/dizziness or imbalance. AIS lesions were located in the anterior cerebellar lobe, disturbing cerebellar-pontomesencephalic networks for posture and gait control. AVS lesions affected the posterior cerebellar/flocculonodular lobe and associated vestibulo-ocular reflex networks. Recognition of both clinical phenotypes is essential to identify all strokes among patients with vertigo/dizziness in the emergency setting. DRKS00008992; U1111-1172-8719.
中文摘要:卒中是急性眩晕或头晕/失衡患者的主要鉴别诊断。当前的诊断算法如头脉冲试验、凝视诱发性眼震和偏斜试验,主要针对具有自发性眼震(SPN)的表现进行优化,传统上称为急性前庭综合征(AVS)。然而,在最近的研究中,有相当比例的卒中相关眩晕/头晕患者没有SPN,而是表现为姿势或步态失衡,这种表型最近被称为急性失衡综合征(AIS)。我们旨在概述卒中相关的AIS与AVS的病理解剖差异及其临床意义。本研究在LMU医院急诊科进行了一项前瞻性队列研究,纳入了经MRI证实的卒中相关急性眩晕/头晕或失衡患者。记录了前庭、眼动和姿势体征(包括通过视频眼动仪记录的SPN存在/强度,通过后测图记录的姿势失衡)。根据是否存在SPN将患者分类为AIS或AVS。在蒙特利尔神经学研究所空间中描绘卒中病灶分布,并通过从病灶核心进行的结构断开连接映射进行补充。应用基于支持向量回归的多变量病灶症状映射和断开连接映射,以SPN强度和摇摆路径作为AVS和AIS的替代标志物。在75名患者(年龄:65.7±13.3岁,40%女性)中,58.7%被诊断为AIS,38.7%为AVS,2.7%为中枢性位置性眩晕。在AIS中,病灶核心位于小脑前叶和小脑深部核团(小脑上动脉/小脑后下动脉区域),通过小脑上脚连接至双侧桥中脑被盖。AVS卒中病灶主要位于小脑后叶/绒球小结叶(小脑后下动脉/小脑前下动脉区域),并通过小脑下脚连接至患侧前庭核(VN)和双侧内侧纵束(MLF)。SPN强度与小脑VI-IX小叶中连接至VN和MLF的体素相关。姿势摇摆与一个小脑Crus I局部簇相关。AIS占卒中相关眩晕/头晕或失衡患者的一半以上。AIS病灶位于小脑前叶,干扰了小脑-桥中脑网络以控制姿势和步态。AVS病灶影响小脑后叶/绒球小结叶及相关的前庭眼反射网络。在急诊环境中识别这两种临床表型对于识别所有眩晕/头晕患者中的卒中至关重要。DRKS00008992;U1111-1172-8719。
Early intensive blood pressure (BP) lowering is now recognized as an effective approach to improve outcome after acute intracerebral hemorrhage (ICH). However, whether the effect varies by hematoma location is uncertain. We aimed to determine the heterogeneity of the treatment effect of intensive BP lowering on functional outcome by hematoma location. We conducted a pooled analysis of individual patient-level data (IPD) from all 4 Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials (INTERACT) and the second Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II) trial, which were international, randomized, open, blinded end point assessed, controlled trials that investigated the effectiveness of early intensive BP control in acute ICH. ICH location was classified as lobar or deep hemisphere or infratentorial. The primary outcome was death or disability (modified Rankin Scale scores 3-6) at 90 days or 6 months (for INTERACT3). The heterogeneity of the treatment effect of intensive BP lowering on the primary outcome by ICH location was estimated using generalized linear mixed models with trial as a random effect and adjustment for prespecified clinical covariates and an interaction term of "treatment-by-location." Among 11,288 patients (mean age 62.5 years [SD 12.7]; 4,056 [35.9%] women), 1,141 (10.1%) had lobar ICH, 9,202 (81.5%) had deep ICH and 945 (8.4%) had infratentorial ICH. Compared with deep or infratentorial ICH, lobar ICH occurred in older patients, was less often associated with intraventricular hemorrhage, and had larger hematoma volumes (all p < 0.001). The effect of intensive BP lowering on the primary outcome of death or disability differed by ICH location (p for interaction = 0.033). A clear benefit was only seen in deep ICH (adjusted odds ratio 0.81, 95% CI 0.74-0.89; p < 0.001). Hematoma location modifies the treatment effect of intensive BP lowering on functional outcome after ICH, with the benefit observed only in deep ICH. These trials are registered at ClinicalTrials.gov (INTERACT1 NCT00226096; INTERACT2 NCT00716079; INTERACT3 NCT03209258; INTERACT4 NCT03790800; and ATACH-II NCT01176565).
中文摘要:早期强化降压被公认为改善急性脑出血(ICH)预后的有效方法。然而,其疗效是否因血肿位置不同而异尚不明确。本研究旨在确定强化降压对功能结局的治疗效果在不同血肿位置中的异质性。我们对来自4项Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials (INTERACT) 和第2项Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II) 试验的个体患者水平数据(IPD)进行了汇总分析。这些是国际性的随机、开放标签、终点盲法评估的对照试验,旨在探讨早期强化血压控制在急性ICH中的有效性。ICH位置被分类为叶性、深部半球性或幕下。主要结局为90天或6个月(INTERACT3)时的死亡或残疾(改良Rankin量表评分3-6分)。使用广义线性混合模型估计强化降压对主要结局的治疗效果异质性,以试验作为随机效应,并调整预设的临床协变量以及「治疗-位置」交互项。在11,288名患者中(平均年龄62.5岁 [标准差12.7];女性4,056名 [35.9%]),1,141名 (10.1%) 为叶性ICH,9,202名 (81.5%) 为深部ICH,945名 (8.4%) 为幕下ICH。与深部或幕下ICH相比,叶性ICH多见于老年患者,较少伴有脑室内出血,且血肿体积更大(均p < 0.001)。强化降压对死亡或残疾这一主要结局的影响因ICH位置而异(交互作用p = 0.033)。仅在深部ICH中观察到明确的益处(调整后的比值比0.81,95%置信区间0.74-0.89;p < 0.001)。血肿位置修饰了强化降压对ICH后功能结局的治疗效果,且益处仅见于深部ICH。这些试验已在ClinicalTrials.gov注册(INTERACT1 NCT00226096;INTERACT2 NCT00716079;INTERACT3 NCT03209258;INTERACT4 NCT03790800;ATACH-II NCT01176565)。
The Michigan Structural Heart Consortium showed that transcatheter aortic valve replacement (TAVR) stroke rates were associated with hospital Comprehensive Stroke Center (CSC) designation, suggesting that hospital structural factors affect stroke reporting. We sought to determine whether CSC designation is nationally associated with reported stroke rates and the potential impact on hospital performance and Transcatheter Valve Therapy National Data Registry (TVTR) public reporting. Consecutive TVTR cases from January 2016 through June 2023 were included, excluding sites reporting to the TVTR <1 year or performing <20 total TAVR procedures. The primary outcome was in-hospital stroke rate. Secondary outcomes were disabling stroke and 30-day stroke. Major bleeding, death, acute renal failure, and a composite end point were falsification end points to determine whether CSC status was uniquely associated with stroke. Multivariable hierarchical models were created starting with patient covariates and sequentially adding hospital variables to account for determinants of stroke. The impact of CSC status on hospital performance was estimated by correcting CSC hospital stroke rates in the validated TVTR 30-day composite model. A total of 525 919 TAVRs at 800 sites were included, and 10 963 strokes (2.1%) were reported within 30 days: 8284 (1.6%) in-hospital and 2679 (0.5%) after discharge. A total of 4733 (0.9%) were disabling strokes. Multivariate analysis showed that CSC status and participation in TAVR trials were independent predictors of in-hospital stroke rate (P=0.033 and 0.012) and disabling stroke (P=0.033 and 0.007), but not falsification end points (P=NS). Participation in TAVR trials and operator volume were independent predictors of 30-day stroke (P=0.039 and P=0.041). The impact of CSC status on the 30-day composite model showed performance improvement for 8 of 153 CSC hospitals. CSC hospital status and participation in TAVR trials are significant predictors unique for stroke. Correcting for the association of CSC status on stroke rate resulted in an estimated 8 of 153 hospitals improving their TVTR 30-day composite model performance. Further work is needed to account for potential ascertainment bias for stroke in public reporting.
中文摘要:密歇根结构心脏联盟显示经导管主动脉瓣置换术卒中率与医院综合卒中中心认定状态相关,提示医院结构性因素影响卒中报告。本研究旨在确定综合卒中中心认定状态在全国范围内是否与报告的卒中率相关及其对医院绩效和经导管瓣膜治疗国家数据注册库公开报告的影响。纳入2016年1月至2023年6月连续病例,排除向注册库报告不足一年或总手术量少于20例的机构。主要结局为院内卒中率。次要结局包括致残性卒中和30天卒中。大出血、死亡、急性肾衰竭和复合终点作为假阳性终点以确定综合卒中中心状态是否特异性关联于卒中。构建多变量分层模型,从患者协变量开始并逐步加入医院变量以解释卒中决定因素。通过校正验证的经导管瓣膜治疗注册库30天复合模型中的综合卒中中心医院卒中率来评估其对医院绩效的影响。共纳入800个机构的525919例手术,报告30天内卒中10963例(2.1%),其中院内8284例(1.6%),出院后2679例(0.5%)。致残性卒中4733例(0.9%)。多变量分析显示综合卒中中心状态和参与经导管主动脉瓣置换术试验是院内卒中率和致残性卒中的独立预测因子,而非假阳性终点。参与试验和操作者经验是30天卒中的独立预测因子。综合卒中中心状态对30天复合模型的影响显示153家机构中有8家绩效改善。综合卒中中心状态和参与试验是卒中的特异性显著预测因子。校正综合卒中中心状态与卒中率的相关性后估计有8家机构在经导管瓣膜治疗注册库30天复合模型中绩效提升。需进一步工作以解决公开报告中潜在的卒中检出偏倚。
The efficacy of prophylactic mechanical circulatory support with micro-axial flow pump or veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with severely reduced left ventricular ejection fraction (LVEF) undergoing high-risk percutaneous coronary intervention (PCI) remains unclear. Patients with complex three-vessel disease, unprotected left main coronary disease or last patent conduit and LVEF ≤ 35% were assigned to receive either a micro-axial flow pump (SynFlow 3.0) or VA-ECMO support during a non-emergent high-risk PCI procedure in this prospective, multicentre, randomized, open-label, non-inferiority trial. The primary endpoint was the incidence of 30-day major adverse events, defined as any of: all-cause death, myocardial infarction, stroke/transient ischaemic attack, repeat revascularization, major bleeding, acute kidney injury, cardiopulmonary resuscitation/cardioversion, cardiac surgery/limb ischaemia, or serious device-related complications. Safety endpoints included adverse events and serious adverse events. The primary endpoint, 30-day major adverse events, occurred in 8 of 109 patients (7.34%) in the SynFlow 3.0 group and 13 of 113 patients (11.5%) in the VA-ECMO group (absolute difference adjusted for centre effect, -4.6%; 95% confidence interval, -12.6% to 3.5%; P for non-inferiority < .001). Patients with SynFlow 3.0 had shorter post-procedural hospital stay (4.1 days vs 5.2 days on average, P = .047) and fewer device-related adverse events (3.7% vs 11.5%; P = .041). Anaemia occurred more often with VA-ECMO than with SynFlow 3.0 (20.4% vs 9.2%; P = .023). The prophylactic use of a micro-axial flow pump during high-risk PCI procedures was non-inferior to VA-ECMO in the incidence of 30-day major adverse events. The use of a micro-axial flow pump was associated with shorter post-procedural hospital stay and fewer device-related adverse events.
中文摘要:在左心室射血分数严重降低的患者接受高危经皮冠状动脉介入治疗时,预防性使用微轴流泵或静脉动脉体外膜肺氧合的有效性尚不明确。本研究是一项前瞻性、多中心、随机、开放标签的非劣效试验,将患有复杂三支血管疾病、 unprotected 左主干冠状动脉疾病或唯一通畅桥血管且左心室射血分数小于等于35%的患者,分配至在非紧急高危经皮冠状动脉介入治疗期间接受微轴流泵(SynFlow 3.0)或静脉动脉体外膜肺氧合支持。主要终点为30天内主要不良事件的发生率,定义为全因死亡、心肌梗死、卒中/短暂性脑缺血发作、重复血运重建、大出血、急性肾损伤、心肺复苏/电复律、心脏手术/肢体缺血或严重的器械相关并发症。安全性终点包括不良事件和严重不良事件。结果显示,SynFlow 3.0组109名患者中有8名(7.34%)发生主要不良事件,VA-ECMO组113名患者中有13名(11.5%)发生主要不良事件(经中心效应调整的绝对差异为负4.6%,95%置信区间为负12.6%至3.5%,非劣效性P值小于0.001)。SynFlow 3.0组患者术后住院时间较短(平均4.1天对比5.2天,P等于0.047),器械相关不良事件较少(3.7%对比11.5%,P等于0.041)。VA-ECMO组的贫血发生率高于SynFlow 3.0组(20.4%对比9.2%,P等于0.023)。在高危经皮冠状动脉介入治疗中预防性使用微轴流泵在30天主要不良事件发生率方面非劣效于VA-ECMO。使用微轴流泵与较短的术后住院时间和较少的器械相关不良事件相关。
There is a lack of long-term outcome data supporting the role of nurses in cardiovascular (CV) risk management. The ALLEPRE [ALLiance for sEcondary PREvention after an acute coronary syndrome (ACS)] trial was a pragmatic, randomized, multicentre, interventional trial comparing the efficacy of a nurse-coordinated prevention program (NCPP) with standard of care (SOC). The NCPP patients attended nine individual educational sessions over four years at which a centrally trained nurse provided counselling aimed at identifying CV risk factors and encouraging healthier lifestyles and medication adherence; the SOC patients followed the standard practices of their hospitals. The trial's primary endpoint was the composite of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke (MACE). A total of 2057 ACS patients were randomized 1:1 to the NCCP (n=1031) or SOC group (n=1026). In comparison with SOC, the NCPP significantly reduced MACE [16.2% vs 22.6%; hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.57-0.85; P-value <0.001], a benefit mainly driven by a reduction in non-fatal MI (9.3% vs 15.2%; HR 0.60; 95% CI 0.46-0.77; P-value=0.0001). The occurrence of the pre-specified secondary outcome of MACE plus ischaemia-driven revascularization was significantly reduced (HR 0.77, 95% CI 0.64-0.92; P-value= 0.005). Exercise frequency (P<0.0001), body weight control (P=0.003), and medication adherence (P<0.001) improved more in the NCPP group. The NCPP significantly reduced long-term MACE, improved physical activity, body weight control, and pharmacotherapy adherence in post-hospitalization ACS patients. Including an NCPP in healthcare provision may contribute to the successful implementation of secondary prevention strategies.
中文摘要:目前缺乏支持护士在心血管风险管理中作用长期结局数据。ALLEPRE试验是一项务实、随机、多中心的干预性试验,比较了护士协调预防项目与标准护理的疗效。接受护士协调预防项目的患者在四年内参加了九次个体化教育课程,由中心培训的护士提供咨询,旨在识别心血管危险因素并鼓励更健康的生活方式及药物依从性;而标准护理组患者则遵循其所在医院的常规实践。该试验的主要终点为心血管死亡、非致死性心肌梗死和非致死性卒中组成的复合终点。共2057名急性冠脉综合征患者按1:1比例随机分配至护士协调预防项目组或标准护理组。与标准护理相比,护士协调预防项目显著降低了主要不良心血管事件发生率,这一获益主要由非致死性心肌梗死减少所驱动。预先指定的次要结局即包含缺血驱动血运重建的主要不良心血管事件发生率也显著降低。护士协调预防项目组在运动频率、体重控制和药物依从性方面的改善更为明显。护士协调预防项目显著降低了急性冠脉综合征患者出院后的长期主要不良心血管事件,改善了体力活动、体重控制和药物治疗依从性。将护士协调预防项目纳入医疗保健服务可能有助于成功实施二级预防策略。
Effective stroke prevention relies on identifying at-risk individuals before neurological symptoms arise, yet this is severely limited by the absence of scalable screening tools. To address this, we developed RetCEVD, a diagnostic framework that uses rapid, non-invasive retinal Optical Coherence Tomography Angiography (OCTA) for auxiliary assessment of ICVD. At its core, RetCEVD introduces a memory-guided mutual information optimization strategy that maximizes shared disease-relevant information within the same diagnostic category while suppressing redundant or confounding dependencies across different categories. This dual information constraint encourages compact, discriminative representations of subtle retinal microvascular abnormalities. Trained and validated on a multi-center cohort of 24,438 retinal images, RetCEVD addresses three primary tasks: auxiliary detection of existing ICVD, etiological subtyping (large artery atherosclerosis vs. small vessel disease), and current symptomatic-status classification (asymptomatic vs. symptomatic LAA). The model achieved AUCs of 0.95 internal and 0.94 external for ICVD detection, 0.83 internal and 0.81 external for etiological subtyping, and 0.75 internal and 0.76 external for current symptomatic-status classification. The two-year ALAA follow-up provided supplementary longitudinal validation for subsequent stroke events (AUC, 0.71). By comprehensively evaluating the model's clinical interpretability, including its learned pathological features and alignment with established clinical patterns, we provide novel insights into retina-based stroke evaluation. Ultimately, RetCEVD may serve as an efficient, low-cost screening and triage tool to identify individuals who may benefit from confirmatory neurovascular imaging and specialist assessment.
中文摘要:有效的卒中预防依赖于在神经系统症状出现前识别高危人群,但这一目标因缺乏可扩展的筛查工具而受到严重限制。为解决这一问题,我们开发了RetCEVD诊断框架,利用快速、非侵入性的视网膜光学相干断层扫描血管成像(OCTA)对缺血性脑血管病(ICVD)进行辅助评估。RetCEVD的核心是一种记忆引导的互信息优化策略,该策略在最大化同一诊断类别内共享的疾病相关信息的同时,抑制不同类别间冗余或混淆的依赖关系。这种双重信息约束鼓励形成紧凑且具有判别力的视网膜微血管细微异常表征。基于包含24,438张视网膜图像的多中心队列进行训练和验证,RetCEVD完成了三项主要任务:现有ICVD的辅助检测、病因分型(大动脉粥样硬化与腔隙性小血管病)以及当前症状状态分类(无症状与有症状的大动脉粥样硬化)。该模型在ICVD检测方面取得了0.95的内部AUC和0.94的外部AUC,在病因分型方面取得了0.83的内部AUC和0.81的外部AUC,在当前症状状态分类方面取得了0.75的内部AUC和0.76的外部AUC。为期两年的大动脉粥样硬化(ALAA)随访为后续卒中事件提供了补充性的纵向验证数据(AUC为0.71)。通过全面评估模型的临床可解释性,包括其学习的病理特征与既定临床模式的一致性,我们为基于视网膜的卒中评估提供了新见解。最终,RetCEVD可作为高效、低成本的筛查和分诊工具,用于识别可能从确认性神经血管影像检查和专科评估中受益的人群。
We aimed to determine whether two-channelled near-infrared spectroscopy (NIRS) was feasible for recognising anterior large vessel occlusion (LVO) with a device suitable for prehospital use and whether probe placement (frontal vs. parietal) made a difference. We analysed NIRS readings of six computed tomography angiography (CTA)-confirmed LVO-stroke patients at Tampere University Hospital during the six-month study period. We placed four sensors on patients' heads: two frontally and two parietally. We provided a detailed description and analysis of these recordings and their correlation with imaging-confirmed changes in perfusion. In the frontally placed sensors, the rSO2 was 1-8 percentage points higher on the affected side before and 0-9 percentage points higher on the affected side after endovascular treatment (EVT). rSO2 values did not change significantly. One patient showed higher rSO2 on the healthy side (5 percentage points) before and after EVT. We could not recover frontal values from one patient. In parietally placed censors, all patients had 3-9 percentage points higher rSO2 on the healthy side before EVT. After EVT, 3 patients had 3-7 percentage points higher rSO2 on the healthy side. In two cases, after EVT, the difference in rSO2 changed to 1-2 percentage points higher on the affected side. We could not record parietal readings in one patient. Neither NIRS sensor placement detected differences in rSO2 in LVO; therefore, NIRS appears unsuitable as a diagnostic tool for LVO. Future research should focus on other technologies.
中文摘要:本研究旨在确定双通道近红外光谱(NIRS)是否适用于识别前循环大血管闭塞(LVO),并评估探头放置位置(额部与顶叶)是否存在差异。我们在六个月的观察期内,对坦佩雷大学医院经计算机断层扫描血管造影(CTA)确诊的六名LVO卒中患者的NIRS读数进行了分析。我们在患者头部放置了四个传感器:两个位于额部,两个位于顶叶。我们对这些记录及其与影像确认的血流灌注变化之间的相关性进行了详细描述和分析。在额部放置的传感器中,治疗前受影响侧的rSO2比健康侧高1至8个百分点,血管内治疗(EVT)后受影响侧仍高出0至9个百分点,但rSO2值无显著变化。一名患者在EVT前后显示健康侧rSO2较高(高出5个百分点)。其中一名患者的额部数据未能恢复。在顶叶放置的传感器中,所有患者在EVT前健康侧的rSO2均高出3至9个百分点。EVT后,三名患者健康侧rSO2仍高出3至7个百分点。在两种情况下,EVT后受影响侧rSO2的差异变为高出1至2个百分点。一名患者的顶叶读数未能记录。由于NIRS探头放置均未检测到LVO的rSO2差异,因此NIRS似乎不适合作为LVO的诊断工具。未来的研究应聚焦于其他技术。
Infections have been linked as short-term triggers for stroke, but the extent of their contribution is unclear. We examined population-level temporal and spatiotemporal associations between common respiratory viruses and stroke in an ecological study in Victoria, Australia. The statewide Victorian Admitted Episodes data set, covering all hospital admissions for stroke between June 2010 and December 2022, was analyzed against statewide representative data from SnotWatch respiratory polymerase chain reaction tests. Population size, climate, and air pollution data sets for the same period were treated as population-level confounders. Time-series analysis was used to model weekly stroke events and respiratory virus levels (% of polymerase chain reaction tests positive for each pathogen), and attributable fractions were computed using distributed lag nonlinear modeling. To examine spatiotemporal variation, the weekly association by Statistical Area Level 2 was modeled using a Bayesian Integrated Nested Laplace Approximation. We analyzed 153 730 stroke events (61% ischemic, 25% hemorrhagic, and 14% unspecified) and 6 180 896 respiratory specimens. In the time-series analysis, higher weekly levels of specific respiratory viruses were associated with increased rates of stroke after controlling for confounders. Our model estimated that the fractions of strokes attributed to enterovirus and human metapneumovirus 4.6% (95% CI, 2.5-6.6) and 1.3% (95% CI, 0.3-2.3), respectively, which rose during peak viral weeks. The attributable fractions differed between ischemic stroke (human metapneumovirus 3.7%) and hemorrhagic stroke (enterovirus, 5.8%; parainfluenza, 3.2%). Spatiotemporal analysis revealed greater effect sizes in areas potentially associated with agricultural/industrial activity, as well as in outer-urban areas, based on the regionality of the Statistical Area Level 2 of usual patient residence. At the population level, there were clear, observable time- and space-time-related associations between respiratory virus activity and stroke. People living in higher-risk areas during peak respiratory virus periods may be more susceptible to acute stroke. This warrants further investigation.
中文摘要:感染已被证实是卒中的短期诱因,但其贡献程度尚不明确。本研究在澳大利亚维多利亚州开展了一项生态学研究,旨在探讨常见呼吸道病毒与卒中之间的人群水平时间及时空关联。研究分析了2010年6月至2022年12月期间涵盖所有卒中住院病例的维多利亚州全州 admitted episodes 数据集,并与代表全州的 SnotWatch 呼吸道聚合酶链反应检测数据进行对比。人口规模、气候和空气污染数据作为人群水平的混杂因素纳入分析。采用时间序列分析对每周卒中事件和呼吸道病毒水平(每种病原体聚合酶链反应检测阳性率)进行建模,并利用分布滞后非线性模型计算归因分数。为考察时空变异,基于统计区域二级(Statistical Area Level 2)按周建模了关联关系。研究共分析了153730起卒中事件(其中缺血性占61%,出血性占25%,未指定类型占14%)和6180896份呼吸道标本。时间序列分析显示,在控制混杂因素后,特定呼吸道病毒每周水平的升高与卒中发生率增加相关。模型估计,肠道病毒和人偏肺病毒导致的卒中归因分数分别为4.6%(95% CI, 2.5-6.6)和1.3%(95% CI, 0.3-2.3),且在病毒高峰期上升。缺血性卒中与人偏肺病毒(3.7%)相关,而出血性卒中则与肠道病毒(5.8%)和副流感病毒(3.2%)相关。时空分析显示,在可能与农业或工业活动相关的区域以及基于患者常住地统计区域二级划分的远郊区域,效应量更大。在人群水平上,呼吸道病毒活动与卒中之间存在清晰可辨的时间及时空关联。在呼吸道病毒高峰期居住于高风险区域的人群可能对急性卒中更为易感。这一发现值得进一步调查。
Therapeutic options for neurological recovery remain limited in acute ischemic stroke (AIS) patients ineligible for thrombolysis, and while multitarget drugs like Danhong injection (DHI) demonstrate efficacy, their polypharmacological mechanisms remain understood. In this trial including 1505 thrombolysis-ineligible AIS patients with anterior-circulation and blood stasis syndrome (NCT01677208), 14-day treatment with DHI (n = 1002) versus placebo (n = 503) demonstrated superior 90-day outcomes (modified Rankin scale [mRS] score ≤1: 64.57 vs. 59.24%; adjusted odds ratio 1.43, 95%CI 1.10-1.86, p = 0.007), particularly in females and hypertensive patients, and no significant between-group differences in any serious adverse events (all p > 0.05). In the exploratory RNA-sequencing substudy of 39 patients (24 DHI, 15 placebo), we identified 19 differentially expressed modules, including two paired targeted modules "HBG2" and "TMEM108," whose topological features showed opposite correlations with the primary clinical outcome (δmRS at Day 90). Furthermore, a combination effect model was introduced to describe the time-dependent joint association of these modules with outcome (combination effect score: -0.729 at Day 0, 0.227 at Day 14, and 1 at Day 90). These findings demonstrate DHI may be a favorable treatment option for thrombolysis-ineligible AIS patients and provide a proposed analytical framework for future, independently validated studies of multitarget drug actions in complex diseases.
中文摘要:溶栓 ineligible 的急性缺血性卒中(AIS)患者神经功能恢复治疗选择有限,尽管丹红注射液(DHI)等多靶点药物显示出疗效,但其多药理学机制尚不明确。本试验纳入1505名前循环及血瘀综合征的溶栓 ineligible AIS患者(NCT01677208),结果显示与安慰剂组(n=503)相比,接受DHI治疗14天组(n=1002)在90天功能结局方面表现更优(改良Rankin量表[mRS]评分≤1的比例为64.57% vs 59.24%;调整后的比值比1.43,95%CI 1.10-1.86,p=0.007),尤其在女性和高血压患者中更为显著,且两组间任何严重不良事件均无显著差异(所有p>0.05)。在39名患者的探索性RNA测序亚组研究中(24例DHI,15例安慰剂),我们鉴定出19个差异表达模块,包括两个配对的靶向模块HBG2和TMEM108,其拓扑特征与主要临床结局(第90天的δmRS)呈相反相关性。此外,引入了一种组合效应模型来描述这些模块与结局随时间变化的联合关联(组合效应得分:第0天为-0.729,第14天为0.227,第90天为1)。这些发现表明DHI可能是溶栓 ineligible AIS患者的有利治疗选择,并为未来独立验证的多靶点药物在复杂疾病中作用的分析框架提供了依据。
Polygenic risk scores (PRS) promise improved cardiovascular risk stratification, but most validation derives from UK or Nordic biobanks. The transferability of these scores to Central European populations and their incremental value over classical risk factors in routine care remain unestablished. To determine whether a coronary PRS derived from external European data transfers to a Polish primary-care population and adds discrimination for prevalent cardiovascular disease beyond classical risk factors. In the nationwide Polish LIPIDOGEN2015 primary-care cohort, we derived PRS for coronary heart disease, myocardial infarction (MI) and stroke from FinnGen data with continuous shrinkage priors and applied them to imputed genotypes. We compared allele frequencies of 1397 unrelated participants with a non-Finnish European (NFE) reference and, in 1328 participants with clinical data, related the PRS to coronary artery disease (CAD), MI and stroke recorded at baseline and to a composite including death during follow-up, with and without classical risk factors or SCORE2. Allele frequencies correlated with the NFE reference (r = 0.97). Per standard deviation (SD), the coronary PRS was associated with prevalent CAD (odds ratio 1.36, 95% CI 1.11 to 1.67) and the composite endpoint (1.26, 95% CI 1.04 to 1.51), as were two validated genome-wide scores. Adding it to classical risk factors changed the area under the curve (AUC) for the composite endpoint by 0.0017 (95% CI -0.0005 to 0.0076), from 0.860 to 0.861; results with SCORE2 were similar. The study had 80% power for odds ratios per SD of 1.31 (CAD) and 1.27 (composite). A coronary PRS derived from external European data retains its association with prevalent CAD without re-derivation in this Polish primary-care cohort but, in this cross-sectional, event-limited sample, adds little discrimination to classical risk factors. Its value for predicting future events in this setting remains to be tested against incident outcomes.
中文摘要:多基因风险评分(PRS)有望改善心血管风险分层,但大多数验证数据来自英国或北欧生物银行。这些评分向中欧人群的转移性及其在常规护理中超越经典风险因素的增量价值尚未确立。本研究旨在确定源自外部欧洲数据的冠心病PRS是否适用于波兰初级保健人群,并在经典风险因素之外增加对现患心血管疾病的判别能力。在波兰全国LIPIDOGEN2015初级保健队列中,我们利用连续收缩先验从FinnGen数据推导出冠心病、心肌梗死(MI)和中风的PRS,并将其应用于插补基因型数据。我们将1397名无亲缘关系参与者的等位基因频率与非芬兰欧洲(NFE)参考数据进行比较,并在1397名具有临床数据的参与者中,将PRS与基线记录的心血管疾病(CAD)、MI和中风以及随访期间的死亡复合终点相关联,分析包含或不包含经典风险因素或SCORE2评分的情况。等位基因频率与NFE参考数据高度相关(r=0.97)。每增加一个标准差(SD),冠心病PRS与现患CAD(比值比1.36,95%置信区间1.11至1.67)和复合终点(1.26,95%置信区间1.04至1.51)均相关,两个经过验证的全基因组评分也呈现类似结果。将其添加到经典风险因素中使复合终点的曲线下面积(AUC)变化为0.0017(95%置信区间-0.0005至0.0076),从0.860变为0.861;使用SCORE2评分的结果相似。该研究对每标准差的比值比具有80%的统计功效,分别为CAD的1.31和复合终点的1.27。源自外部欧洲数据的冠心病PRS在此波兰初级保健队列中无需重新推导即可保持与现患CAD的相关性,但在这种横断面、事件有限的样本中,对经典风险因素的判别能力增加有限。其在该环境中预测未来事件的价值仍有待针对发病结局进行验证。
In a target-directed low-density lipoprotein cholesterol (LDL-C)-lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease. We compared the efficacy and safety of initial statin-ezetimibe combination therapy versus statin monotherapy within intensive or conventional LDL-C-targeting strategies. In this prespecified second randomization of the randomized Ez-PAVE trial (Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease: Randomized Comparison of LDL Cholesterol Targeting <70 versus <55 mg/dL) conducted at 17 centers in South Korea, a total of 3048 patients with atherosclerotic cardiovascular disease were enrolled between January 2021 and July 2022. Following the first randomization to either an intensive (<55 mg/dL) or conventional (<70 mg/dL) LDL-C-targeting strategy, patients underwent subsequent randomization (initial statin-ezetimibe combination therapy [n=1525] versus statin monotherapy [n=1523]) and were followed up for 3 years. Lipid-lowering therapy was adjusted according to a predefined protocol to achieve LDL-C targets. The primary end point was a 3-year composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable angina. The mean±SD age was 64.4±9.0 years, and 638 patients (20.9%) were female. The incidence of the primary end point did not differ between statin-ezetimibe combination therapy (128 patients [8.5%]) and statin monotherapy (119 patients [7.9%]; hazard ratio, 1.07 [95% CI, 0.83-1.37]; P=0.596). Patients who received statin-ezetimibe combination therapy achieved lower median LDL-C levels during follow-up than those who received statin monotherapy in both the intensive-targeting (53 mg/dL [interquartile range, 45-62 mg/dL] versus 62 mg/dL [interquartile range, 53-74 mg/dL]) and conventional-targeting (63 mg/dL [interquartile range, 55-73 mg/dL] versus 70 mg/dL [interquartile range, 62-81 mg/dL]) strategies. During follow-up, ezetimibe was added to the treatment regimen of 241 patients (34.3%) and 177 patients (24.8%) who initially received statin monotherapy in the intensive- and conventional-targeting strategies, respectively. The treatment effect of intensive-targeting versus conventional-targeting strategies was consistent regardless of therapy regimens without significant heterogeneity (Pinteraction=0.583). The safety end points were similar between the groups. Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04626973.
中文摘要:在靶向低密度脂蛋白胆固醇(LDL-C)降低策略中,初始治疗方案的疗效尚未在动脉粥样硬化性心血管疾病患者中得到充分研究。本研究比较了强化或常规LDL-C靶向策略下,初始他汀-依折麦布联合治疗与他汀单药治疗的疗效和安全性。该预指定的二次随机分析基于在韩国17个中心进行的Ez-PAVE试验(针对动脉粥样硬化性心血管疾病患者的依折麦布联合疗法:LDL胆固醇靶值<70与<55 mg/dL的随机比较),于2021年1月至2022年7月间纳入3048名患者。首次随机分配至强化(<55 mg/dL)或常规(<70 mg/dL)LDL-C靶向策略后,患者接受后续随机分组(初始他汀-依折麦布联合治疗组n=1525 vs. 他汀单药治疗组n=1523),随访期为3年。脂质降低治疗根据预定义方案调整以实现LDL-C靶值。主要终点为3年内心血管原因死亡、非致死性心肌梗死、非致死性卒中、任何血运重建或不稳定心绞痛住院的复合事件。平均年龄为64.4±9.0岁,女性638名(20.9%)。他汀-依折麦布联合治疗组主要终点发生率为128例(8.5%),他汀单药治疗组为119例(7.9%);风险比为1.07(95% CI, 0.83-1.37;P=0.596),两组间无显著差异。在强化靶向策略中,联合治疗组随访期间的中位LDL-C水平低于单药组(53 mg/dL [四分位距45-62] vs. 62 mg/dL [四分位距53-74]);在常规靶向策略中同样更低(63 mg/dL [四分位距55-73] vs. 70 mg/dL [四分位距62-81])。随访期间,初始接受他汀单药治疗的患者中有241名(34.3%)在强化策略组和177名(24.8%)在常规策略组加用了依折麦布。无论采用何种治疗方案,强化靶向与常规靶向策略的治疗效果一致且无显著异质性(P交互作用=0.583)。两组安全性终点相似。在靶向LDL-C降低策略中,无论是初始采用他汀-依折麦布联合治疗还是他汀单药治疗,心血管疗效和安全性均无显著差异,但联合治疗有助于实现更低的LDL-C靶值。
Pelacarsen is an antisense oligonucleotide that reduces serum levels of lipoprotein(a). In a randomized placebo-controlled trial in patients with established cardiovascular disease, pelacarsen did not reduce the risk of major adverse cardiovascular events compared to placebo. We further investigated the association of pelacarsen treatment with cardiovascular outcomes. We report the association of pelacarsen treatment with a primary composite end point of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization. Analyses included on-treatment, uninterrupted treatment, total primary end point events (first and recurrent events), landmark analyses classified by changes in and achieved lipoprotein(a) at 3 months, and key subgroups including baseline lipoprotein(a), low-density lipoprotein (LDL) cholesterol, high-sensitivity C-reactive protein (CRP), and time from qualifying event to enrollment. For participants on treatment, a primary end point occurred in 434 participants (10.4%) randomly assigned to placebo and 380 participants (9.1%) assigned to pelacarsen (hazard ratio, 0.98; 95% confidence interval [CI], 0.85 to 1.12). When evaluating participants with uninterrupted treatment, a primary end point event occurred in 167 participants (11.0%) in the pelacarsen group and 204 participants (10.1%) in the placebo group (hazard ratio, 1.09; 95% CI, 0.89 to 1.34). When evaluating total primary end point events, there were 644 events in the pelacarsen group and 646 events in the placebo group (rate ratio, 1.00; 95% CI, 0.87 to 1.14). In landmark analyses evaluating participants alive and free of the composite end point at 3 months, when compared to placebo there was no association between pelacarsen treatment and the primary end point either in participants with reduction in lipoprotein(a) greater than or equal to the median (170 nmol/l) (hazard ratio, 1.09; 95% CI, 0.92 to 1.29) or in participants who achieved lipoprotein(a) lower than or equal to the median (69.5 nmol/l) (hazard ratio, 1.10; 95% CI, 0.93 to 1.29). There was also no association between pelacarsen treatment and the primary end point in any of the evaluated key subgroups including classification by median baseline lipoprotein(a), LDL cholesterol, high-sensitivity CRP, or time from qualifying cardiovascular disease to enrollment. Pelacarsen was not associated with a reduction in major adverse cardiovascular events when evaluated by treatment exposure, changes in or achieved lipoprotein(a) levels at 3 months, considering total events, or within subgroups of baseline lipoprotein(a), LDL cholesterol, or high-sensitivity CRP levels.
中文摘要:Pelacarsen是一种可降低血清脂蛋白a水平的反义寡核苷酸。在针对已确诊心血管疾病患者的随机安慰剂对照试验中,与安慰剂相比,Pelacarsen未能降低主要不良心血管事件的风险。我们进一步调查了Pelacarsen治疗与心血管结局的关联。报告了Pelacarsen治疗与主要复合终点(包括心血管原因死亡、非致死性心肌梗死、非致死性卒中或紧急冠状动脉血运重建)的关联。分析包括治疗期间、不间断治疗、主要终点总事件数(首次和复发事件)、按3个月时脂蛋白a的变化和达到的水平分类的地标分析,以及关键亚组包括基线脂蛋白a、低密度脂蛋白胆固醇、高敏C反应蛋白和从合格事件到入组的时间。对于接受治疗的患者,安慰剂组随机分配的434名参与者(10.4%)发生了主要终点事件,而Pelacarsen组分配的380名参与者(9.1%)发生了主要终点事件(风险比0.98;95%置信区间0.85至1.12)。在评估接受不间断治疗的参与者时,Pelacarsen组的167名参与者(11.0%)和安慰剂组的204名参与者(10.1%)发生了主要终点事件(风险比1.09;95%置信区间0.89至1.34)。在评估主要终点总事件时,Pelacarsen组有644个事件,安慰剂组有646个事件(率比1.00;95%置信区间0.87至1.14)。在地标分析中,评估3个月时存活且无复合终点的参与者,与安慰剂相比,Pelacarsen治疗与主要终点的关联在脂蛋白a降低大于或等于中位数(170 nmol/l)的参与者中(风险比1.09;95%置信区间0.92至1.29)或在达到脂蛋白a小于或等于中位数(69.5 nmol/l)的参与者中(风险比1.10;95%置信区间0.93至1.29)均未观察到关联。在按基线脂蛋白a、低密度脂蛋白胆固醇、高敏C反应蛋白或从合格心血管疾病到入组的时间分类的任何关键亚组中,也未观察到Pelacarsen治疗与主要终点的关联。通过治疗暴露、3个月时脂蛋白a水平的变化或达到水平、考虑总事件或在基线脂蛋白a、低密度脂蛋白胆固醇或高敏C反应蛋白水平的亚组中评估,Pelacarsen与主要不良心血管事件的减少无关。
Intra-arterial tenecteplase during endovascular treatment (EVT) may increase first-pass recanalization and dissolve microcirculatory thrombi, but its efficacy and safety are uncertain. We hypothesised that this strategy would improve functional outcomes versus EVT alone. This phase 3, randomised, adaptive-enrichment, open-label, blinded-endpoint multicentre study aims to evaluate whether intra‑arterial tenecteplase improves clinical outcomes for patients with acute ischemic stroke. Patients with large‑vessel occlusion eligible for EVT within 24 hours of symptom onset were randomly assigned (1:1) to the tenecteplase group receiving intra‑arterial tenecteplase during EVT or the control group receiving EVT alone. The primary endpoint was favorable functional outcome. Of 380 randomised patients (192 in the tenecteplase group and 188 in the control group), primary outcome data were available for 190 and 186 patients, respectively. Favorable 90-day functional outcomes (modified Rankin Scale 0-2) occurred in 40.0% of the tenecteplase group versus 46.8% of the control group (unadjusted odds ratio 0.76, [95% CI 0.50-1.14], P = 0.19). This work suggests intra-arterial tenecteplase during thrombectomy did not improve 90-day functional outcomes in this population. (Funded by National Science and Technology Major Project and hospital-initiated grants; ClinicalTrials.gov registration: NCT05657444).
中文摘要:在血管内治疗期间进行动脉内替奈普酶输注可能提高首次再通率并溶解微循环血栓,但其疗效和安全性尚不确定。我们假设该策略相比单纯血管内治疗能改善功能预后。这项三期、随机、适应性富集、开放标签、盲法终点评估的多中心研究旨在评估动脉内替奈普酶是否能改善急性缺血性卒中患者的临床结局。发病24小时内符合血管内治疗适应证的大血管闭塞患者被随机分配(1:1)至接受血管内治疗期间动脉内注射替奈普酶的替奈普酶组,或仅接受血管内治疗的对照组。主要终点为良好的功能预后。在380名随机分组的患者中(替奈普酶组192人,对照组188人),分别有190人和186人具备主要结局数据。替奈普酶组40.0%的患者在90天时获得良好功能预后(改良Rankin量表0-2分),而对照组为46.8%(未调整比值比0.76,95%置信区间0.50-1.14,P=0.19)。本研究结果表明,在该人群中,血栓切除术期间使用动脉内替奈普酶并未改善90天的功能预后。
In patients with acute ischemic stroke caused by medium vessel occlusion (MeVO), intra-arterial tenecteplase may offer a targeted strategy to improve recanalization; we hypothesized that intra-arterial tenecteplase would increase successful reperfusion compared with standard care with a comparable safety profile. This phase 2, prospective, randomised, open-label, blinded-endpoint, multicentre study aims to assess the efficacy and safety of intra-arterial tenecteplase for patients with acute ischemic stroke caused by MeVO. Patients with MeVO were randomly (1:1) assigned to receive intra-arterial tenecteplase or standard care. The primary outcome was successful reperfusion of medium vessel occlusion. A total of 80 patients were randomized to either the tenecteplase group (n = 41) or control group (n = 39). Successful reperfusion reached 61.0% (25/41) in the tenecteplase group versus 28.2% (11/39) in the control group (unadjusted odds ratio 3.98, 95% CI 1.56-10.16; P = 0.004). Symptomatic intracranial hemorrhage within 24 h was similar between the tenecteplase and control groups. This work suggests that intra-arterial tenecteplase significantly increased the probability of successful reperfusion compared with standard care, with a comparable safety profile in this stroke population. (Funded by Shenyang Science Tech Project and hospital-initiated grants; ClinicalTrials.gov registration: NCT05657470).
中文摘要:在中血管闭塞(MeVO)引起的急性缺血性卒中患者中,动脉内替奈普酶可能提供一种靶向策略以改善再通;我们假设与标准治疗相比,动脉内替奈普酶能增加成功再灌注且安全性相当。这项二期、前瞻性、随机、开放标签、盲法终点评估的多中心研究旨在评估动脉内替奈普酶对MeVO引起的急性缺血性卒中患者的疗效和安全性。MeVO患者按1:1比例随机分配接受动脉内替奈普酶或标准治疗。主要结局是中血管闭塞的成功再灌注。共80名患者被随机分配至替奈普酶组(n=41)或对照组(n=39)。替奈普酶组的成功再灌注率为61.0%(25/41),而对照组为28.2%(11/39)(未调整比值比3.98,95%置信区间1.56-10.16;P=0.004)。替奈普酶组和对照组在24小时内症状性颅内出血的发生率相似。这项工作表明,与标准治疗相比,动脉内替奈普酶显著提高了卒中人群成功再灌注的概率,且具有相当的安全性。(由沈阳市科技项目和医院发起的资助提供资金;ClinicalTrials.gov注册号:NCT05657470)。
The past decade has seen a transformation in our understanding of the genetics of stroke. However, a commonly asked question is how do these advances impact the practicing clinician now, and what are their implications for clinical care in the future? This review outlines the major recent advances in stroke genetics and addresses 4 questions most relevant to the clinician: What do we now know about the genetic architecture of stroke? When and how should genetic testing be used to identify monogenic stroke? How can genetic information be applied to risk stratification and prevention? And what therapeutic implications are emerging from genetic discoveries? It highlights the success of genome-wide association studies in stroke and how these have transformed how we understand the genetic architecture of stroke. An increasing number of monogenic forms of cerebral small vessel disease are being identified, and guidance on when and how to test for them is covered. Polygenic risk scores are gaining increasing attention. How these can be applied, and the challenges in their use are discussed. Lastly, the impact of genomics on stroke therapeutics, whether by identifying new targets, assessing causality using techniques such as Mendelian randomization, or pharmacogenomics, is discussed.
中文摘要:过去十年间我们对脑卒中的遗传学理解发生了转变。然而一个常被问到的问题是这些进展如何影响当前的临床医生以及它们对未来临床护理意味着什么。本综述概述了脑卒中遗传学的主要最新进展并回答了与临床医生最相关的四个问题:我们现在对脑卒中的遗传结构了解多少?何时以及如何利用基因检测来识别单基因型脑卒中?如何利用遗传信息进行风险分层和预防?遗传发现带来了哪些治疗方面的启示?文章强调了全基因组关联研究在脑卒中领域的成功及其如何改变了我们对脑卒中遗传结构的理解。越来越多的脑小血管病单基因形式被鉴定出来并涵盖了关于何时以及如何对其进行检测的指导。多基因风险评分正受到越来越多的关注讨论了其应用方式及使用中的挑战。最后探讨了基因组学对脑卒中治疗的影响无论是通过识别新靶点、使用孟德尔随机化等技术评估因果关系还是药物基因组学。
The best management approach for renin-angiotensin system (RAS) inhibitor use before surgery is controversial. Some studies have suggested that continuation could increase the risk of clinically significant peri-operative hypotension and, thus, organ injury. By contrast, others believe that withholding them significantly increases the risk of severe hypertension and heart failure. To determine the most effective strategy, this systematic review and meta-analysis of randomized controlled trials compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgeries. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for randomized controlled trials that compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgery. Five randomized controlled trials (n = 10 773 patients; 5388 randomized to discontinuation) were included. Discontinuation of an RAS inhibitor probaby reduced peri-operative hypotension (27.66% vs 34.06%; risk ratio [RR] 0.81, 95% confidence interval [CI] 0.73-0.89; moderate certainty). The evidence is very uncertain about effects on peri-operative hypertension (9.46% vs 8.05%; RR 1.38, 95% CI 0.66-2.89; very low certainty). For major clinical outcomes, discontinuation suggested little to no difference in acute kidney injury (10.45% vs 10.69%; RR 0.98, 95% CI 0.66-1.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.76-1.31; low certainty), myocardial infarction (1.22% vs 1.00%; RR 1.19, 95% CI 0.60-2.39; low certainty), stroke (0.42% vs 0.40%; RR 1.04, 95% CI 0.56-1.93; low certainty), and arrhythmias (1.80% vs 1.40%; RR 1.28, 95% CI 0.69-2.38; low certainty). These findings suggest that discontinuation of RAS inhibitors is likely to reduce peri-operative hypotension in patients undergoing non-cardiac, non-vascular surgery, but the evidence is very uncertain about effects on peri-operative hypertension and major clinical outcomes.
中文摘要:关于术前是否继续使用肾素-血管紧张素系统(RAS)抑制剂的最佳管理方案存在争议。部分研究提示继续用药可能增加临床显著性围术期低血压及器官损伤的风险,而另一些观点认为停药会显著增加严重高血压和心力衰竭的风险。为确定最有效的策略,本研究对比较非心脏和非血管手术患者中停用与继续使用RAS抑制剂的随机对照试验进行了系统评价和荟萃分析。检索了PubMed、Embase和Cochrane对照试验中心注册库(CENTRAL)中的相关随机对照试验。共纳入5项随机对照试验,涉及10773名患者(其中5388名被随机分配至停药组)。结果显示,停用RAS抑制剂可能降低围术期低血压发生率(27.66% vs 34.06%;风险比[RR] 0.81,95%置信区间[CI] 0.73-0.89;中等确定性证据)。关于对围术期高血压的影响,证据不确定性很高(9.46% vs 8.05%;RR 1.38,95% CI 0.66-2.89;极低确定性证据)。在主要临床结局方面,停药组与继续用药组在急性肾损伤(10.45% vs 10.69%;RR 0.98,95% CI 0.66-1.45;低确定性)、急性心力衰竭(5.38% vs 5.32%;RR 1.00,95% CI 0.76-1.31;低确定性)、心肌梗死(1.22% vs 1.00%;RR 1.19,95% CI 0.60-2.39;低确定性)、卒中(0.42% vs 0.40%;RR 1.04,95% CI 0.56-1.93;低确定性)和心律失常(1.80% vs 1.40%;RR 1.28,95% CI 0.69-2.38;低确定性)方面差异微小或无差异。这些发现表明,对于接受非心脏、非血管手术的患者,停用RAS抑制剂可能降低围术期低血压风险,但关于其对围术期高血压及主要临床结局影响的证据不确定性很高。
基础研究 (5篇)
The basal ganglia (BG) underlie motor control, reward processing, and many neurological and psychiatric disorders, yet cell-type-resolved epigenomic and 3D genome maps of the human BG remain limited. Here, we present a multimodal single-cell atlas of DNA methylation (261,331 nuclei) and 3D chromatin conformation (229,286 nuclei) from eight subregions, harmonized under the BG consensus taxonomy and integrated with matched data across multiple regulatory layers. We identify millions of differentially methylated regions across cell types, enriched for distinct transcription factor motifs, and link them to disease-associated heritability. We characterize the POU6F2+ STR D2 SMYD2-HTR7 spiny projection neuron (SPN) subtype, with concordant signatures across multiple modalities, and reveal region-specific methylation and contact gradients. Integrative gene regulatory networks (GRNs) predict cell-type-resolved enhancer-promoter interactions, nominating candidate regulatory mechanisms for Parkinson's disease (PD) risk variants at SNCA. Finally, multiplexed error-robust fluorescence in situ hybridization (MERFISH) profiling combined with cross-species Patch-seq identifies a neuronal subtype, STR FS PTHLH-PVALB GABA, with electrophysiological differences across the striatal matrix-striosome (MS) boundary.
中文摘要:基底神经节(BG)主导运动控制、奖赏处理及多种神经精神疾病,但人类BG细胞类型分辨的表观基因组和三维基因组图谱仍然有限。本研究构建了来自8个亚区的DNA甲基化(261,331个细胞核)和三维染色质构象(229,286个细胞核)的多模态单细胞图谱,在BG共识分类法下进行了标准化,并整合了跨多个调控层的匹配数据。我们鉴定了数百万个跨细胞类型的差异甲基化区域,这些区域富集于不同的转录因子基序,并与疾病相关的遗传力相关联。我们表征了POU6F2+ STR D2 SMYD2-HTR7棘突投射神经元(SPN)亚型,该亚型在多模态下具有 Concordant 特征,并揭示了区域特异性的甲基化和接触梯度。整合基因调控网络(GRNs)预测了细胞类型分辨的增强子-启动子相互作用,提名了帕金森病(PD)风险变异在SNCA处的候选调控机制。最后,多重误差鲁棒性荧光原位杂交(MERFISH)分析与跨物种Patch-seq结合鉴定了一种神经元亚型STR FS PTHLH-PVALB GABA,其在纹状体基质-条纹体(MS)边界两侧表现出电生理差异。
Ischemic stroke preventive therapies have been slow to emerge due to a limited understanding of the underlying molecular mechanisms. We aimed to discover new protein risk factors that are potential etiologic factors and may be candidates for therapeutic intervention. We included ARIC study (Atherosclerosis Risk in Communities) and CHS (Cardiovascular Health Study) participants without prevalent stroke at the time of proteomic profiling (1990-1992 in ARIC and 1992-1993 in CHS). Relative concentrations of proteins in blood were assessed with aptamers (n=4954). Ischemic stroke events were adjudicated through 2019 in ARIC and 2015 in CHS. Study-specific Cox regression adjusting for ischemic stroke risk factors was used to estimate associations between proteins and incident ischemic stroke. Study-specific estimates were combined using fixed-effects meta-analysis. Replication was conducted in 2 independent cohorts (AGES-Reykjavik, UK Biobank). Proteins with a false discovery rate q value <0.05 were considered replicated. Mendelian randomization analyses assessed for potential causal associations between proteins and ischemic stroke. Median follow-up was 25 and 12 years in ARIC and CHS. 1397 out of 14 139 (10%) participants experienced an ischemic stroke. 44 proteins were significantly associated with ischemic stroke risk (P<1.0×10-5), of which 26 are novel. In 2 independent cohorts, 37 (84%) associations were directionally concordant, and 26 (59%) met criteria for replication. Mendelian randomization analyses suggested MMP12 (matrix metallopeptidase-12) and CNTN1 (contactin-1) may be causally related to ischemic stroke risk. In multivariable Mendelian randomization analyses, higher MMP12 levels had a direct protective effect on ischemic stroke risk, while CNTN1 had a direct harmful effect. This proteomic and genomic investigation of ischemic stroke identified novel risk biomarkers and 2 potential etiologic CNTN1 factors that are regulated in response to atherosclerosis and obesity. If future studies confirm our findings, these results may have implications for the development of new preventive therapies.
中文摘要:由于对潜在分子机制理解有限,缺血性卒中的预防疗法进展缓慢。本研究旨在发现新的蛋白风险因素,这些因子可能是病因候选者并具备治疗干预潜力。研究纳入了在蛋白质组学分析时(ARIC研究为1990-1992年,CHS研究为1992-1993年)无卒中病史的ARIC研究和CHS研究参与者。利用适配体技术评估血液中的蛋白质相对浓度(n=4954)。截至2019年(ARIC)和2015年(CHS),通过 adjudication 确定缺血性卒中事件。采用调整了缺血性卒中风险因素的特定于研究的Cox回归模型估算蛋白质与首次发生缺血性卒中的关联,并使用固定效应荟萃分析合并各研究估计值。在两个独立队列(AGES-Reykjavik和UK Biobank)中进行复制验证。假发现率q值小于0.05的蛋白质被视为已复制。孟德尔随机化分析评估了蛋白质与缺血性卒中之间潜在的因果关联。ARIC和CHS的中位随访时间分别为25年和12年。在14139名参与者中有1397人(10%)发生了缺血性卒中。44种蛋白质与缺血性卒中风险显著相关(P<1.0×10-5),其中26种为新型蛋白。在两个独立队列中,37个(84%)关联方向一致,26个(59%)满足复制标准。孟德尔随机化分析提示MMP12(基质金属肽酶12)和CNTN1(接触蛋白1)可能与缺血性卒中风险存在因果关联。在多变量孟德尔随机化分析中,较高的MMP12水平对缺血性卒中风险具有直接保护作用,而CNTN1则具有直接有害作用。这项针对缺血性卒中的蛋白质组学和基因组学研究鉴定了新的风险生物标志物以及两种受动脉粥样硬化和肥胖调节的潜在病因因子CNTN1。如果未来研究证实我们的发现,这些结果可能对新预防疗法的开发产生影响。
Ambient air pollution is a leading global health risk and disproportionately affects populations of Low- and Middle-Income Countries (LMICs). In 2021, WHO revised its Air Quality Guidelines (AQG), lowering recommended annual limits for fine particulate matter (PM2.5) and nitrogen dioxide (NO2). We estimated the potential health and economic impacts of achieving WHO Interim Target 3 (IT3) and AQG concentrations across LMICs. We conducted a quantitative health impact assessment across 136 LMICs using gridded population data, high-resolution global PM2.5 and NO2 concentration estimates, and country-level Global Burden of Disease 2021 mortality and incidence rates. Published concentration-response functions were applied at ∼ 1 km x 1 km resolution to estimate one-year changes in mortality and disease incidence under IT3 (PM2.5; 15, NO2; 20 μg/m3) and AQG (PM2.5; 5, NO2; 10 μg/m3) counterfactual scenarios. Outcomes were all-cause and cause-specific mortality (chronic obstructive pulmonary disease [COPD], ischaemic heart disease [IHD], and stroke) and disease incidence (COPD, dementia, IHD, and stroke). Mortality changes were valued using country-adjusted value of a statistical life (VSL, Int$ PPP-adjusted 2021). Direct medical and productivity-related costs associated with incidence changes were estimated using a cost-of-illness (COI) framework. Uncertainty intervals (UI) reflect uncertainty in concentration-response functions only and likely underestimate uncertainty if all sources were propagated in the estimates. Estimated health impact of attaining WHO IT3 and AQG concentrations for PM2.5 was 16.04% reduction (6.58 million, UI: 4.7-8.3 million) and 22.97% reduction (9.43 million, UI: 6.8-11.7million) in annual mortality, respectively. Corresponding VSL-based estimates of annual mortality reductions were Int$5.5 trillion (7.0% of aggregate LMIC GDP) and Int$8.4 trillion (10.7% of GDP), respectively. For NO2, estimated reductions in mortality were approximately 1.06% (435,000, UI: 268,000-594,000) and 2.79% (1.1 million; UI: 706,000-1.6 million), yielding gains of Int$0.6 trillion (0.7% of GDP) and Int$1.5 trillion (1.9% of GDP), for IT3 and AQG scenarios, respectively. Disease-specific mortality reductions were most prominent for IHD and stroke in Asia and Africa. Under the PM2.5 AQG scenario, an estimated 2.82 million (2.2-3.4) COPD, 1.10 million (0.3-1.7) dementia, 7.3 million (3.3-10.4) IHD, and 2.3 million (1.8-2.7) stroke reductions in annual incidence was projected. Associated reductions in direct medical and productivity-related costs were greatest for IHD, COPD, and stroke. NO2-related morbidity reductions were smaller across all outcomes. All health impact estimates are potential reductions relative to current disease burden and reflect postponed all-cause mortality, or the avoidance of disease-specific mortality or incidence, within a single year. Effects for each exposure-outcome pair should be interpreted independently and not summed. Estimates should be interpreted considering data limitations, modelling assumptions, the one-year counterfactual design and the incomplete propagation of uncertainty beyond the CRFs. Achieving both WHO IT3 and AQG values in LMICs could yield substantial reductions in mortality and disease incidence, particularly for cardiovascular and respiratory conditions, alongside large, monetised welfare gains from reduced mortality risk. These findings quantify the potential societal benefit of air quality improvements and support accelerated action toward meeting WHO guideline levels in regions bearing the highest pollution burden.
中文摘要:环境空气污染是全球主要的健康风险,且对中低收入国家人口影响尤为严重。世界卫生组织于2021年修订了空气质量指南,降低了细颗粒物(PM2.5)和二氧化氮(NO2)的推荐年度限值。本研究评估了在中低收入国家实现世界卫生组织临时目标3(IT3)和空气质量指南(AQG)浓度的潜在健康与经济影响。研究利用网格化人口数据、高分辨率全球PM2.5和NO2浓度估算值以及各国全球疾病负担2021年的死亡率和发病率数据,对136个中低收入国家进行了定量健康影响评估。在约1公里乘1公里的分辨率下应用已发表的浓度反应函数,估算了在IT3(PM2.5为15微克每立方米,NO2为20微克每立方米)和AQG(PM2.5为5微克每立方米,NO2为10微克每立方米)反事实情景下一年内的死亡率和疾病发病率变化。结局指标包括全因及特定原因死亡率(慢性阻塞性肺病、缺血性心脏病和中风)以及疾病发病率(慢性阻塞性肺病、痴呆、缺血性心脏病和中风)。死亡率变化采用各国调整后的统计生命价值进行估值,直接医疗费用和与发病率变化相关的生产力损失成本则通过疾病成本框架进行估算。不确定性区间仅反映浓度反应函数的不确定性,若将所有来源的不确定性纳入估算,实际不确定性可能被低估。估计实现WHO IT3和AQG浓度的PM2.5健康影响分别为年死亡率降低16.04%(658万人,不确定性区间:470万至830万人)和22.97%(943万人,不确定性区间:680万至1170万人)。基于统计生命价值的相应年死亡率减少估值分别为5.5万亿美元(占中低收入国家国内生产总值的7.0%)和8.4万亿美元(占10.7%)。对于NO2,估计的死亡率降低幅度分别约为1.06%(43.5万人,不确定性区间:26.8万至59.4万人)和2.79%(110万人,不确定性区间:70.6万至160万人),在IT3和AQG情景下分别带来0.6万亿美元(占国内生产总值的0.7%)和1.5万亿美元(占1.9%)的收益。特定疾病的死亡率降低在亚洲和非洲的缺血性心脏病和中风中最为显著。在PM2.5 AQG情景下,预计年发病率减少分别为慢性阻塞性肺病282万人(220万至340万)、痴呆110万人(30万至170万)、缺血性心脏病730万人(330万至1040万)和中风230万人(180万至270万)。直接医疗费用和生产力损失成本的相应减少在缺血性心脏病、慢性阻塞性肺病和中风中最为显著。NO2相关的发病率降低在所有结局指标中均较小。所有健康影响估算均为相对于当前疾病负担的潜在减少量,反映的是推迟的全因死亡或避免特定疾病的死亡或发病率,且仅针对单一年份。每个暴露-结局对的影响应独立解读,不得简单相加。在解释估算结果时应考虑数据局限性、建模假设、单一年反事实设计以及不确定性传播的不完整性。在中低收入国家同时实现WHO IT3和AQG标准值可显著降低死亡率及疾病发病率,特别是心血管和呼吸系统疾病,并带来巨大的货币化福利收益。这些发现量化了空气质量改善的潜在社会效益,支持在污染负担最重的地区加速采取行动以达成世界卫生组织指南水平。
Phytocannabinoids are pharmacologically diverse constituents of Cannabis sativa whose actions go beyond canonical cannabinoid receptors. Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are best characterized, while cannabigerol, cannabidivarin, tetrahydrocannabivarin, cannabichromene, cannabinol, and related compounds are emerging candidates. This review integrates molecular pharmacology, pharmacokinetics, safety, and therapeutic evidence across neurologic, neuropsychiatric, inflammatory, pain, cardiovascular and metabolic, hepatic, renal, and neoplastic disorders. The strongest evidence supports pharmaceutical-grade oral CBD as adjunctive therapy for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, and standardized THC-CBD formulations for selected patients with multiple sclerosis-associated spasticity. Emerging clinical signals in schizophrenia, pain, fibromyalgia, sleep disturbance, substance-use disorders, dermatologic conditions, sickle cell disease, and other symptom-focused indications support continued development. However, efficacy remains compound-, formulation-, exposure-, and indication-specific. In oncology, supportive-care applications must remain distinct from tumor-directed treatment, for which clinical efficacy has not been established. Preclinical studies show coherent effects on neuronal excitability, glial and immune activation, endothelial dysfunction, oxidative and nitrative stress, mitochondrial injury, fibrosis, and regulated cell death. These findings support further investigation in neurodegeneration, ischemia-reperfusion injury, diabetic cardiovascular disease, immune-mediated disorders, hepatic and renal injury, and selected cancers. Translation is constrained by product heterogeneity, variable exposure, uncertain target engagement, model differences, drug interactions, and underpowered trials. Standardized products, exposure-informed dosing, pharmacodynamic biomarkers, responder-enriched designs, and indication-specific randomized studies can address these barriers. Phytocannabinoids therefore represent a promising therapeutic platform whose potential will be best realized by matching defined compounds and formulations to biologically coherent diseases, mechanisms, treatment windows, and patient populations.
中文摘要:植物大麻素是大麻植物的药理活性成分,其作用超越经典大麻素受体。Δ9-四氢大麻酚(THC)和大麻二酚(CBD)研究最为充分,而大麻萘酚、大麻二酚变体、四氢大麻酚变体、大麻色烯、大麻酚及相关化合物正成为新兴候选药物。本综述整合了神经精神疾病、炎症、疼痛、心血管代谢、肝脏、肾脏及肿瘤性疾病领域的分子药理学、药代动力学、安全性及治疗证据。最强证据支持药用级口服CBD作为Dravet综合征、Lennox-Gastaut综合征和结节性硬化症相关癫痫的辅助治疗,以及标准化THC-CBD制剂用于特定多发性硬化相关痉挛患者。精神分裂症、疼痛、纤维肌痛、睡眠障碍、物质使用障碍、皮肤病及镰状细胞病等其他症状导向适应症中的新兴临床信号支持持续开发。然而疗效具有化合物、制剂、暴露量和适应症特异性。在肿瘤学领域,支持性护理应用必须与抗肿瘤治疗区分开来,后者尚未确立临床疗效。临床前研究显示其对神经元兴奋性、胶质细胞和免疫激活、内皮功能障碍、氧化和亚硝化应激、线粒体损伤、纤维化和调节性细胞死亡具有连贯作用。这些发现支持在神经退行性疾病、缺血再灌注损伤、糖尿病心血管疾病、免疫介导疾病、肝肾损伤及特定癌症中进一步研究。转化受限于产品异质性、暴露量差异、靶点结合不确定性、模型差异、药物相互作用及样本量不足的试验。标准化产品、基于暴露量的给药、药效学生物标志物、反应者富集设计及适应症特异性随机研究可解决这些障碍。植物大麻素代表了一种有前景的治疗平台,其潜力将通过将特定化合物和制剂与生物学一致的疾病、机制、治疗窗口及患者人群相匹配而得到最佳实现。
Junctional cadherin 5-associated protein (JCAD/KIAA1462) is an endothelial junctional protein encoded by a locus robustly associated with coronary artery disease and myocardial infarction in genome-wide association studies. Initially identified as a structural component of endothelial cell-cell junctions, JCAD has since emerged as a mechanosensor and regulator of key intracellular pathways (i.e. Hippo/YAP, PI3K/Akt, and mitogen-activated protein kinase/extracellular signal-regulated kinase) with functional consequences for endothelial homeostasis, inflammation, and vascular tone. In this review, we summarize the current understanding of JCAD biology, from its molecular features and pathway interactions to its experimental roles in atherosclerosis, arterial thrombosis, and ischaemic stroke. We further discuss emerging translational evidence suggesting circulating JCAD as an independent predictor of adverse cardiovascular events in patients with acute coronary syndromes, and its prognostic potential in ischaemic stroke. The review also addresses the expanding biology of JCAD within the cardiovascular system, hypothesizing links to conditions, such as hypertension, heart failure with preserved ejection fraction, and calcific aortic valve disease, as well as key limitations and therapeutic challenges. Overall, the available evidence highlights JCAD as a biologically plausible and potentially clinically relevant endothelial mediator, though independent validation and substantial mechanistic work remain necessary before its translational potential can be fully realized.
中文摘要:连接区钙黏蛋白5相关蛋白(JCAD/KIAA1462)是一种内皮连接蛋白,由全基因组关联研究中与冠心病和心肌梗死强相关的基因座编码。JCAD最初被鉴定为内皮细胞间连接的结构成分,随后被发现是机械传感器并调节关键细胞内通路(即Hippo/YAP、PI3K/Akt以及丝裂原活化蛋白激酶/细胞外信号调节激酶),对内皮稳态、炎症和血管张力具有功能影响。本综述总结了当前对JCAD生物学的理解,涵盖其分子特征、通路相互作用及其在动脉粥样硬化、动脉血栓形成和缺血性卒中中的实验作用。我们进一步讨论了新兴的转化证据,表明循环JCAD是急性冠脉综合征患者不良心血管事件的独立预测因子,并在缺血性卒中中具有预后潜力。该综述还探讨了JCAD在心血管系统中不断扩展的生物学特性,假设其与射血分数保留的心力衰竭、高血压和钙化主动脉瓣疾病等条件存在联系,并指出了关键的限制因素和治疗挑战。总体而言,现有证据表明JCAD是一种生物学上合理且可能具有临床相关性的内皮介质,但在其转化潜力得到充分实现之前,仍需进行独立验证和大量的机制研究。
2痴呆与认知障碍 (21篇)
临床研究 (6篇)
Slow waves during sleep are fundamental for neural homeostasis, metabolic regulation, and waste clearance and are known to be altered in neurodegenerative diseases. Sleep-like slow waves (SLSWs) have been observed in awake, healthy individuals, where they are linked to fluctuations in vigilance and mind-wandering. Whether SLSWs are altered in Parkinson's disease (PD), and whether such alterations contribute to psychiatric or cognitive complications, remains unknown. In a cohort of 84 nondemented patients with PD and 30 healthy older adults, we found that SLSWs occurred more frequently in patients with PD. Hallucinatory traits in patients with PD were associated with higher SLSW amplitude, especially over frontocentral regions. Moreover, more prominent SLSWs were associated with poorer cognitive functions. We conclude that, whereas slow waves during sleep have positive physiological functions, exacerbated diurnal SLSWs may reflect responses related to PD neuropathology, at the cost of hallucinations and reduced cognitive function.
中文摘要:睡眠中的慢波对神经稳态、代谢调节和废物清除至关重要,且在神经退行性疾病中已知会发生改变。在清醒的健康个体中已观察到类似睡眠的慢波(SLSWs),它们与警觉性波动和思维游移有关。SLSWs 是否帕金森病(PD)患者中发生改变,以及这种改变是否导致精神或认知并发症,目前尚不清楚。在一组包含84名非痴呆PD患者和30名健康老年人的队列中,我们发现PD患者的SLSWs出现频率更高。PD患者的幻觉特征与较高的SLSW振幅相关,尤其是在额中央区。此外,更显著的SLSWs与较差的认知功能相关。我们得出结论,尽管睡眠中的慢波具有积极的生理功能,但加剧的日间SLSWs可能反映与PD神经病理学相关的反应,代价是出现幻觉和认知功能降低。
Associations of common infections with Alzheimer disease (AD) risk have been reported. A hypothesized mechanism for these is cerebral β-amyloid (Aβ) aggregation as a defense to infection. We studied whether serologic measures of several infections in the UK population are associated with measures of AD neuropathology. This prospective association study used data from the 1946 British birth cohort. Circulating antibodies against 14 pathogens, measured at age 60-64 years, were modelled as pathogen serostatus (indicating lifetime exposure to an agent), pathogen burden indices (measuring cumulative exposure to 2+ pathogens), and seroreactivity tertiles (indicating recent immunologic activity against pathogens). Associations of these were tested with plasma phosphorylated tau at threonine 217 (p-tau217) (primary outcome) and Aβ status (secondary outcome), measured with PET scans, at ages 69-71 years. Modelling used multivariable quantile and logistic regression. Model 1 adjusted for sex and ages at serology and outcome assessment, and models 2 and 3 additionally adjusted for APOE ε4 carriage and education, respectively. We also tested for interactions in associations by APOE ε4 carriage, education, and sex, and for interactions between herpes simplex virus 1 exposure with cytomegalovirus (CMV) and varicella zoster virus (VZV) exposure. A total of 1,356 and 424 individuals had complete data for p-tau217 and Aβ-PET analyses, respectively. Mean age at p-tau217 was 69.9 years (SD 0.7), and 51.3% of participants were female. Median p-tau217 was 0.30 pg/mL (interquartile range 0.21-0.44). 28.3% had Aβ-positive scans. No notable associations were observed for serology measures with either outcome in main models, except for an unexpected association of herpes simplex virus 2 seropositivity with lower p-tau217 at the 75th quantile (-0.07 pg/mL in seropositive individuals; 95% CI -0.10 to -0.03). Odds of Aβ-PET positivity may have been higher for individuals seropositive for Epstein-Barr virus (odds ratio [OR] 2.84; 95% CI 0.95-8.52) and Toxoplasma gondii (OR 1.69; 95% CI 0.94-3.05). There were also potential interactions in p-tau217 associations by APOE ε4 carriage (for Helicobacter pylori and CMV) and educational attainment (for H pylori). These findings do not imply associations between exposures to many common infections and AD neuropathologies. The possibility of pathogen interactions with APOE ε4 carriage and education in relation to AD neuropathology warrants further study.
中文摘要:常见感染与阿尔茨海默病风险的关联已有报道,其假设机制是大脑β-淀粉样蛋白聚集作为对感染的防御反应。本研究旨在探讨英国人群中几种感染的血清学指标是否与阿尔茨海默病的神经病理指标相关。该前瞻性关联研究使用了1946年英国出生队列的数据。在60至64岁年龄组测量的针对14种病原体的循环抗体被建模为病原体血清状态(指示终生暴露于某病原体)、病原体负担指数(测量暴露于2种及以上病原体的累积情况)和血清反应三分位数(指示对病原体的近期免疫活性)。这些指标与69至71岁时通过PET扫描测量的血浆磷酸化tau蛋白(T217位点,p-tau217,主要结局)和淀粉样蛋白β状态(次要结局)之间的关联采用多变量分位数回归和逻辑回归模型进行测试。模型1调整了性别以及血清学和结局评估时的年龄,模型2和3分别额外调整了APOE ε4携带情况和教育程度。我们还测试了由APOE ε4携带情况、教育程度和性别引起的关联交互作用,以及单纯疱疹病毒1型暴露与巨细胞病毒和水痘-带状疱疹病毒暴露之间的交互作用。共有1,356名个体拥有p-tau217分析的完整数据,424名个体拥有Aβ-PET分析的完整数据。p-tau217的平均年龄为69.9岁(标准差0.7),51.3%的参与者为女性。中位p-tau217为0.30 pg/mL(四分位距0.21-0.44)。28.3%的个体Aβ扫描呈阳性。在主模型中,血清学指标与任一结局均未观察到显著关联,除了单纯疱疹病毒2型血清阳性在75百分位数处与较低的p-tau217存在意外关联(血清阳性个体为-0.07 pg/mL;95%置信区间-0.10至-0.03)。EB病毒血清阳性和弓形虫血清阳性个体的Aβ-PET阳性可能性可能较高(比值比分别为2.84和1.69,95%置信区间分别为0.95-8.52和0.94-3.05)。此外,还存在由APOE ε4携带情况(针对幽门螺杆菌和巨细胞病毒)和教育程度(针对幽门螺杆菌)引起的p-tau217关联的潜在交互作用。这些发现并不暗示许多常见感染暴露与阿尔茨海默病神经病理学之间存在关联。病原体与APOE ε4携带情况及教育程度在阿尔茨海默病神经病理学方面的相互作用可能性值得进一步研究。
Plasma biomarkers of Alzheimer disease (AD) neuropathology (amyloid-β42 to amyloid β40 [Aβ42/40] ratio, phosphorylated tau at threonine [p-tau181]), neurodegeneration (neurofilament light [NfL]), and neuroinflammation (glial fibrillary acidic protein [GFAP]) in late-life are associated with cognitive decline. Whether these biomarkers in midlife are predictive of subsequent cognitive decline, and whether they are associated with different cognitive domains, is uncertain. In this study, we investigated associations of midlife and late-life plasma Aβ42/40, p-tau181, NfL, and GFAP with late-life change in domain-specific (memory, language, and executive function) and global cognitive function. We performed a prospective cohort analysis of the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Outcome follow-up was from ARIC visit 5 (2011-2013) to visit 9 (2021-2022). We included all individuals from ARIC field centers (Jackson, Mississippi; Forsyth County, North Carolina; Washington County, Maryland; and Minneapolis suburbs, Minnesota) with biomarkers measured from stored specimens in midlife (visit 3, 1993-1995, mean age 59.0 years) and late-life (visit 5, 2011-2013, mean age 76.8 years). Aβ42/40, p-tau181, NfL, and GFAP were measured with the Quanterix Simoa platform and standardized to visit 3 to facilitate cross-biomarker comparisons of their rate of change from midlife to late-life. We estimated change in memory, language, executive function, and global cognition factor scores from visit 5 to visit 9 with linear mixed-effect models. In 1,515 included participants, 60.7% (n = 920) were female and 25.5% (n = 387) were Black. Each SD increase in p-tau181 in midlife was significantly associated with faster late-life memory decline (β = -0.030 [95% CI -0.059 to -0.001] SD. Midlife Aβ42/40, NfL, and GFAP were not associated with subsequent decline in any cognitive domain. In late-life, p-tau181, NfL, and GFAP were significantly associated with faster decline in different cognitive domains, with the strongest associations seen with memory (β = -0.091 [95% CI -0.123 to -0.058] SD; β = -0.064 [95% CI -0.106 to -0.023] SD; and β = -0.048 [95% CI -0.082 to -0.013] SD, respectively). Midlife p-tau181 was associated with faster 11-year memory decline beginning 20 years later in the ARIC cohort, which underscores a potentially long prodromal phase of cognitive decline that could precede dementia onset. In late-life, biomarkers for AD, neurodegeneration, and neuroinflammation were associated with faster decline across different cognitive domains, but associations remained strongest for p-tau181 and memory.
中文摘要:晚期阿尔茨海默病血液生物标志物与11年认知衰退相关。中年期这些生物标志物是否预测后续认知衰退及其与不同认知领域的关联尚不明确。本研究调查了中年和晚期血浆淀粉样蛋白β42/40比值、磷酸化tau蛋白(p-tau181)、神经丝轻链(NfL)和胶质纤维酸性蛋白(GFAP)与晚期特定领域(记忆、语言和执行功能)及整体认知功能变化的关联。我们对动脉粥样硬化风险社区神经认知研究进行了前瞻性队列分析,随访期为ARIC第5次访视至第9次访视。纳入所有在中年和晚期储存标本中测量生物标志物的参与者。使用Quanterix Simoa平台测量生物标志物并标准化以比较其中晚期变化率。采用线性混合效应模型估计从第5次到第9次访视的记忆、语言、执行功能和整体认知因子得分变化。在1515名参与者中,60.7%为女性,25.5%为黑人。中年期p-tau181每增加1个标准差与晚期更快的记忆衰退显著相关。中年期的Aβ42/40、NfL和GFAP与任何认知领域的后续衰退均无关联。在晚期,p-tau181、NfL和GFAP与不同认知领域的更快衰退显著相关,其中与记忆的关联最强。中年期p-tau181与ARIC队列中20年后开始的11年记忆加速衰退相关,强调了痴呆发作前可能存在较长的前驱阶段。晚期阿尔茨海默病、神经变性和神经炎症生物标志物与不同认知领域的更快衰退相关,但p-tau181与记忆的关联依然最强。
APOE ɛ4 is the strongest genetic risk factor for late-onset Alzheimer disease, while ɛ2 is associated with decreased risk. However, it is unclear how these genotypes relate to cognitive decline among those aged older than 90+. We examined associations of ɛ4 and ɛ2 with longitudinal change in 3 cognitive domains among individuals aged 90+. LifeAfter90 is an ongoing longitudinal multiethnic cohort study of those aged 90+. APOE genotyping was conducted using DNA extracted from saliva. Two dichotomous exposures were defined as ɛ4 carriers (ɛ2/ɛ4, ɛ3/ɛ4, or ɛ4/ɛ4 genotypes) vs non-ɛ4-carriers with no ɛ4 allele and ɛ2 carriers (ɛ2/2, ɛ2/3 genotypes) vs non-ɛ2-carriers (ɛ3/ɛ3, ɛ2/ɛ4, ɛ3/ɛ4, or ɛ4/ɛ4). Executive function (EF), semantic memory (SM), and verbal episodic memory (VEM) were measured every 6 months on up to 11 occasions using the Spanish and English Neuropsychological Scales. Time to all-cause mortality was calculated from baseline to death. We fit linear mixed-effects (LME) models and joint models (LME and Cox proportional hazard submodels) to account for the competing risk of death. Models adjusted for age and sex. We evaluated 445 participants (mean age at baseline 93 years, SD 2.31, range 90-104; 59% female). In total, 20% were ɛ4 carriers, 15% were ɛ2 carriers, and 54% died during follow-up. The ethnoracial composition was 21% African American/Black, 22% as Asian, 16% as Hispanic/Latinx, 9% as multiracial/other, and 32% as White. The mean follow-up time was 3.9 years (SD 1.63, range 0.68-6.67). Neither ɛ4 nor ɛ2 carriers averaged substantially greater or lesser mortality hazard than noncarriers. In joint models, ɛ4 carriers had faster decline in EF (β = -0.07, 95% CI -0.12 to -0.02), but similar decline in VEM (β = -0.01, 95% CI -0.08 to 0.05) and SM (β = -0.03; 95% CI -0.08 to 0.02). APOE ɛ2 carriers had similar decline in EF (β = 0.01, 95% CI -0.05 to 0.08) and SM (β = 0.01, 95% CI -0.05 to 0.08) but slower decline in VEM (β = 0.07, 95% CI 0.00-0.15) compared with noncarriers. Longitudinal results were similar for LME and joint models. After accounting for the competing risk of death, the negative consequences of ɛ4 on EF decline extend to those with exceptional longevity.
中文摘要:APOE ε4是晚发性阿尔茨海默病最强的遗传风险因素,而ε2与风险降低相关。然而,这些基因型与90岁以上人群认知衰退的关系尚不明确。我们考察了ε4和ε2与90岁以上个体三个认知领域纵向变化的关联。LifeAfter90是一项针对90岁以上人群的持续进行的纵向多民族队列研究。使用从唾液提取的DNA进行APOE基因分型。定义了两个二分暴露变量:ε4携带者(ε2/ε4、ε3/ε4或ε4/ε4基因型)与非ε4携带者(无ε4等位基因)以及ε2携带者(ε2/ε2、ε2/ε3基因型)与非ε2携带者(ε3/ε3、ε2/ε4、ε3/ε4或ε4/ε4)。每6个月使用西班牙语和英语神经心理量表对执行功能、语义记忆和言语情景记忆进行测量,最多11次。计算从基线到死亡的全因死亡率时间。拟合线性混合效应模型和联合模型(线性混合效应和Cox比例风险子模型)以考虑死亡的竞争风险。模型调整了年龄和性别。我们评估了445名参与者(基线平均年龄93岁,标准差2.31,范围90-104;女性占59%)。其中20%为ε4携带者,15%为ε2携带者,54%在随访期间死亡。族裔构成为非裔美国人/黑人21%,亚裔22%,西班牙裔/拉丁裔16%,多种族/其他9%,白人32%。平均随访时间为3.9年(标准差1.63,范围0.68-6.67)。ε4和ε2携带者的平均死亡风险并未显著高于或低于非携带者。在联合模型中,ε4携带者的执行功能下降更快,但言语情景记忆和语义记忆的下降相似。APOE ε2携带者与执行功能和语义记忆的下降相似,但与言语情景记忆的下降较慢相比,与非携带者存在差异。纵向结果在线性混合效应模型和联合模型中相似。在考虑死亡的竞争风险后,ε4对执行功能下降的负面影响延伸至具有非凡长寿的人群。
From 2021 to 2024, 3 amyloid monoclonal antibody medications (aducanumab, lecanemab, and donanemab) were approved by the US Food and Drug Administration for treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer disease (AD). We determined the demographics and social drivers of health associated with utilization and initial adherence of these medications. We used the Vizient database to identify patients with MCI or dementia using an ICD-10 coding definition. Propensity score matching was used to match patients who received an antiamyloid medication to those who did not, based on date of MCI/dementia diagnosis and follow-up. Social drivers of health were assessed using the Vizient Vulnerability Index (VVI), a neighborhood-level measure of socioeconomic vulnerability. Logistic regression determined associations between demographics, Elixhauser comorbidity, and VVI, with utilization of antiamyloid medications. Poisson regression determined associations between demographic, Elixhauser comorbidity, and VVI and initial adherence (measured as days supplied) of antiamyloid medications. We identified 1,198,362 participants with MCI/dementia, of whom 2,427 (0.2%) were prescribed an antiamyloid medication. Of those prescribed an antiamyloid medication, 1,696 (69.9%) were matched to participants with MCI/dementia that were not prescribed antiamyloid medications (mean age 75.5 [SD 9.5], 56.1% female, 80.1% non-Hispanic White). We found that higher age (odds ratio [OR] 0.93, 95% CI 0.92-0.94), higher Elixhauser comorbidity index (OR 0.56, 95% CI 0.52-0.59), being non-Hispanic Black (OR 0.14, 95% CI 0.09-0.23), and being Hispanic (OR 0.21, 95% CI 0.13-0.36) associated with lower odds of receiving an antiamyloid medication. Furthermore, having greater VVI was associated with lower odds of receiving an antiamyloid medication. By contrast, only higher Elixhauser comorbidity score was associated with lower initial medication adherence (rate ratio 0.94, 95% CI 0.93-0.96), but not age, sex, race/ethnicity, and overall vulnerability. We found that younger, non-Hispanic White patients, with fewer comorbidities, and lower vulnerability, were more likely to receive antiamyloid medications. By contrast, among patients receiving an antiamyloid medication, only higher comorbidity score associated with lower initial medication adherence. These findings indicate a potential disparity in medication access for US patients with MCI/dementia that could become problematic barriers to care as medications for dementia continue to evolve.
中文摘要:2021年至2024年,美国食品药品监督管理局批准了三种抗淀粉样蛋白单克隆抗体药物(阿杜卡奴单抗、仑卡奈单抗和多奈单抗)用于治疗轻度认知障碍及阿尔茨海默病所致轻度痴呆。本研究确定了与这些药物使用及初始依从性相关的人口统计学特征和健康社会决定因素。我们利用Vizient数据库,通过ICD-10编码定义识别患有轻度认知障碍或痴呆的患者。采用倾向评分匹配法,根据轻度认知障碍或痴呆的诊断日期和随访时间,将接受抗淀粉样蛋白药物治疗的患者与未接受该治疗的患者进行匹配。使用Vizient脆弱性指数评估健康社会决定因素,这是一个衡量社会经济脆弱性的社区层面指标。逻辑回归分析确定了人口统计学特征、Elixhauser合并症指数及脆弱性指数与抗淀粉样蛋白药物使用之间的关联。泊松回归分析确定了人口统计学特征、Elixhauser合并症指数及脆弱性指数与抗淀粉样蛋白药物初始依从性(以供应天数衡量)之间的关联。我们共识别出1,198,362名患有轻度认知障碍或痴呆的参与者,其中2,427人(0.2%)被处方了抗淀粉样蛋白药物。在那些被处方抗淀粉样蛋白药物的患者中,有1,696人(69.9%)与未被处方抗淀粉样蛋白药物的轻度认知障碍或痴呆患者进行了匹配(平均年龄75.5岁,标准差9.5,女性占56.1%,非西班牙裔白人占80.1%)。我们发现,年龄较大(比值比0.93,95%置信区间0.92-0.94)、Elixhauser合并症指数较高(比值比0.56,95%置信区间0.52-0.59)、为非西班牙裔黑人(比值比0.14,95%置信区间0.09-0.23)以及为西班牙裔(比值比0.21,95%置信区间0.13-0.36)与接受抗淀粉样蛋白药物的几率较低相关。此外,较高的脆弱性指数也与接受抗淀粉样蛋白药物的几率较低相关。相比之下,只有较高的Elixhauser合并症评分与较低的初始药物依从性相关(率比0.94,95%置信区间0.93-0.96),而年龄、性别、种族/民族和整体脆弱性则无此关联。我们发现,较年轻、非西班牙裔白人、合并症较少且脆弱性较低的患者更有可能接受抗淀粉样蛋白药物治疗。相比之下,在接受抗淀粉样蛋白药物的患者中,只有较高的合并症评分与较低的初始药物依从性相关。这些发现表明,美国轻度认知障碍或痴呆患者在药物获取方面可能存在差异,随着痴呆治疗药物的不断演进,这可能成为护理的潜在障碍。
To systematically evaluate the effects of probiotics or synbiotics on cognitive function in individuals with mild cognitive impairment, Alzheimer's disease, and related cognitive decline. PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 20 September 2026. Randomized controlled trials comparing viable probiotics or synbiotics with placebo or usual care were included. Cognitive changes were pooled as standardized mean differences (SMDs) using a random-effects model. Subgroup, sensitivity, RoB 2, Egger, and GRADE assessments were conducted. Ten trials involving 739 participants were included. Probiotics or synbiotics were associated with a possible improvement in cognitive function (SMD = 0.50, 95% CI: 0.19, 0.81; P = 0.002; Ι2 = 76%). The approximate 95% prediction interval was -0.57-1.57. No statistically significant differences in treatment effects were detected between subgroups defined by disease category, intervention duration, intervention type, study-level mean age, strain composition, dosage, or cognitive instrument. The effect was numerically larger in studies with a mean age ≤ 70 years, but this difference was not significant (P = 0.17) and was sensitive to individual studies. Sensitivity analyses maintained the direction and statistical significance of the pooled effect. Egger's test showed no significant small-study effects (Z = 1.00, P = 0.318). The certainty of evidence was very low. Probiotics or synbiotics may improve cognitive test performance, but the certainty of evidence is very low because of risk of bias, substantial heterogeneity, and imprecision. Exploratory subgroup analyses did not provide clear evidence that disease category, intervention duration, intervention type, study-level mean age, strain composition, dosage, or cognitive assessment instrument modified the treatment effect. Larger, well-designed randomized trials are needed.
中文摘要:目的:系统评估益生菌或合生元对轻度认知障碍、阿尔茨海默病及相关认知衰退个体认知功能的影响。方法:检索PubMed、Embase、Web of Science和Cochrane Library数据库,纳入时间从建库至2026年9月20日。纳入比较活体益生菌或合生元与安慰剂或常规护理的随机对照试验。采用随机效应模型汇总认知变化的标准化均数差(SMD)。进行亚组、敏感性分析、RoB 2偏倚风险评估、Egger检验和GRADE评估。结果:共纳入10项涉及739名参与者的试验。益生菌或合生元可能与认知功能改善相关(SMD = 0.50,95% CI: 0.19, 0.81;P = 0.002;I² = 76%)。近似95%预测区间为-0.57至1.57。按疾病类别、干预持续时间、干预类型、研究水平平均年龄、菌株组成、剂量或认知量表划分的亚组间,治疗效果的统计学差异均不显著。在平均年龄≤70岁的研究中效应值数值较大,但该差异无统计学意义(P = 0.17)且对单项研究敏感。敏感性分析保持了汇总效应的方向和统计学显著性。Egger检验显示无显著的小样本效应(Z = 1.00,P = 0.318)。证据确定性很低。结论:益生菌或合生元可能改善认知测试表现,但由于偏倚风险、高度异质性和不精确性,证据确定性很低。探索性亚组分析未提供明确证据表明疾病类别、干预持续时间、干预类型、研究水平平均年龄、菌株组成、剂量或认知评估工具修饰了治疗效果。需要更大规模、设计良好的随机对照试验。
基础研究 (15篇)
Brain aging is a complex process with profound health and societal consequences. However, the molecular and cellular pathways that govern its progression, and inter- and intra-individual variation, remain poorly defined. We present a transcriptomic atlas of 5.3 million cells from 582 samples spanning 11 brain regions of 55 rhesus macaques (aged 0.5-21 years). We identify age-depleted and vulnerable neuronal populations and subtle, age-associated compositional differences in glia-detectable only at single-cell resolution. We chart convergent and divergent age-associated molecular signatures across regions and cell types, which include sex-specific signatures that could underlie biases in neurological disorders. These signatures overlap those of Alzheimer's disease (AD), which suggests that aging and AD share molecular roots that emerge at different ages and in region- and sex-specific windows of vulnerability. This work provides a temporal, regional, and sex-stratified atlas of the aging primate brain, offering insights into cell-type-specific vulnerabilities and regional heterogeneity with translational human relevance.
中文摘要:脑老化是一个具有深远健康和社会影响的复杂过程。然而,控制其进展的分子和细胞通路以及个体间和个体内的变异仍不明确。我们构建了涵盖55只恒河猴(年龄0.5至21岁)11个脑区的582个样本中530万个细胞的转录组图谱。我们鉴定了随年龄减少和易感的神经元群体,以及在单细胞分辨率下才可检测到的胶质细胞微妙的年龄相关组成差异。我们绘制了跨脑区和细胞类型的收敛与发散年龄相关分子特征,其中包括可能导致神经系统疾病偏见的性别特异性特征。这些特征与阿尔茨海默病(AD)的特征重叠,表明老龄化和AD共享在不同年龄和区域及性别特异性易感窗口中出现的分子根源。这项工作提供了灵长类动物大脑老化的时间、区域和性别分层图谱,为理解细胞类型特异性脆弱性和区域异质性提供了具有转化人类相关性的见解。
Aging is the major risk factor for neurodegenerative disease, yet how it affects different cells in the primate brain remains unclear. In this issue of Cell, Yang et al. present a single-nucleus atlas of the aging macaque brain that, together with recent work by Zhang et al., reveals context-dependent aging programs, sex-biased transcriptional aging, and molecular links to Alzheimer's disease.
中文摘要:衰老是神经退行性疾病的主要风险因素,然而其如何影响灵长类动物大脑中的不同细胞仍不清楚。在本期Cell杂志中,Yang等人展示了一个衰老猕猴大脑的单细胞核图谱,结合Zhang等人的近期研究,揭示了情境依赖性的衰老程序、性别偏向的转录组衰老以及阿尔茨海默病的分子联系。
TDP-43 nuclear depletion is a defining pathological feature of amyotrophic lateral sclerosis and frontotemporal dementia that induces widespread cryptic splicing defects in hundreds of transcripts1-8. Despite this, whether TDP-43 loss affects synaptic function has remained unclear. Here we show that TDP-43 loss induces a predegenerative state in which neurons remain structurally intact but suffer a substantial breakdown in synaptic communication. Genetic correction of a single cryptic splicing event in UNC13A was sufficient to rescue these deficits. We developed splice-switching antisense oligonucleotides that correct UNC13A cryptic splicing in human cortical and spinal motor neurons and in a humanized mouse model. In human neurons this intervention restored spontaneous and evoked synaptic vesicle release, release probability at individual synapses and wider network synchrony. Together, this establishes UNC13A splice correction as a mechanistically defined and genetically validated therapeutic strategy relevant to roughly 97% of patients with amyotrophic lateral sclerosis and roughly 50% of patients with frontotemporal dementia with TDP-43 pathology.
中文摘要:TDP-43核内耗竭是肌萎缩侧索硬化症和额颞叶痴呆的定义性病理特征,会导致数百种转录本出现广泛的隐蔽剪接缺陷。尽管存在这一现象,但TDP-43缺失是否影响突触功能仍不清楚。本研究显示,TDP-43缺失会诱导神经元进入一种退行前期状态,即神经元结构保持完整但突触通讯发生严重障碍。对UNC13A单个隐蔽剪接事件进行遗传学纠正足以挽救这些缺陷。我们开发了剪接转换反义寡核苷酸,在人皮层和脊髓运动神经元以及人源化小鼠模型中纠正了UNC13A的隐蔽剪接。在人源神经元中,该干预措施恢复了自发性和诱发性突触囊泡释放、单个突触的释放概率以及更广泛的网络同步性。综上所述,这确立了UNC13A剪接纠正作为一种机制明确且经遗传学验证的治疗策略,适用于约97%的肌萎缩侧索硬化症患者和约50%伴有TDP-43病理改变的额颞叶痴呆患者。
Prion diseases are inevitably fatal, rare, and infectious neurodegenerative diseases of humans and animals. Initially, they were thought to be caused by unconventional slow viruses, and early research therefore relied heavily on experimental approaches used in virology. This view changed with the discovery that the causative agent of these diseases is not a virus but a conformational variant of a host-encoded protein. The conversion of the normally soluble host prion protein into an insoluble, infectious form enables the spread of pathology between cells and throughout the host. Over the past two decades, it has become clear that similar prion-like mechanisms of protein misfolding and templated self-propagation also underlie more common, non-infectious neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Thus, just as the cell biology of viruses provided important insights into the first studies of prion cell biology, discoveries in prion research have profoundly influenced our understanding of the cell biology of other amyloid-forming proteins. In this review, we discuss common principles and differences in the cell biology of prions and prion-like particles. We also highlight the seminal contributions of the late Dr. Byron Caughey and his laboratory, whose pioneering work has helped to shape our current understanding of how pathogenic protein aggregates form, propagate, and ultimately cause devastating neurological diseases.
中文摘要:朊病毒疾病是人和动物中必然致命、罕见且具有传染性的神经退行性疾病。最初人们认为它们由非典型慢病毒引起,因此早期研究严重依赖病毒学领域的实验方法。随着发现该疾病的致病因子并非病毒而是宿主编码蛋白的构象变体,这一观点发生了改变。正常可溶性宿主朊病毒蛋白转化为不溶性、具有感染性的形式,使得病理过程能够在细胞间及整个宿主体内传播。过去二十年的研究清楚地表明,类似的朊病毒样蛋白质错误折叠和模板化自我复制机制也是阿尔茨海默病和帕金森病等更常见且非传染性神经退行性疾病的基础。因此,正如病毒细胞生物学为朊病毒细胞生物学的早期研究提供了重要见解一样,朊病毒研究的发现也深刻影响了我们对其他淀粉样蛋白形成蛋白细胞生物学的理解。在本综述中,我们讨论了朊病毒和朊病毒样颗粒在细胞生物学上的共同原则与差异。我们还重点介绍了已故的拜伦·考吉博士及其实验室做出的开创性贡献,他们的工作帮助塑造了我们对致病性蛋白质聚集体如何形成、传播并最终导致毁灭性神经系统疾病的当前理解。
Mitochondrial DNA (mtDNA)-driven innate immune signaling sustains chronic neuroinflammation in neurological diseases such as Alzheimer's disease (AD), yet how this pathway is regulated in microglia remains poorly understood. Here, we identify the histone acetyltransferase KAT7 (HBO1) as a central epigenetic regulator that links chromatin remodeling to mitochondrial immune activation. KAT7 and its histone mark H3K14ac are elevated in microglia from 5×FAD mice and human AD brains. Integrative transcriptomic and epigenomic analyses reveal that KAT7 activates transcription of cytidine/uridine monophosphate kinase 2 (Cmpk2), a mitochondrial kinase essential for mtDNA synthesis. Loss of KAT7 reduces Cmpk2 expression, impairs mtDNA replication and release, and consequently suppresses cyclic guanosine monophosphate-AMP synthase (cGAS)-stimulator of interferon genes (STING) and NLRP3 signaling. Importantly, both microglia-specific deletion and pharmacological inhibition of KAT7 mitigate cytosolic mtDNA-induced neuroinflammation, decrease β-amyloid burden, restore synaptic plasticity, and improve cognitive function in 5×FAD mice. Together, these findings uncover an epigenetic-mitochondrial axis sustaining microglial pathogenicity and establish KAT7 as a potential therapeutic target for AD.
中文摘要:线粒体DNA驱动的先天免疫信号维持着阿尔茨海默病等神经系统疾病的慢性神经炎症,然而该通路在小胶质细胞中的调控机制尚不明确。本研究鉴定出组蛋白乙酰转移酶KAT7(HBO1)为连接染色质重塑与线粒体免疫激活的核心表观遗传调节因子。在5×FAD小鼠及人类阿尔茨海默病大脑的小胶质细胞中,KAT7及其组蛋白标记H3K14ac水平升高。整合转录组和表观基因组分析显示,KAT7激活胞苷尿苷单磷酸激酶2(Cmpk2)的转录,后者是线粒体DNA合成所必需的线粒体激酶。KAT7缺失会降低Cmpk2表达,损害线粒体DNA复制与释放,进而抑制cGAS-STING和NLRP3信号通路。重要的是,小胶质细胞特异性敲除或药理学抑制KAT7均可减轻胞质线粒体DNA诱导的神经炎症,降低β-淀粉样蛋白负荷,恢复突触可塑性并改善5×FAD小鼠的认知功能。综上所述,这些发现揭示了一个维持小胶质细胞致病性的表观遗传-线粒体轴,并将KAT7确立为阿尔茨海默病的潜在治疗靶点。
Extracellular vesicles (EVs) can modify pathological progression in Alzheimer's disease (AD), the most common neurodegenerative disease in older adults, by spreading pathogenic factors. However, the function of mitovesicles (mtVs)-a recently identified subset of EVs-in AD remain unknown. Here we show that release of mtVs is enriched in brain tissue from patients with AD and 5×FAD mice. Administration of 5×FAD mouse brain-derived mtVs (ADmtVs) induced AD-like behavioral and pathological changes in wild-type mice and accelerated disease progression of AD mice. Moreover, the release of mtVs was regulated by mitochondrial respiratory metabolism, and blocking the release of mtVs significantly alleviated AD-like phenotypes. Proteomic analysis identified Ggt1 as a highly enriched protein in ADmtVs. Inhibiting Ggt1 expression and activity mitigated AD-like phenotypes of 5×FAD mice and delayed ADmtV-induced disease progression, suggesting Ggt1 as a pathological cargo of ADmtVs. Our findings highlight the pathological roles of mtVs in AD and highlight mtVs and Ggt1 as potential therapeutic targets.
中文摘要:细胞外囊泡可通过传播致病因子改变阿尔茨海默病的病理进程,该病是老年人中最常见的神经退行性疾病。然而,线粒体来源的囊泡这一新近鉴定的细胞外囊泡亚群在阿尔茨海默病中的功能尚不明确。本研究显示,阿尔茨海默病患者脑组织及5×FAD小鼠脑组织中富含线粒体来源囊泡的释放。给予野生型小鼠5×FAD小鼠脑来源的线粒体来源囊泡可诱导其出现类似阿尔茨海默病的行为与病理改变,并加速阿尔茨海默病小鼠的疾病进展。此外,线粒体来源囊泡的释放受线粒体呼吸代谢调节,阻断其释放可显著缓解类似阿尔茨海默病的表型。蛋白质组学分析鉴定出谷氨酰转移酶1为阿尔茨海默病来源线粒体来源囊泡中高度富集的蛋白。抑制谷氨酰转移酶1的表达与活性可减轻5×FAD小鼠的类似阿尔茨海默病表型并延缓其诱导的疾病进展,表明谷氨酰转移酶1是阿尔茨海默病来源线粒体来源囊泡的病理货物。本研究结果强调了线粒体来源囊泡在阿尔茨海默病中的病理作用,并指出线粒体来源囊泡与谷氨酰转移酶1作为潜在的治疗靶点。
Retinal imaging has traditionally described tissue and layer level pathology, whereas direct assessment of individual cells in the living human retina has been limited by ocular aberrations, optical contrast and image analysis constraints. Adaptive optics (AO) has substantially changed this landscape by improving lateral resolution and enabling in vivo visualization of photoreceptors, retinal pigment epithelium (RPE), ganglion-cell-layer structures, immune cells and microvasculature. This review discusses human retinal cellular imaging across three major AO-enhanced platforms: flood-illumination adaptive optics (FIAO), adaptive optics optical coherence tomography (AO-OCT) and adaptive optics scanning laser ophthalmoscopy (AOSLO). These modalities provide complementary capabilities, including rapid en face imaging, depth-resolved volumetric assessment and flexible confocal, non-confocal and fluorescence-based contrast. Recent progress is also being shaped by faster wavefront correction, wider-field acquisition, compressed multichannel imaging, sensorless AO and artificial intelligence (AI)-assisted reconstruction, segmentation and quantification. Beyond optical resolution, molecular labeling strategies are beginning to add biological specificity to retinal cellular imaging. Indocyanine green (ICG) supports AO-assisted assessment of RPE mosaic contrast, annexin V-based Detection of Apoptosing Retinal Cells (DARC) provides a molecular readout of retinal cell stress and apoptosis, and curcumin-based imaging has been explored as an experimental retinal amyloid marker in Alzheimer's disease. Together, these advances indicate a shift from high-resolution visualization alone towards cellular and molecular biomarkers of disease activity, progression and treatment response. Further translation will require standardized acquisition, robust automated analysis, multimodal validation and larger prospective studies across devices, disease populations and clinical sites.
中文摘要:视网膜成像传统上描述组织和层级的病理改变,而活体人眼视网膜单个细胞的直接评估受限于眼部像差、光学对比度和图像分析约束。自适应光学显著改变了这一局面,通过提高横向分辨率并实现视杆细胞、视网膜色素上皮、神经节细胞层结构、免疫细胞和微血管的体内可视化。本综述讨论了三种主要自适应光学增强平台上的活体人眼视网膜细胞成像:泛光照明自适应光学、自适应光学光学相干断层扫描和自适应光学扫描激光检眼镜。这些模式提供了互补的能力,包括快速面内成像、深度分辨体积评估以及灵活的共聚焦、非共聚焦和基于荧光的对比度。最近的进展还受到更快的波前校正、更宽视野采集、压缩多通道成像、无传感器自适应光学以及人工智能辅助重建、分割和量化的影响。除了光学分辨率外,分子标记策略开始为视网膜细胞成像增加生物学特异性。吲哚菁绿支持对视网膜色素上皮马赛克对比度的自适应光学辅助评估,基于膜联蛋白V的凋亡视网膜细胞检测提供了视网膜细胞应激和凋亡的分子读数,而基于姜黄素的成像在阿尔茨海默病中已被探索作为实验性视网膜淀粉样蛋白标记。这些进展共同表明,从单纯的高分辨率可视化向疾病活动、进展和治疗反应的细胞及分子生物标志物转变。进一步转化需要标准化的采集、稳健的自动分析、多模态验证以及跨设备、疾病人群和临床站点的大规模前瞻性研究。
Alzheimer's disease (AD) is driven by amyloid-β (Aβ) accumulation and a cascade of interconnected neurotoxic events, including oxidative stress, glutamate excitotoxicity, calcium dysregulation, and impaired neuroactive ligand-receptor signaling. To address the multifactorial nature of AD pathology, chiral d- or l-cysteine-functionalized covalent organic framework (COF) nanoparticles are developed as a multitarget nanotherapeutic platform. Both enantiomers effectively inhibit Aβ aggregation, scavenge reactive oxygen species, reduce extracellular glutamate levels, and attenuate calcium dysregulation. In parallel, d/l-Cys-COFs rescue compromised neuroactive ligand-receptor signaling, as evidenced by normalized expression of neuropeptide Y and brain-derived neurotrophic factor. In transgenic AD mice, d/l-Cys-COF treatment significantly improves memory and cognitive performance. Notably, the d-enantiomer affords superior neuroprotection through enhanced suppression of pathological intracellular calcium overload, whereas restoration of neuroactive ligand-receptor signaling remains chirality-independent. These findings identify chirality as a key design element for multitarget nanotherapeutics against AD, with enantioselective efficacy arising primarily from differential regulation of calcium dysregulation and shared restoration of neuroactive signaling contributing to the overall therapeutic benefit.
中文摘要:阿尔茨海默病由淀粉样蛋白β积累及氧化应激、谷氨酸兴奋性毒性、钙稳态失衡和神经活性配体受体信号受损等相互关联的神经毒性事件驱动。为应对该病理的多因素特性,本研究开发了手性D或L半胱氨酸功能化的共价有机框架纳米颗粒作为多靶点纳米治疗平台。两种对映体均能有效抑制淀粉样蛋白β聚集、清除活性氧、降低细胞外谷氨酸水平并减轻钙稳态失衡。同时,D/L-Cys-COFs挽救了受损的神经活性配体受体信号,表现为神经肽Y和脑源性神经营养因子表达恢复正常。在转基因阿尔茨海默病小鼠中,D/L-Cys-COF治疗显著改善了记忆和认知功能。值得注意的是,D对映体通过增强抑制病理性细胞内钙超载提供更优越的神经保护作用,而神经活性配体受体信号的恢复则具有手性非依赖性。这些发现确定手性是设计抗阿尔茨海默病多靶点纳米药物的关键要素,其对映选择性疗效主要源于钙稳态失衡的差异调节,而共享的神经活性信号恢复共同贡献了整体治疗效益。
Early detection of tauopathies is crucial for identifying disease onset and enabling effective management of disorders such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Alzheimer's disease (AD). Here, we present a highly sensitive and specific method for detecting early, non-fibrillar Tau oligomers before tangle formation. Among a series of synthesized quantum dots, only the nitrogen-phosphorus-doped carbon quantum dots (N,P-CQDs) demonstrated the desired specificity. These N,P-CQDs are derived from phosphoserine dimers linked through an unusual phosphate ester bond rather than a conventional amide bond. They are characterized as 3-7 nm in diameter and emit bright red fluorescence at 600 nm, enabling the specific detection of toxic oligomeric and fibrillar Tau species in vitro and in tau pathogenic brain tissues and cerebrospinal fluid (CSF). The N,P-CQD nanoprobe offers an advantage over conventional Thioflavin T staining because of its large 300-nm Stokes shift between excitation and emission, which minimizes background noise. The calculated fluorescence half-life (t1/2) was 1.66 μs, with a fluorescence decay time (τ) of approximately 3.0 μs, demonstrating the potential of the probe for ultrasensitive detection. The proposed integrated bio-opto-electronic platform, leveraging the specific and highly sensitive spectral response of N,P-CQD-functionalized nanoneedles to oligomeric tau aggregates, as determined in conjunction with biolayer interferometry (BLI), establishes a foundation for a real-time, minimally invasive future diagnostic tool for the detection of neurodegenerative disorders.
中文摘要:早期检测tau蛋白病对于识别疾病 onset 并有效管理皮质基底变性(CBD)、进行性核上性麻痹(PSP)和阿尔茨海默病(AD)等疾病至关重要。本研究提出了一种高灵敏度和特异性的方法,用于在缠结形成之前检测早期的非纤维化Tau寡聚体。在一系列合成的量子点中,只有氮磷掺杂碳量子点(N,P-CQDs)表现出所需的特异性。这些N,P-CQDs源自通过不寻常的磷酸酯键而非传统酰胺键连接的丝氨酸二聚体。其直径为3-7 nm,在600 nm处发出明亮的红色荧光,从而能够在体外以及tau致病脑组织和脑脊液(CSF)中特异性检测有毒的寡聚体和纤维化Tau物种。与传统的硫黄素T染色相比,N,P-CQD纳米探针具有激发和发射之间300 nm的大斯托克斯位移优势,这最大限度地减少了背景噪声。计算得出的荧光半衰期(t1/2)为1.66 μs,荧光衰减时间(τ)约为3.0 μs,证明了该探针用于超灵敏检测的潜力。所提出的集成生物光电子平台利用N,P-CQD功能化纳米针针对寡聚tau聚集体的特异性和高灵敏度光谱响应,并结合生物层干涉技术(BLI)确定,为未来实时、微创的诊断工具检测神经退行性疾病奠定了基础。
Neurotoxic intermediates formed during amyloid-β (Aβ) aggregation are thought to drive Alzheimer's disease, yet their rarity and transient nature have obscured their identity and formation pathways in the human brain. Here, we combine super-resolution microscopy and single-molecule functional imaging with kinetic modelling to classify Aβ intermediates according to their membrane-disrupting activity and connect their damaging effects to the aggregation pathways that generate them. Applying this framework to recombinant Aβ42, an Alzheimer's knock-in mouse model and human Alzheimer's brain tissue, we find two functionally distinct intermediate populations present across all systems. They form through separate aggregation routes and differ in their neurotoxicity, abundance and susceptibility to inhibition. Both damage neurons and glia, but only one converts into plaques. Suppressing these intermediates pharmacologically in mice reduces plaque burden, attenuates astrogliosis and improves cognition. Our findings connect model systems with human pathology and identify intermediate formation pathways as actionable therapeutic targets across protein-misfolding disorders.
中文摘要:淀粉样蛋白β(Aβ)聚集过程中形成的神经毒性中间体被认为驱动阿尔茨海默病,但其稀有性和瞬态特性使其在人类大脑中的身份和形成途径难以明确。本研究结合超分辨率显微镜、单分子功能成像与动力学建模,根据膜破坏活性对Aβ中间体进行分类,并将其损伤效应与生成它们的聚集途径联系起来。将该框架应用于重组Aβ42、阿尔茨海默病敲入小鼠模型及人类阿尔茨海默病脑组织,发现所有系统中均存在两种功能不同的中间体群体。它们通过独立的聚集途径形成,在神经毒性、丰度及对抑制的敏感性方面存在差异。两者均可损伤神经元和胶质细胞,但仅有一种可转化为斑块。在小鼠中药理抑制这些中间体可减少斑块负荷、减轻星形胶质细胞增生并改善认知功能。研究结果将模型系统与人类病理联系起来,并将中间体的形成途径确定为蛋白质错误折叠疾病中具有可行性的治疗靶点。
Univariate differential expression analysis dominates single-cell transcriptomic studies of Alzheimer's disease, yet marginal testing alone cannot resolve multivariate disease-associated structure or distinguish clinical from neuropathological signatures. Here we introduce TriSCOPE, a framework integrating multivariate predictive modeling, donor-aware differential expression, and pseudotime inference, applied to six Alzheimer's disease snRNA-seq datasets comprising ~4.2 million nuclei from 627 donors. Across six major brain cell types and 41 subclusters, we identify cell-type-specific predictively expressed genes that are largely non-overlapping with differentially expressed genes, revealing disease-relevant signals invisible to univariate approaches. Conditional GWAS-eQTL colocalization anchors a subset of these predictively expressed genes to inherited Alzheimer's disease risk loci, including 27 genetically supported gene-cell type pairs (among them ARL17B, JAZF1) with no significant differential expression. Integration across all three analytical branches nominates high-confidence convergent programs including astrocytic stress markers (such as GFAP, MT2A), neuronal signaling genes (like RASGEF1B, LINGO1, NRG1), and microglial and oligodendrocyte regulators (including SYTL3, SPP1, APOD). Comparison of clinical and neuropathological models reveals cell-type-specific divergence between cognitive and pathological Alzheimer's disease signatures. Key predictively expressed genes including ARL17B, LINGO1, and APOE replicate across independent cohorts, with cross-cohort generalizability confirmed across all three analytical branches of TriSCOPE.
中文摘要:单变量差异表达分析主导了阿尔茨海默病的单细胞转录组学研究,但仅靠边际检验无法解析多变量疾病相关结构或区分临床与神经病理特征。本研究引入TriSCOPE框架,整合多变量预测建模、供体感知的差异表达和拟时序推断,应用于包含627名捐赠者约420万个细胞核的六个阿尔茨海默病单细胞RNA测序数据集。在六种主要脑细胞类型和41个亚群中,我们鉴定出细胞类型特异性预测表达基因,这些基因大多与差异表达基因不重叠,揭示了单变量方法无法察觉的疾病相关信号。条件性GWAS-eQTL共定位将这些预测表达基因中的一部分锚定到遗传性阿尔茨海默病风险位点,包括27个具有遗传支持的基因-细胞类型对(如ARL17B、JAZF1),这些基因无显著差异表达。整合三个分析分支提名了高置信度的收敛程序,包括星形胶质细胞应激标志物(如GFAP、MT2A)、神经元信号基因(如RASGEF1B、LINGO1、NRG1)以及小胶质细胞和少突胶质细胞调节因子(如SYTL3、SPP1、APOD)。临床与神经病理模型的比较揭示了认知与病理阿尔茨海默病特征之间的细胞类型特异性差异。关键预测表达基因包括ARL17B、LINGO1和APOE在独立队列中得到重复验证,TriSCOPE三个分析分支的跨队列泛化能力均得到确认。
Single-cell genomics is transformative for characterizing cellular heterogeneity, but many biological questions require comparing samples rather than individual cells. Typical analyses compare "case" and "control" groups, ignoring sample-level variation within them. Here, we present scSLIDE (single-cell sample-level inference using density estimation), a framework that transforms each sample's single-cell data into a compact profile describing where its cells are distributed in high-dimensional space. By comparing these density profiles, scSLIDE calculates embeddings to characterize variation across samples. We implement scSLIDE in version 6 of our Seurat package and apply it to COVID-19 infection, Alzheimer's disease, and zebrafish embryogenesis. scSLIDE reveals patient subgroups, reconstructs disease trajectories, and identifies coordinated cellular programs across samples. We discover separable axes of infection and severity, a trajectory of Alzheimer's progression, and embryonic "pseudostages" that vary across and within time points. Our results demonstrate how case-control analyses collapse rich biological variation into binary labels and how sample-level embedding represents a powerful analytical alternative.
中文摘要:单细胞基因组学在表征细胞异质性方面具有变革性意义,但许多生物学问题需要比较样本而非单个细胞。典型分析通常比较病例组与对照组,忽略了样本内部的变异。本文提出scSLIDE框架,利用密度估计将每个样本的单细胞数据转化为描述其细胞在高维空间中分布的紧凑特征谱。通过比较这些密度特征谱,scSLIDE计算嵌入向量以表征样本间的变异。我们将scSLIDE实现于Seurat软件包的第6版中,并将其应用于COVID-19感染、阿尔茨海默病及斑马鱼胚胎发育研究。scSLIDE揭示了患者亚群,重构了疾病轨迹并识别了跨样本的协调细胞程序。我们发现可分离的感染与严重程度轴线、阿尔茨海默病的进展轨迹以及随时间点变化且在时间点上存在的胚胎伪阶段。结果证明病例对照分析如何将丰富的生物学变异简化为二元标签,而样本级嵌入代表了一种强大的替代分析方法。
Abnormal aggregation of amyloid-β (Aβ) peptides is a central pathological event in Alzheimer's disease (AD), closely associated with neurotoxicity and disease progression. The development of molecules or materials with high selectivity and affinity toward Aβ aggregates constitutes an essential component for the early diagnosis and intervention of AD. Aβ peptides, composed of homochiral amino acids, undergo intermolecular β-sheet assembly to form supramolecular chiral aggregates, providing a structural basis for chirality-sensitive recognition. Therefore, chiral materials have attracted significant attention in Aβ aggregates recognition and regulation. Previous reviews have examined different types of chiral materials for the inhibition of Aβ aggregation, including chiral small molecules, amino acids, peptides, and various chiral interfaces or nanomaterials. The present review organizes reported chiral materials according to three intervention strategies for modulating Aβ aggregation: conformation-locking, self-assembly-induced remodeling, and multifunctional intervention. We summarize representative materials in each category, along with the corresponding design principles and modulation performance toward Aβ aggregation. Current challenges and potential directions for the development of chiral therapeutics for AD are also discussed.
中文摘要:淀粉样蛋白β(Aβ)肽的异常聚集是阿尔茨海默病(AD)的核心病理事件,与神经毒性和疾病进展密切相关。开发对Aβ聚集体具有高选择性和亲和力的分子或材料是AD早期诊断和干预的重要组成部分。由同手性氨基酸组成的Aβ肽通过分子间β折叠组装形成超分子手性聚集体,为手性敏感识别提供了结构基础。因此,手性材料在Aβ聚集体的识别和调控方面引起了广泛关注。先前的综述考察了不同类型的用于抑制Aβ聚集的手性材料,包括手性小分子、氨基酸、肽以及各种手性界面或纳米材料。本综述根据调节Aβ聚集的三种干预策略对手性材料进行了分类:构象锁定、自组装诱导的重塑以及多功能干预。我们总结了每个类别中的代表性材料及其对应的设计原理和对Aβ聚集的调控性能。最后讨论了当前面临的挑战以及开发AD手性治疗药物的潜在方向。
Creative cognition is central to human thought and is affected by brain disease. Recent findings by Altmayer and colleagues link creative impairment in frontotemporal dementia to rostral prefrontal functional differentiation. These findings motivate a framework for investigating network coordination, circuit physiology, experience-dependent plasticity, and bodily and social regulation in creativity and health.
中文摘要:创造性认知是人类思维的核心,并受脑部疾病影响。Altmayer及其同事的最新研究将额颞叶痴呆中的创造性损害与眶额前额叶的功能分化联系起来。这些发现为探索创造力与健康中的网络协调、回路生理、经验依赖性可塑性以及身体和社会调节提供了一个框架。
Identifying the neurobiological basis of cognitive vulnerability is essential for preventing Alzheimer's disease (AD). We derived the Alzheimer's Resilience-Vulnerability Connectome (ARC) by contrasting SuperAgers (SA), an extreme phenotype of preserved late-life memory, with AD using resting-state fMRI. ARC distinguished SA from AD in a discovery cohort (N = 290; AUC = 0.85) and replicated independently (N = 143), involving prefrontal, temporal, and insular networks and associating with brain age. Applied to cognitively unimpaired adults (discovery: N = 818; replication: N = 497), ARC-based subtyping revealed SA-like and AD-like subgroups with comparable baseline cognition but divergent longitudinal trajectories. AD-like individuals exhibited faster cognitive decline, greater amyloid-β accumulation, and higher AD conversion risk. Exploratory GWAS nominated CLYBL and FRMD6 as candidate novel loci associated with the subtype difference. These findings suggest that ARC captures a continuous connectomic dimension of cognitive aging spanning SA, cognitively typical aging, and AD, highlighting the potential of functional connectomic variation for early risk stratification in AD.
中文摘要:识别认知脆弱性的神经生物学基础对于预防阿尔茨海默病(AD)至关重要。我们通过对比静息态功能磁共振成像中保留晚期记忆能力的超常老化者(SA,一种极端表型)与AD患者,构建了阿尔茨海默病韧性-脆弱性连接组(ARC)。在发现队列(N=290;AUC=0.85)中,ARC成功区分了SA与AD,并在独立队列(N=143)中得到复现。该连接组涉及前额叶、颞叶和岛叶网络,并与脑年龄相关。将其应用于认知正常的成年人(发现队列:N=818;复制队列:N=497),基于ARC的分型揭示了SA样和AD样亚组,两者基线认知能力相当但纵向轨迹不同。AD样个体表现出更快的认知衰退、更大的淀粉样蛋白β积累以及更高的AD转化风险。探索性全基因组关联分析(GWAS)提名CLYBL和FRMD6为与亚型差异相关的候选新位点。这些发现表明,ARC捕捉到了跨越SA、典型认知老化及AD的认知衰老连续连接组维度,突显了功能连接组变异在AD早期风险分层中的潜力。
3神经肌肉病与周围神经 (9篇)
临床研究 (5篇)
Loneliness is common in ageing population, we aim to identify the association between loneliness and cardiometabolic disease (CMD) across diverse settings, particularly cardiometabolic multimorbidity, and investigate whether unhealthy lifestyles and socioeconomic status (SES) help explain or amplify their relationships. Data were obtained from six cohort studies across 33 countries, including the China Health and Retirement Longitudinal Study (CHARLS), English Longitudinal Study of Ageing (ELSA), Health and Retirement Study (HRS), Survey of Health, Ageing and Retirement in Europe (SHARE), Korean Longitudinal Study of Aging (KLoSA), and Mexican Health and Aging Study (MHAS). Eligible participants were aged 45 years or older. We applied time-varying Cox mixed-effects regression models to evaluate the association between loneliness and incident cardiometabolic diseases. The mediation role of unhealthy lifestyles and the joint effects of socioeconomic status, unhealthy lifestyles, and loneliness on incident cardiometabolic disease outcomes were also explored. Among 81 978 participants, with a median follow-up of 5 years, 15 750 participants developed CMD. Loneliness was associated with higher risk of any CMD (aHR 1.23, [95% CI: 1.20, 1.26]), with a stronger association for multimorbidity (aHR 1.48, [95% CI: 1.37, 1.60]) than for single CMD (aHR 1.18, [95% CI: 1.15, 1.22]). Unhealthy lifestyles mediated 5.19% (95% CI: 3.06, 7.64) of the association with any CMD. Individuals experiencing a combination of low SES, multiple unhealthy lifestyle factors, and loneliness demonstrated the greatest cardiometabolic disease risk (adjusted HR: 1.89, [95% CI: 1.76, 2.02]). Building on prior evidence that has largely come from single-cohort studies, our findings highlighted loneliness as a global risk factor in predicting the incident CMD, particularly cardiometabolic multimorbidity. The highest risk was observed among socioeconomically disadvantaged individuals with multiple unhealthy lifestyles. These findings underscore the needs to address the combined risk of socioeconomic disadvantage, loneliness, and unhealthy lifestyle in multicomponent health interventions.
中文摘要:孤独在老年人群中普遍存在,本研究旨在识别不同环境下孤独与心血管代谢疾病(CMD)之间的关联,特别是心血管代谢共病,并探讨不健康生活方式和社会经济地位(SES)是否有助于解释或放大其关系。数据来源于涵盖33个国家的六项队列研究,包括中国健康与养老追踪调查(CHARLS)、英国老龄化纵向研究(ELSA)、健康与退休研究(HRS)、欧洲健康、老龄化和退休调查(SHARE)、韩国老龄化纵向研究(KLoSA)以及墨西哥健康与老龄化研究(MHAS)。符合条件的参与者年龄为45岁及以上。我们应用时间依赖性Cox混合效应回归模型评估孤独与心血管代谢疾病发病之间的关联。同时探讨了不健康生活方式的中介作用以及社会经济地位、不健康生活方式和孤独对心血管代谢疾病发病结果的联合效应。在81978名参与者中,中位随访时间为5年,其中15750名参与者发生了CMD。孤独与任何CMD的高风险相关(aHR 1.23,[95% CI: 1.20, 1.26]),与共病的关联强于单一CMD(aHR 1.48,[95% CI: 1.37, 1.60] vs aHR 1.18,[95% CI: 1.15, 1.22])。不健康生活方式介导了与任何CMD关联的5.19%(95% CI: 3.06, 7.64)。经历低SES、多种不健康生活方式因素和孤独相结合的个体表现出最大的心血管代谢疾病风险(调整HR:1.89,[95% CI: 1.76, 2.02])。基于此前主要来自单队列研究的证据,我们的研究结果强调了孤独作为预测CMD发病的全球风险因素的作用,特别是心血管代谢共病。在面临社会经济劣势且拥有多种不健康生活方式的个体中观察到最高风险。这些发现强调了在多组分健康干预中解决社会经济劣势、孤独和不健康生活方式的联合风险的必要性。
Generalized myasthenia gravis (gMG) is a chronic fluctuating neuromuscular disease. Some patients keep experiencing symptoms or adverse events (AEs) despite tailored therapeutic schemes. The aim of this study was to characterize adequately controlled gMG and describe patients' evolution and outcomes, including estimated direct health costs in a universal health care system. Spanish expert neurologists developed a definition of adequately controlled gMG using Delphi methodology. This was applied to an existing cohort of patients recently diagnosed with gMG during 1998-2020 in a Spanish referral neuromuscular diseases' unit. Control status, clinical outcomes, AEs, and health care resource utilization (HCRU) were described biennially. We assessed 220 patients diagnosed with gMG (54.5% women; mean age at onset of 58 years; 84% anti-AChR, 6% anti-MuSK, 10% seronegative). Adequately controlled gMG was defined as achieving Myasthenia Gravis Foundation of America Post-Intervention Status classification of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year; having an MG-ADL score ≤2; experiencing no clinical exacerbations during the last year requiring a change in immunosuppressive therapy or rescue therapy; and having no or mild AE to therapies (100% of experts in agreement or total agreement). The proportion adequately controlled (AC) patients increased from 62.0% at 2 years after first visit to 81.9% after 8 years of follow-up. 47.3% of patients remained AC in every observation, and 17.7% remained not adequately controlled (NC) in every observation. No features were significantly associated with adequate control. AE-related drug interruption rates were higher in NC patients (ranging from 50% to 100% during the study). The mean cost per patient/year ranged from 2,718.6€ in the first biennial period to 843.1€ in the last biennial period for AC patients and from 10,190.1€ to 5,827.4€ for NC patients. Based on the new gMG control consensus definition, almost 1 in 5 patients do not reach disease control even after 8 years of evolution. Those patients lacked specific clinical features, underscoring the unpredictability of the gMG course. Burden of AE-related drug interruptions, HCRU, and costs per patients/year were higher among those patients NC. However, our study is unicentric and included patients from a referral unit, with a possible overrepresentation of NC patients.
中文摘要:重症肌无力(gMG)是一种慢性波动性神经肌肉疾病。部分患者即使接受个体化治疗方案仍持续出现症状或不良事件(AE)。本研究旨在充分表征控制良好的gMG,并描述患者的演变及结局,包括在全民医疗保健系统中的估计直接医疗成本。西班牙专家神经病学家采用德尔菲法制定了控制良好的gMG定义。该定义应用于1998至2020年间在西班牙一家转诊神经肌肉疾病单位新确诊的gMG患者队列。每两年描述一次控制状态、临床结局、不良事件及医疗保健资源利用(HCRU)。我们评估了220名诊断为gMG的患者(女性占54.5%;起病平均年龄58岁;抗AChR抗体阳性84%,抗MuSK抗体阳性6%,血清阴性10%)。控制良好的gMG定义为:达到重症肌无力基金会术后干预状态分类中的临床稳定缓解、药理学缓解或最小表现且持续一年;MG-ADL评分≤2;过去一年无需要改变免疫抑制治疗或救援治疗的临床加重;以及无或轻度治疗相关不良事件(100%专家一致同意或完全同意)。控制良好(AC)患者比例从首次就诊后2年的62.0%增加到随访8年后的81.9%。47.3%的患者在所有观察中保持AC,17.7%的患者在所有观察中保持未充分控制(NC)。未发现与控制良好的显著相关特征。NC患者的AE相关药物中断率较高(研究中从50%到100%不等)。AC患者的人均年成本范围从第一个双年度周期的2,718.6欧元降至最后一个双年度周期的843.1欧元;NC患者则从10,190.1欧元降至5,827.4欧元。基于新的gMG控制共识定义,即使经过8年的演变,仍有近五分之一的患者未能达到疾病控制。这些患者缺乏特定的临床特征,凸显了gMG病程的不可预测性。AE相关药物中断、HCRU及人均年成本负担在NC患者中更高。然而,本研究为单中心研究,纳入的是转诊单位患者,可能存在NC患者过度代表的问题。
Ethambutol-induced optic neuropathy (EtON) is a dose-dependent adverse drug effect that may cause irreversible visual impairment, with no established therapeutic interventions beyond drug cessation. The study aimed to evaluate the efficacy and safety of high-dose, short-term intravenous methylprednisolone (IVMP) among patients with EtON. This was a prospective, double-blind, placebo-controlled, randomized clinical trial (RCT) conducted at a tertiary care center in India (March 2021 to August 2024). Patients reporting visual loss while receiving ethambutol and diagnosed with EtON using a pre-defined diagnostic criteria were enrolled. A total of 100 patients with EtON were randomized (1:1) using block randomization. Participants received either high-dose IVMP (1gram per day for 5 days) or placebo, alongside standard-of-care therapy. The primary endpoint was two or more lines improvement in best-corrected visual acuity (BCVA) on Snellen's chart (equivalent to at least ten letters on the logMAR) at 6 months. Secondary endpoints included improvement in mean deviation (MD) and visual field index (VFI) on automated perimetry, along with safety, and adjusted treatment effects. At 6 months, 36 (72.0%) patients in the IVMP arm versus 23 (46.0%) in the placebo arm achieved an improvement of two or more lines in BCVA (p=0.008). However, the between-group difference in mean final BCVA was not statistically significant (0.54 (0.6) vs 0.61 (0.6), p=0.534). Significant improvement in visual field parameters was noted in IVMP arm: mean MD (-9.40 vs -13.99 (mean difference: 4.59, 95% CI: 1.35-7.83)) and mean VFI (71.27 vs 62.35 (mean difference: 8.92; 95% CI: 0.20-17.65)). Adjusted analysis confirmed improvement in visual outcomes with IVMP (adjusted risk ratio: 1.62; 95% CI: 1.14, 2.29), consistent across subgroups. No serious treatment-related adverse events were observed. Short-term high-dose IVMP administration was associated with a greater proportion of BCVA responders and better visual field parameters in patients with EtON. This is the first RCT to evaluate the role of corticosteroids in EtON. The findings are hypothesis-generating and require confirmation in larger trials.
中文摘要:乙胺丁醇诱导的视神经病变(EtON)是一种剂量依赖性药物不良反应,可能导致不可逆的视力损害,目前除停药外尚无确立的治疗干预措施。本研究旨在评估高剂量短期静脉注射甲泼尼龙(IVMP)在EtON患者中的疗效和安全性。这是一项于2021年3月至2024年8月在印度一家三级医疗中心开展的前瞻性、双盲、安慰剂对照随机临床试验(RCT)。研究纳入了服用乙胺丁醇期间出现视力丧失且符合预设诊断标准的EtON患者。共100名EtON患者通过区组随机化以1:1比例分配至两组。参与者接受高剂量IVMP(每日1克,连续5天)或安慰剂,并联合标准治疗。主要终点为6个月时Snellen视力表最佳矫正视力(BCVA)改善两行或以上(相当于logMAR至少增加10个字母)。次要终点包括自动视野计平均偏差(MD)和视野指数(VFI)的改善情况以及安全性与调整后的治疗效果。在6个月时,IVMP组有36名患者(72.0%)实现BCVA改善两行或以上,而安慰剂组为23名(46.0%)(p=0.008)。然而,两组间最终平均BCVA的差异无统计学意义(0.54 (0.6) vs 0.61 (0.6),p=0.534)。IVMP组在视野参数方面观察到显著改善:平均MD(-9.40 vs -13.99,均值差:4.59,95% CI: 1.35-7.83)和平均VFI(71.27 vs 62.35,均值差:8.92;95% CI: 0.20-17.65)。调整后的分析证实IVMP改善了视觉结局(调整后风险比:1.62;95% CI: 1.14, 2.29),且在亚组中结果一致。未观察到严重的治疗相关不良事件。短期高剂量IVMP给药与EtON患者中更高比例的BCVA反应者及更好的视野参数相关。这是首个评估皮质类固醇在EtON中作用的RCT。研究结果为假设生成性质,需在更大规模的试验中进一步验证。
Autoimmune cerebellar ataxias are debilitating neurological syndromes that need early detection and intervention. Antineural antibodies are a crucial diagnostic marker, however, lack of knowledge of specific autoantibodies in seronegative patients remains a significant challenge. To pair a cutting-edge, standardized, and rigorous autoantibody detection pathway with global clinical networks to identify novel autoantibody markers of autoimmune ataxia. This was a multicenter case series study that included samples of patients with uncharacterized central nervous system disorders, collected between 2015 and 2020 at the University of California, San Francisco (UCSF). A comprehensive screening for additional patients was conducted using a blinded cell-based and tissue-based assay in the French reference center on paraneoplastic neurological syndrome (PNS) and autoimmune encephalitis (AE). Analysis was completed in 2026. Referred participants included those with idiopathic neurological disease with suspicion of autoimmune etiology, controls with noninflammatory disease, and patients with known paraneoplastic autoantibody associations who served as positive controls. Sera and cerebrospinal fluid were collected for autoantibody screening and validation experiments. Autoantibody screening and candidate antibody validations. Detection of autoantibodies and characterization of their usefulness as biomarkers of autoimmune clinical symptoms. A total of 35 patients were referred, and 8 patients (median [IQR] age, 65 [47-74] years; 6 male [75%]) were identified to have IgG targeting the intracellular neural protein ribosomal modification protein RimK-like family member A (RIMKLA). Initially, cerebrospinal fluid (CSF) from a UCSF index patient with small cell lung cancer and inflammatory cerebellar ataxia showed a specific staining pattern in the deep nuclei of the cerebellum and brainstem but was seronegative on all known panels of PNS biomarkers. Subsequent screening identified 7 additional patients sharing a similar clinical profile characterized by progressive cerebellar ataxia, diplopia, cranial VI paresis, and sensory and motor abnormalities. The majority of patients (6 of 8 [75%]) had associated small cell lung cancer. All patients also exhibited inflammatory CSF and immunoglobulin synthesis. In this case series, novel PNS autoantibodies targeting the neural protein RIMKLA were identified in patients with small cell lung cancer and cerebellar ataxia. RIMKLA-IgG represents a new diagnostic biomarker for an intracellular-antigen PNS associated with cerebellar and hindbrain encephalitis with possible peripheral and motor involvement.
中文摘要:自身免疫性小脑共济失调是一种致残性神经综合征,需要早期检测和干预。抗神经抗体是关键诊断标志物,然而对血清阴性患者中特定自身抗体的知识缺乏仍是一个重大挑战。本研究旨在将前沿、标准化且严格的自身抗体检测途径与全球临床网络相结合,以识别自身免疫性共济失调的新型自身抗体标志物。这是一项多中心病例系列研究,纳入了2015年至2020年间在加州大学旧金山分校(UCSF)收集的中枢神经系统疾病特征不明患者的样本。在法国副肿瘤性神经综合征(PNS)和自身免疫性脑炎(AE)参考中心使用盲法细胞基和组织基检测对更多患者进行了全面筛查。分析于2026年完成。转诊参与者包括疑似自身免疫病因的特发性神经系统疾病患者、非炎症性疾病对照组以及作为阳性对照的已知副肿瘤自身抗体关联患者。收集血清和脑脊液进行自身抗体筛查和验证实验。研究内容包括自身抗体筛查和候选抗体验证,检测自身抗体并评估其作为自身免疫临床症状生物标志物的有用性。共转诊35名患者,其中8名患者(中位年龄[IQR]65[47-74]岁;男性6名[75%])被发现具有针对细胞内神经蛋白核糖体修饰蛋白RimK样家族成员A(RIMKLA)的IgG。最初,一名患有小细胞肺癌和炎症性小脑共济失调的UCSF索引患者的脑脊液(CSF)在小脑深部核团和脑干显示出特定的染色模式,但在所有已知的PNS生物标志物面板中均为血清阴性。随后的筛查确定了另外7名具有相似临床特征的患者,其特征为进行性小脑共济失调、复视、颅神经VI麻痹以及感觉和运动异常。大多数患者(8例中的6例[75%])伴有小细胞肺癌。所有患者均表现出炎症性CSF和免疫球蛋白合成。在该病例系列中,在小细胞肺癌和小脑共济失调患者中发现了针对神经蛋白RIMKLA的新型PNS自身抗体。RIMKLA-IgG代表了与小脑和后脑脑炎(可能伴有周围和中枢运动受累)相关的细胞内抗原PNS的新诊断生物标志物。
In CARDIO-TTRansform, the TTR (transthyretin) silencer eplontersen did not significantly reduce the primary end point of cardiovascular death and recurrent cardiovascular events in patients with TTR amyloidosis with cardiomyopathy, although treatment effects varied by baseline TTR stabilizer use. Whether eplontersen favorably affects cardiac structure and function is unknown. CARDIO-TTRansform randomized 1432 patients with TTR amyloidosis with cardiomyopathy to eplontersen (45 mg) subcutaneously every 4 weeks or placebo. Echocardiograms were performed at baseline and weeks 61, 97, and 140. Associations of baseline echocardiographic measures with all-cause mortality and the primary end point were evaluated using Cox and semiparametric proportional rates models. Between-group differences at week 140 were analyzed with mixed models for repeated measures. Among 1426 participants with baseline echocardiograms (mean age, 76±7 years, 91% men, 85% wild type, 57% receiving stabilizers), baseline measures of left ventricular systolic function (LV ejection fraction, global longitudinal strain, stroke volume, myocardial contraction fraction), diastolic function (E wave deceleration time, septal e', average E/e'), and right ventricular function and hemodynamics were independently associated with all-cause mortality or the primary end point. At week 140 (echocardiograms available in 554 patients in the eplontersen group and 506 in the placebo group), eplontersen attenuated increases in mean LV wall thickness (least-squares mean [LSM] difference, -0.24 mm [95% CI, -0.48 to -0.01]) and declines in LV stroke volume (LSM difference, 1.88 mL [95% CI, 0.07-3.69]), myocardial contraction fraction (LSM difference, 0.88% [95% CI, 0.25-1.57]), average E/e' (LSM difference, -0.71 [95% CI, -1.36 to -0.07]), and right ventricular outflow tract velocity-time integral (LSM difference, 0.42 [95% CI, 0.00-0.85]) versus placebo in the overall cohort. Beneficial effects were driven almost exclusively by patients not receiving stabilizers at baseline. No significant treatment effects were observed in patients receiving stabilizers. Among patients with TTR amyloidosis with cardiomyopathy, eplontersen modestly attenuated deterioration in prognostically important measures of LV systolic, diastolic and right ventricular function, primarily among patients not receiving stabilizers at baseline. These findings complement the clinical findings of CARDIO-TTRansform and suggest that TTR silencing may attenuate progression of cardiac dysfunction in TTR amyloidosis with cardiomyopathy. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04136171; URL: xxx; Unique identifier: 2019-002835-27.
中文摘要:在CARDIO-TTRansform试验中,TTR(转甲状腺素蛋白)沉默剂eplontersen未能显著降低TTR淀粉样变性伴心肌病患者的主要终点心血管死亡和复发性心血管事件发生率,尽管治疗效果因基线TTR稳定剂的使用情况而异。目前尚不清楚eplontersen是否对心脏结构和功能产生有利影响。CARDIO-TTRansform试验将1432名TTR淀粉样变性伴心肌病患者随机分配至每4周皮下注射一次eplontersen(45 mg)组或安慰剂组。在基线及第61、97和140周进行超声心动图检查。采用Cox模型和半参数比例速率模型评估基线超声心动图指标与全因死亡率及主要终点的关联。采用重复测量混合模型分析第140周的组间差异。在1426名具有基线超声心动图数据的参与者中(平均年龄76±7岁,男性占91%,野生型占85%,57%接受稳定剂治疗),左心室收缩功能(左室射血分数、整体纵向应变、每搏输出量、心肌收缩分数)、舒张功能(E波减速时间、间隔部e'、平均E/e')以及右心室功能和血流动力学的基线指标均独立关联于全因死亡率或主要终点。在第140周(eplontersen组554名患者和安慰剂组506名患者有超声心动图数据),与安慰剂相比,eplontersen减弱了平均左室壁厚度增加(最小二乘均值差异为-0.24 mm [95% CI, -0.48至-0.01])以及左室每搏输出量(LSM差异为1.88 mL [95% CI, 0.07至3.69])、心肌收缩分数(LSM差异为0.88% [95% CI, 0.25至1.57])、平均E/e'(LSM差异为-0.71 [95% CI, -1.36至-0.07])和右心室流出道速度时间积分(LSM差异为0.42 [95% CI, 0.00至0.85])的下降。有益效果几乎完全由基线未接受稳定剂治疗的患者驱动。在接受稳定剂治疗的患者中未观察到显著的治疗效果。在TTR淀粉样变性伴心肌病患者中,eplontersen适度减弱了预后重要指标中左室收缩、舒张及右心室功能的恶化,主要见于基线未接受稳定剂治疗的患者。这些发现补充了CARDIO-TTRansform试验的临床结果,并提示TTR沉默可能减缓TTR淀粉样变性伴心肌病中心脏功能障碍的进展。URL: https://www.clinicaltrials.gov; 唯一标识符: NCT04136171; URL: xxx; 唯一标识符: 2019-002835-27。
基础研究 (4篇)
Orthoflaviviruses, members of the genus Orthoflavivirus in the family Flaviviridae, include major arthropod-borne pathogens, such as dengue, Zika, yellow fever, Japanese encephalitis, and West Nile viruses. Their continued emergence and re-emergence are shaped by viral evolution, vector ecology, urbanization, climate change, human mobility, and uneven population immunity. Understanding the infection biology of these viruses will pave the way for developing therapeutic and preventive countermeasures. Recent discoveries identifying members of the low-density lipoprotein receptor family as functional entry receptors for yellow fever virus and tick-borne encephalitis virus have reshaped our understanding of orthoflavivirus entry. In this review, we analyze these new developments in the context of prior knowledge of orthoflavivirus receptors. We also discuss the evolutionary implications of receptor usage and how receptor identification may accelerate the development of antiviral drugs and vaccines. We propose a framework of orthoflavivirus-host receptor evolution that can be tested experimentally and can guide the development of prediction tools for comprehensive viral receptor usage.
中文摘要:正黄病毒属(Orthoflavivirus)是黄病毒科成员,包括登革热、寨卡、黄热病、日本脑炎和西尼罗河病毒等主要虫媒病原体。其持续出现与再发受到病毒进化、媒介生态、城市化、气候变化、人群流动及群体免疫不均等因素影响。理解这些病毒的感染生物学将为开发治疗和预防对策奠定基础。近期发现低密度脂蛋白受体家族成员是黄热病病毒和蜱传脑炎病毒的功能性进入受体,重塑了我们对正黄病毒进入机制的理解。本综述在既往正黄病毒受体知识背景下分析这些新进展,并讨论受体使用的进化意义以及受体鉴定如何加速抗病毒药物和疫苗的开发。我们提出一个可经实验验证的正黄病毒宿主受体进化框架,以指导全面病毒受体使用预测工具的开发。
Our society is aging. Accordingly, the incidence and prevalence of age-associated diseases are exponentially increasing. Among these diseases, neurodegenerative disorders emerge as major contributors to decreased health span. The molecular mechanisms underlying these disorders are complex and multifaceted. However, increased generation of reactive oxygen species (ROS) and associated oxidative stress have emerged as a potent contributor to the etiopathology of many of these disorders, including Alzheimer's Disease and Parkinson's Disease (AD and PD, respectively). In this context, changes in copper homeostasis have been described as important contributors to increased ROS generation and associated oxidative stress, and targeting Cu homeostasis has been explored as a promising pharmacological approach. In this bibliographical review, we comprehensively discuss the most relevant pharmacological approaches in the field. Most of the research articles discussed here used AD and PD models, but some studies also employed models of less common neurodegenerative disorders. The literature presented here demonstrates the promising effects of targeting Cu homeostasis to halt increased ROS generation and associated oxidative stress in neurodegenerative disorders. However, many of these studies were conducted in vitro, with only a small portion in murine models of the diseases. Consequently, further research is needed to determine whether the promising results are, in fact, translatable to human therapeutics. The urgency for these studies is real, considering the high incidence and prevalence of neurodegenerative disorders and the limited therapeutics in the field.
中文摘要:随着人口老龄化,年龄相关疾病的发病率与患病率呈指数级增长。其中神经退行性疾病是导致健康寿命缩短的主要因素之一。尽管这些疾病的分子机制复杂多样,但活性氧(ROS)生成增加及随之而来的氧化应激已成为阿尔茨海默病(AD)和帕金森病(PD)等多种疾病发病机制的重要驱动因素。在此背景下,铜稳态的改变被证实是促进ROS生成和氧化应激的关键因素,因此靶向铜稳态被视为一种有前景的药理学干预策略。本文献综述全面探讨了该领域最具相关性的药理学方法。文中讨论的研究大多采用AD和PD模型,部分研究也涉及较少见的神经退行性疾病模型。现有文献表明,靶向铜稳态在抑制神经退行性疾病中ROS过度生成及氧化应激方面具有显著潜力。然而,多数研究为体外实验,仅有少量研究使用小鼠疾病模型。鉴于神经退行性疾病的高发病率与患病率以及当前治疗手段的局限性,亟需进一步研究以验证这些 promising 结果能否转化为人类临床治疗应用。
Modern agronomic systems for large-scale oilseed production rely heavily on chemical weed control, presenting a barrier to the adoption of newly domesticated crops that lack herbicide tolerance. Pennycress (Thlaspi arvense L.), a domesticated winter oilseed developed to increase land productivity and support sustainable biofuel production, is highly sensitive to commonly used herbicides targeting acetolactate synthase (ALS) and 4-hydroxyphenylpyruvate dioxygenase (HPPD). Here, we report complementary strategies for identifying and deploying herbicide-tolerant alleles in pennycress. ALS inhibitor tolerance was identified through Ethyl methanesulfonate (EMS)-derived chemical mutagenesis, whereas HPPD inhibitor tolerance was explored using a microbial-based rational enzyme design platform as proof of concept. Selected alleles were introduced into advanced germplasm via homology-directed repair (HDR) and evaluated across developmental stages. Plants carrying the P187S mutation in the ALS gene exhibited robust tolerance at both seedling and rosette stages without detectable penalties to growth or seed yield. In contrast, the G419A allele in the HPPD gene conferred tolerance to residual herbicide activity when overexpressed but showed limited efficacy when expressed from its native locus, indicating context-dependent functionality. Collectively, this study demonstrates the feasibility of integrating herbicide tolerance into a newly domesticated oilseed crop and highlights the utility of combining mutagenesis-based discovery, rational enzyme engineering, and precision genome editing to support agronomic compatibility and crop deployment.
中文摘要:现代大规模油料作物生产体系高度依赖化学除草剂控制,这成为缺乏除草剂耐受性的新驯化作物的主要障碍。作为旨在提高土地生产力并支持可持续生物燃料生产的驯化冬性油料作物,羽衣甘蓝(Thlaspi arvense L.)对靶向乙酰乳酸合成酶(ALS)和4-羟基苯基丙酮酸双加氧酶(HPPD)的常用除草剂高度敏感。本研究报道了识别和部署羽衣甘蓝中除草剂耐受性等位基因的策略。通过甲基磺酸乙酯(EMS)诱导的化学诱变鉴定了ALS抑制剂耐受性,而HPPD抑制剂耐受性则利用基于微生物的理性酶设计平台进行了概念验证。选定的等位基因通过同源定向修复(HDR)导入先进种质并在不同发育阶段进行评估。携带ALS基因P187S突变的植株在苗期和莲座期均表现出强效耐受性,且未对生长或种子产量造成可检测的负面影响。相比之下,过表达的HPPD基因G419A等位基因赋予了对残留除草剂活性的耐受性,但从其天然基因座表达时效果有限,表明其功能具有情境依赖性。综上所述,本研究证明了将除草剂耐受性整合到新驯化油料作物中的可行性,并强调了结合基于诱变发现的策略、理性酶工程及精准基因组编辑以支持农艺兼容性和作物部署的效用。
Glucagon-like peptide-1 (GLP-1) is an incretin to regulate glycemia, activates peripheral and central neural pathways to control appetite, and inhibits upper gut transit to reduce food intake. Peptide and nonpeptide GLP-1 receptor agonists (GLP-1RAs), as well as a combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), agonist are approved for type 2 diabetes, weight reduction, and other indications. GLP-1RA therapy can be complicated by upper gastrointestinal (GI) symptoms, including nausea and vomiting. Delayed gastric emptying secondary to GLP-1RAs may be influenced by drug pharmacokinetics, associated neuropathy, and development of tachyphylaxis with repeated dosing. A theoretical risk of pulmonary aspiration from retained gastric contents is concerning for patients undergoing anesthesia before endoscopy or surgery. Managing upper GI complications of GLP-1RA therapy includes diet modifications, antiemetic medications, and treatments that stimulate gastric emptying. Newer agents in testing include nonpeptide GLP-1RAs and GLP-1RAs acting in concert with GIP, glucagon, or other receptor-mediated pathways.
中文摘要:胰高血糖素样肽-1(GLP-1)是一种调节血糖的肠促胰岛素,通过激活外周和中枢神经通路控制食欲,并抑制上消化道蠕动以减少食物摄入。多肽和非多肽类GLP-1受体激动剂(GLP-1RAs),以及联合胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽(GIP)的激动剂已获批用于2型糖尿病、减重及其他适应症。GLP-1RA治疗可能伴有上消化道症状,包括恶心和呕吐。由GLP-1RAs引起的胃排空延迟可能受药物药代动力学、相关神经病变以及重复给药产生的快速耐受性影响。对于接受内镜或手术前麻醉的患者,保留胃内容物导致肺吸入的理论风险令人担忧。管理GLP-1RA治疗的上消化道并发症包括饮食调整、止吐药物和使用促进胃排空的治疗。正在测试的新型制剂包括非多肽类GLP-1RAs以及协同作用于GIP、胰高血糖素或其他受体介导通路的GLP-1RAs。
4癫痫 (6篇)
临床研究 (4篇)
The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models. With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of - 12.2% at cycle 6, -27.8% at cycle 12, and -55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event. Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.
中文摘要:IDH1/2抑制剂vorasidenib在术后残留或复发的IDH1/2突变型2级胶质瘤中显示出疗效。然而,目前缺乏关于预测反应概率因素的知识。我们开展了一项前瞻性单中心研究,纳入54例接受vorasidenib治疗的IDH1/2突变型星形细胞瘤和IDH1/2突变型1p/19q共缺失型少突胶质细胞瘤(均为2级)。纵向评估了MRI反应(2D和3D)及癫痫结局。使用回归模型探索与反应相关的因素。中位随访时间为17.5个月,vorasidenib在MRI上诱导进行性肿瘤缩小,中位体积减少率在周期6时为-12.2%,周期12时为-27.8%,周期18时为-55.5%。最佳体积反应为完全缓解(CR)1例,部分缓解(PR)5例,微小缓解(MR)9例,疾病稳定(SD)31例,疾病进展(PD)7例。客观缓解率(ORR,即CR+PR+MR)为28%。18例伴有局灶性3级区域的患者的体积反应和ORR相似。基线有癫痫的12例患者中有9例(75%)实现了≥50%的减少或癫痫无发作。MRI反应与早期治疗启动及早期癫痫减少相关。vorasidenib总体耐受性良好,肝酶升高为主要不良事件。vorasidenib诱导了持续的肿瘤缩小和癫痫控制。早期治疗启动和早期癫痫减少与MRI反应相关。
Unrecognized seizures occur in up to 77% of individuals with epilepsy, leading to delays in diagnosis with significant consequences including injury, mortality, impaired psychosocial functioning, and negative socioeconomic impacts. Falls are a common reason to present to the emergency department (ED) and may be a sentinel sign of an unrecognized seizure. Whether falls represent missed opportunities for earlier seizure recognition remains unknown. We therefore evaluated the temporal association between ED visits for falls and first-time seizure. We conducted a retrospective case-crossover study using the State Inpatient Databases and State Emergency Department Databases from 11 states (Arkansas, Florida, Georgia, Iowa, Massachusetts, Maryland, Nebraska, New York, Utah, Vermont, and Wisconsin) between 2016 and 2021. Adults aged 18 years and older with an acute care visit for a first-time seizure were identified using ICD-10 codes. Using patients as their own controls, we applied conditional logistic regression to compare the odds of an ED visit for a fall during prespecified case periods preceding the seizure (1-7, 8-30, 31-90, and 91-180 days prior) vs corresponding control periods 1 year earlier. Prespecified intervals were selected to assess graded temporal proximity. There were 57,547 patients with a first-time seizure and 7,307 patients (mean age 49.3 years and 55.2% female) with at least one prior ED visit for a fall during the case or control periods. ED visits for a fall were more common in case compared with control periods, with the highest odds in the 7 days immediately before the acute care visit for first-time seizure (OR = 2.6, 95% CI 2.2-3.2). In a week-by-week analysis, the association persisted up to 22 weeks before seizure, demonstrating temporal attenuation as time from the event increased. These findings were consistent across age and sex strata and after excluding those who had traumatic brain injury. In analyses restricted to first-time status epilepticus, the association in the 7 days preceding seizure was most pronounced (OR = 4.5, 95% CI 2.5-9.0). ED visits for falls are more common immediately preceding first-time seizure, potentially representing missed opportunities for earlier diagnosis, evaluation, and intervention. Prospective studies are needed to clarify the underlying mechanisms and clinical implications.
中文摘要:未被识别的癫痫发作在高达77%的癫痫患者中发生,导致诊断延迟,并带来包括损伤、死亡、心理社会功能受损及负面社会经济影响在内的严重后果。跌倒作为急诊科就诊的常见原因,可能是未被识别癫痫发作的先兆信号。目前尚不清楚跌倒是否代表了早期识别癫痫发作的错失机会。因此,我们评估了因跌倒就诊急诊科与首次癫痫发作之间的时间关联。本研究利用2016年至2021年11个州的住院患者数据库和急诊科数据库,开展了一项回顾性病例交叉研究。通过ICD-10编码识别出18岁及以上因首次癫痫发作接受急性护理的患者。以患者自身作为对照,我们应用条件逻辑回归比较了在癫痫发作前预设病例期(分别为1至7天、8至30天、31至90天和91至180天)与一年前对应的控制期内,因跌倒就诊急诊科的几率差异。预设的时间间隔旨在评估时间邻近性的梯度变化。研究共纳入57,547名首次癫痫发作患者,其中7,307名患者(平均年龄49.3岁,女性占55.2%)在病例期或控制期内至少有一次因跌倒就诊急诊科的记录。与对照期相比,病例期内因跌倒就诊急诊科更为常见,且在首次癫痫发作急性护理前7天内的几率最高(OR=2.6, 95% CI 2.2-3.2)。按周进行的分析显示,该关联在癫痫发作前22周内持续存在,并随着事件发生时间的推移表现出时间衰减趋势。这一结果在不同年龄和性别亚组中保持一致,且在排除创伤性脑损伤患者后依然成立。在仅限于首次癫痫持续状态的分析中,癫痫发作前7天内的关联最为显著(OR=4.5, 95% CI 2.5-9.0)。因跌倒就诊急诊科在首次癫痫发作前更为常见,这可能代表了早期诊断、评估和干预的错失机会。需要前瞻性研究来阐明其潜在机制及临床意义。
People with epilepsy of child-bearing potential (PWECP) require access to highly effective contraception, yet many antiseizure medications (ASMs) can reduce the effectiveness of some hormonal methods by inducing hepatic enzymes. In this retrospective cohort study, we aimed to identify the proportion of PWECP prescribed a susceptible hormonal contraceptive method who were concurrently prescribed an interacting ASM and patient characteristics associated with coprescription. We obtained Medicaid claims data from 2016 to 2021 for female beneficiaries and defined a cohort of people with epilepsy on ASMs prescribed at least 1 method of hormonal contraception susceptible to hepatic enzyme induction. Using prescription fill dates and contraceptive procedure dates, we identified periods of inducing ASM and susceptible contraceptive overlap lasting at least 14 days. We used descriptive statistics to calculate the proportion experiencing overlap and median days of overlap. We used logistic regression to identify associated patient characteristics with any 14-day period of overlap and binominal regression to identify characteristics associated with greater proportion of overlap days. Our cohort included 110,976 PWECP (median age 24 [interquartile range 18-30] years, 54.8% White non-Hispanic). Of those, 21,923 were prescribed a susceptible contraceptive method from 2018 to 2021. In that group, 7,154 (32.6%) had at least a 14-day period of overlap with an enzyme-inducing ASM. The median days of overlap for this group were 218 days (interquartile range 74-511). Patient characteristics associated with both any period of overlap and longer periods of overlap included intellectual disability (any overlap: adjusted odds ratio [aOR] 2.33, 95% CI 2.19-2.48; longer overlap: 2.27, 95% CI 2.05-2.53), drug-resistant epilepsy (any overlap: aOR 1.73, 95% CI 1.62-1.84; longer overlap: 1.27, 95% CI 1.14-1.41), and age older than 35 years compared with 19-34 years (any overlap: 1.45, 95% CI 1.32-1.59; longer overlap: 1.51, 95% CI 1.29-1.75). Drug interactions with ASMs leading to reduced contraceptive effectiveness are common among PWECP prescribed susceptible hormonal contraception. Certain populations, including those with intellectual disability, drug-resistant epilepsy, or age older than 35 years, were more likely to experience these drug interactions. Limitations include that our data set lacks information on adherence, counseling, pregnancy intentions, sexual orientation and activity, and barrier use.
中文摘要:具有生育潜力的癫痫患者需要获得高效避孕措施,然而许多抗癫痫药物可通过诱导肝酶降低某些激素类避孕方法的有效性。本研究旨在确定被处方易受影响的激素避孕方法的癫痫患者中,同时被处方相互作用抗癫痫药物的比例及与联合用药相关的患者特征。我们获取了2016年至2021年美国医疗补助计划女性受益人的索赔数据,定义了服用抗癫痫药物且至少处方一种易受肝酶诱导影响的激素避孕方法的癫痫患者队列。利用处方填写日期和避孕程序日期,我们识别出诱导性抗癫痫药物与易受影响避孕方法重叠持续时间至少为14天的时期。我们使用描述性统计计算重叠比例及中位重叠天数。使用逻辑回归识别与任何14天重叠期相关的患者特征,并使用二项回归识别与更高比例重叠天数相关的特征。我们的队列包括110976名具有生育潜力的癫痫患者(中位年龄24岁,四分位距18-30岁,54.8%为非西班牙裔白人)。其中,21923人在2018年至2021年间被处方易受影响的避孕方法。在该群体中,7154人(32.6%)存在与酶诱导性抗癫痫药物至少14天的重叠期。该群体的中位重叠天数为218天(四分位距74-511天)。与任何重叠期及更长重叠期相关的患者特征包括智力障碍(任何重叠:调整比值比2.33,95%置信区间2.19-2.48;更长重叠:2.27,95%置信区间2.05-2.53)、药物难治性癫痫(任何重叠:1.73,95%置信区间1.62-1.84;更长重叠:1.27,95%置信区间1.14-1.41)以及年龄大于35岁(与19-34岁相比,任何重叠:1.45,95%置信区间1.32-1.59;更长重叠:1.51,95%置信区间1.29-1.75)。导致避孕效果降低的抗癫痫药物相互作用在处方易受影响激素避孕方法的具有生育潜力的癫痫患者中很常见。包括智力障碍、药物难治性癫痫或年龄大于35岁的人群更可能经历这些药物相互作用。局限性包括数据集缺乏依从性、咨询、妊娠意图、性取向与活动以及屏障使用信息。
Despite more than 30 approved antiseizure medications, many individuals with focal epilepsy continue to experience seizures, indicating a persistent need for novel therapies. To determine efficacy and safety of the novel, potent KV7 channel opener azetukalner for treatment of focal seizures. This phase 3, placebo-controlled randomized clinical trial of azetukalner was conducted over a 12-week double-blind period (November 18, 2022, to February 3, 2026) at 138 sites in North America, South America, Europe, and Asia Pacific. Adults with focal epilepsy experiencing 4 or more focal seizures per month despite stable treatment with 1 to 3 antiseizure medications were enrolled. Data were analyzed using a dataset derived from the database lock dated February 26, 2026. Participants were randomized 1:1:1 to receive placebo or 15 or 25 mg of azetukalner once daily with the evening meal for 12 weeks with no titration period. Participants completing the double-blind period could enter an open-label extension. The primary efficacy end point was median percentage change from baseline in monthly (28-day) focal seizure frequency during the double-blind period for azetukalner vs placebo. Safety and tolerability were assessed by recording treatment-emergent adverse events, changes in clinical laboratory findings, vital signs, and electrocardiogram. Of 607 adults screened, 374 participants (190 [50.8%] female; mean [SD] age, 40.0 [12.9] years) were enrolled, randomized and treated with placebo (125 participants), 15-mg azetukalner (125 participants), or 25-mg azetukalner (124 participants). Participants had a baseline median (IQR) of 12.75 (7.56 to 32.97) seizures per month and had previously tried and stopped a median (IQR) of 5 (3 to 8) antiseizure medications. Most (336 participants [89.8%]) were receiving 2 to 3 concomitant antiseizure medications. The median (IQR) change from baseline in monthly seizure frequency was -10.4% (-39.1% to 8.3%) for the placebo group, -34.5% (-61.6% to -12.3%) for the 15-mg azetukalner group (P < .001 vs placebo), and -53.2% (-77.2% to -28.8%) for the 25-mg azetukalner group (P < .001 vs placebo). Azetukalner was generally well tolerated, and treatment-emergent adverse events were comparable to those observed in the phase 2b X-TOLE trial. This randomized clinical trial found that azetukalner demonstrated robust, rapid, and durable reductions in seizure frequency with a favorable benefit-risk profile. Treatment with azetukalner resulted in one of the largest median percentage reductions in seizure frequency vs placebo reported to date in patients with drug-resistant epilepsy, supporting azetukalner as a promising novel antiseizure medication with significant opportunity to improve clinical outcomes. ClinicalTrials.gov Identifier: NCT05614063.
中文摘要:尽管已有30多种获批的抗癫痫药物,许多局灶性癫痫患者仍持续出现发作,表明对新型疗法的需求依然迫切。本研究旨在确定新型强效KV7通道开放剂azetukalner治疗局灶性发作的疗效和安全性。这项关于azetukalner的3期安慰剂对照随机临床试验在北美、南美、欧洲和亚太地区138个中心进行,双盲期为12周(2022年11月18日至2026年2月3日)。入组标准为尽管接受1至3种抗癫痫药物稳定治疗,每月仍有4次或以上局灶性发作的成年局灶性癫痫患者。数据基于2026年2月26日数据库锁定后的数据集进行分析。参与者按1:1:1比例随机分配接受安慰剂或每日一次晚餐时服用15mg或25mg azetukalner,持续12周,无滴定期。完成双盲期的参与者可进入开放标签延伸阶段。主要疗效终点为双盲期间azetukalner组与安慰剂组相比每月(28天)局灶性发作频率的中位数百分比变化。安全性及耐受性通过记录治疗相关不良事件、临床实验室检查结果变化、生命体征和心电图进行评估。在筛查的607名成年人中,374名参与者(190名女性占50.8%;平均年龄40.0岁,标准差12.9)入组并接受了安慰剂(125人)、15mg azetukalner(125人)或25mg azetukalner(124人)治疗。参与者基线每月发作次数中位数为12.75次(四分位距7.56至32.97),此前曾尝试并停用抗癫痫药物的中位数为5种(四分位距3至8)。大多数参与者(336人占89.8%)正在接受2至3种联合抗癫痫药物治疗。每月发作频率较基线的中位数变化为:安慰剂组-10.4%(-39.1%至8.3%),15mg azetukalner组-34.5%(-61.6%至-12.3%,与安慰剂相比P<0.001),25mg azetukalner组-53.2%(-77.2%至-28.8%,与安慰剂相比P<0.001)。Azetukalner总体耐受性良好,治疗相关不良事件与2b期X-TOLE试验中观察到的相当。本随机临床试验发现azetukalner能显著、快速且持久地降低发作频率,具有有利的获益风险比。与安慰剂相比,azetukalner治疗导致的发作频率中位数百分比降幅为目前报道的难治性癫痫患者中最大之一,支持azetukalner作为一种有前景的新型抗癫痫药物,有望显著改善临床结局。ClinicalTrials.gov标识符:NCT05614063。
基础研究 (2篇)
In a 2010 book chapter on the pioneering encephalographer Mary A.B. Brazier, PhD (1904-1995), a photo of a smiling woman is labeled "Margaret Lennox-Buchthal, wife of Fritz, daughter of William Lennox." Yet, like most women, Margaret Lennox-Buchthal, MD (1913-2001), was more than a wife and a daughter. She was an assistant professor at the Yale School of Medicine and associate professor at the University of Copenhagen Institute of Neurophysiology, and she was editor-in-chief of the journal Epilepsia (1969-1975). Her work had a lasting impact on our current concept of and approach to febrile seizures. She advocated for people with epilepsy and challenged stigmas as an educated divorced woman with a diagnosis of epilepsy. The story of Lennox-Buchthal's life illustrates the unsung roles women played in medicine and research in the mid-1900s, and how their achievements continue to be eclipsed by the men in their lives.
中文摘要:在2010年关于先驱脑电图学家Mary A.B. Brazier博士的一章中,一张微笑女性的照片被标注为「Fritz的妻子、William Lennox的女儿Margaret Lennox-Buchthal」。然而,像大多数女性一样,Margaret Lennox-Buchthal医生(1913-2001)不仅仅是妻子和女儿。她是耶鲁医学院的助理教授,也是哥本哈根大学神经生理研究所的副教授,并担任Epilepsia期刊的主编(1969-1975)。她的工作对我们当前对热性惊厥的概念和方法产生了持久影响。作为一名患有癫痫的教育程度较高的离异女性,她倡导癫痫患者的权益并挑战社会污名。Lennox-Buchthal的一生故事揭示了20世纪中叶女性在医学和研究中扮演的无名角色,以及她们的成就如何继续被其生活中的男性所掩盖。
People with epilepsy have reduced life expectancy and more age-related comorbidities, suggesting a link to faster biological ageing. Direct molecular evidence has been scarce. We applied DNA-methylation-based epigenetic clocks to brain and blood samples from 324 unique individuals with structural or genetic epilepsy and 65 non-epilepsy controls, and to an in utero electroporation mouse model of somatic mTOR pathway activation (etiocopy of human FCD type 2) sampled before and after seizure onset. Epigenetic age acceleration was defined as the residual from a robust regression on chronological age, sex, cell-type composition, and array type. Relative telomere length was measured in the mouse model to independently validate biological ageing. In brain, epigenetic age acceleration was consistent across structural lesion types (median +7.3 years, p < 0.0001), most pronounced in GG (+10 years, adj. p < 0.0001), followed by MOGHE (+8.1 years, adj. p < 0.0001), TLE (+6.6 years, adj. p < 0.001), and FCD (+5.6 years, adj. p < 0.001). In blood, age acceleration was not significant after adjustment for cell composition, age, and sex (median +0.7 years, p = 0.20), except in FCD (+2.3 years, adj. p < 0.05). Across structural epilepsies, acceleration was greater in brain than in blood (median +7.3 vs. + 1.4 years, p < 0.0001). Available VPA-exposure data (n = 175) was not significantly associated with age acceleration. In a drug-naïve mTOR mouse model, mutant epileptic brains, but not blood, showed epigenetic age acceleration (adj. p < 0.05). Ageing signatures were already detectable in brains of animals in the pre-seizure latency phase and were independently supported by shortened relative telomere length (adj. p = 0.05), indicating that biological ageing can precede overt epilepsy. Accelerated epigenetic ageing is a consistent feature of the epileptic brain in drug-resistant structural epilepsies and a candidate pathway for disease modification. The contribution of systemic ageing remains unresolved, and generalisability to other aetiologies will need to be further tested. Else Kröner Fresenius Stiftung, German Science Foundation, L'Institut pour la Recherche en Santé Publique, Interdisziplinäres Zentrum für Klinische Forschung, Czech Science Foundation, Ministry of Health of the Czech Republic, Ministry of Education, Youth and Sports of the Czech Republic, Research Foundation-Flanders FWO.
中文摘要:癫痫患者预期寿命缩短且年龄相关合并症增多,提示与加速生物学衰老存在关联,但直接分子证据稀缺。本研究将基于DNA甲基化的表观遗传时钟应用于324名结构性或遗传性癫痫患者及65名非癫痫对照者的脑组织和血液样本,以及体外电穿孔小鼠模型(模拟人类局灶性皮质发育不良2型体细胞mTOR通路激活)在发作前后采集的样本。表观遗传年龄加速定义为对实际年龄、性别、细胞类型组成和芯片类型的稳健回归残差。在小鼠模型中测量相对端粒长度以独立验证生物学衰老。脑组织中,表观遗传年龄加速在不同结构性病变类型中一致(中位数+7.3年,p < 0.0001),在GG中最为显著(+10年,校正后p < 0.0001),其次为MOGHE(+8.1年,校正后p < 0.0001)、TLE(+6.6年,校正后p < 0.001)和FCD(+5.6年,校正后p < 0.001)。血液中的年龄加速在调整细胞组成、年龄和性别后无统计学意义(中位数+0.7年,p = 0.20),仅在FCD中显著(+2.3年,校正后p < 0.05)。在所有结构性癫痫中,脑组织的加速程度高于血液(中位数+7.3年 vs +1.4年,p < 0.0001)。可用的丙戊酸暴露数据(n = 175)与年龄加速无显著关联。在未用药的mTOR小鼠模型中,突变癫痫脑组织而非血液显示出表观遗传年龄加速(校正后p < 0.05)。在动物发作前潜伏期的脑组织中已可检测到衰老特征,并由缩短的相对端粒长度独立支持(校正后p = 0.05),表明生物学衰老可能先于显性癫痫发生。加速的表观遗传衰老是难治性结构性癫痫患者脑组织的一致特征,也是疾病修饰的候选通路。系统性衰老的贡献仍未明确,其向其他病因的推广性需进一步验证。
5神经遗传/影像与基础转化 (6篇)
基础研究 (6篇)
The blood-brain barrier (BBB) has been defined primarily by what it excludes, yet the scale and function of physiological blood-to-brain protein transport remain largely unknown. Using bioorthogonal proteomics, we find that the healthy BBB samples 191 plasma proteins and permits 92 into the brain parenchyma. Enriched for carrier and metabolic functions, these proteins home to distinct brain cell types, such as apolipoprotein A1 (APOA1) to astrocytes and alpha-1 antitrypsin (SERPINA1) to microglia. This cell-type tropism relies on a BBB-parenchyma receptor hand-off: APOA1 crosses the BBB via SR-B1 and engages astrocytic ATP-binding cassette transporter A1 (ABCA1), a key Alzheimer's risk gene, driving cholesterol efflux that supports synapse integrity. Unlike LPS-induced nonspecific leakage, early-stage 5xFAD mice show selective BBB transport remodeling, with reduced APOA1 and increased SERPINA1 uptake. Hepatic APOA1 overexpression restores APOA1 in the 5xFAD brain, rescuing astrocytic, synaptic, and behavioral deficits. These findings recast the BBB as a selective interface that recruits neuroprotective circulatory proteins for brain health.
中文摘要:血脑屏障(BBB)主要被定义为排除物质的结构,但其生理性血液至大脑蛋白质运输的规模和功能仍 largely unknown。利用生物正交蛋白质组学技术,我们发现健康的血脑屏障采样了191种血浆蛋白并允许92种进入脑实质。这些富含载体和代谢功能的蛋白归巢于特定的脑细胞类型,例如载脂蛋白A1(APOA1)归巢于星形胶质细胞,而α-1抗胰蛋白酶(SERPINA1)归巢于小胶质细胞。这种细胞类型趋向性依赖于血脑屏障与实质间的受体接力:APOA1通过SR-B1穿过血脑屏障并与星形胶质细胞的ATP结合盒转运体A1(ABCA1)结合,ABCA1是关键阿尔茨海默病风险基因,驱动胆固醇外流以支持突触完整性。与非特异性的脂多糖(LPS)诱导渗漏不同,早期5xFAD小鼠模型显示选择性血脑屏障运输重塑,表现为APOA1摄取减少和SERPINA1摄取增加。肝脏APOA1过表达可恢复5xFAD大脑中的APOA1水平,挽救星形胶质细胞、突触及行为缺陷。这些发现将血脑屏障重新定义为招募神经保护性循环蛋白以维持大脑健康的选择性界面。
Neuromelanins (NMs) accumulate in large amounts in catecholaminergic neurons of the substantia nigra (SN) and locus coeruleus (LC), which selectively degenerate in Parkinson's disease (PD) and Alzheimer's disease (AD). Lower amounts of NMs are also present in other human brain regions. NMs are contained in specialized autolysosomes with lipid bodies, proteins, and metals. Their structure, synthesis, functions, and cellular localization differ from those of melanins in non-nervous tissues. Purified NMs have a complex structure, are composed of melanic moieties, lipids, proteins, and inorganic components, and are insoluble. NMs can exert either a protective or toxic role depending on cellular context. NMs synthesis is driven by cytosolic catecholamines and is a protective process, as it removes excess cytosolic catechols that would otherwise trigger neurotoxicity. NMs can bind reactive/toxic metals, forming stable and non-toxic complexes, thereby playing a neuroprotective role. However, NMs released from degenerating neurons in PD and AD activate microglia, which release reactive species and proinflammatory factors, thereby exacerbating neuroinflammation and neurodegeneration. The major histocompatibility complex class I is present within NM-containing organelles of SN and LC neurons and can bind antigens, presenting them on the neuronal membrane. Subsequently, CD8+ T-cells may target catecholaminergic NM-containing neurons, contributing to neurodegeneration. The loss of NM-containing neurons in PD and AD causes a decrease of NMs concentration within the SN and LC, which can be visualized using magnetic resonance imaging (MRI). NM-sensitive MRI of the SN and LC is increasingly being used for the diagnosis and treatment monitoring of neurodegenerative and psychiatric disorders.
中文摘要:神经黑素在帕金森病和阿尔茨海默病中选择性退化的黑质多巴胺能神经元和蓝斑去甲肾上腺素能神经元内大量积累。其他人类脑区也存在少量神经黑素。神经黑素存在于含有脂体、蛋白质和金属的特化自噬溶酶体中。其结构、合成、功能和细胞定位与非神经组织中的黑色素不同。纯化的神经黑素结构复杂,由类黑色素部分、脂质、蛋白质和无机成分组成且不溶于水。根据细胞环境的不同,神经黑素可发挥保护性或毒性作用。神经黑素的合成由胞质儿茶酚胺驱动,是一种保护性过程,因为它能清除多余的胞质儿茶酚酚从而避免神经毒性。神经黑素能结合反应性/毒性金属形成稳定且无毒的复合物,从而发挥神经保护作用。然而,在帕金森病和阿尔茨海默病中从退化神经元释放出的神经黑素会激活小胶质细胞,后者释放活性物质和促炎因子,从而加剧神经炎症和神经退行性变。主要组织相容性复合体I类存在于黑质和蓝斑神经元含神经黑素的细胞器内并可结合抗原将其呈递于神经元膜上随后CD8+T细胞可能靶向含儿茶酚胺的神经黑素神经元从而促进神经退行性变。帕金森病和阿尔茨海默病中含神经黑素神经元的丢失导致黑质和蓝斑内神经黑素浓度降低这可通过磁共振成像进行可视化。针对黑质和蓝斑的神经黑素敏感磁共振成像越来越多地用于神经退行性疾病和精神障碍的诊断和治疗监测。
Region-specific synapse loss is an early hallmark of Alzheimer's disease, yet the upstream signals that render synapses vulnerable remain unclear. In a mouse model of amyloidosis, we identify an early astrocyte state that emerges in vulnerable brain regions before widespread plaque deposition and overt gliosis. These astrocytes exhibit bulbous-looking perisynaptic processes enriched in p62 and glycogen, impaired autophagic flux and calcium signaling, and diminished astrocyte-synapse coverage. Rather than exhibiting increased synapse engulfment, bulbous astrocytes show elevated milk fat globule-epidermal growth factor 8 (MFG-E8) and are associated with increased local microglial synapse engulfment. Astrocyte-specific gain- and loss-of-function experiments demonstrate that astrocyte-derived MFG-E8 is required for microglial synapse engulfment and acts through microglial β3 integrin signaling. Astrocytic Mfge8 deletion reduces microglial engulfment and synapse loss across amyloidosis models and is associated with reduced amyloid pathology, gliosis, and cognitive impairment. Together, these findings define an astrocyte-microglia MFG-E8 signaling axis that contributes to region-specific synaptic vulnerability during early amyloid pathology.
中文摘要:突触丢失是阿尔茨海默病的早期标志,但导致突触易感的上游信号尚不明确。在淀粉样变性小鼠模型中,我们鉴定出一种在广泛斑块沉积和明显胶质增生之前即出现在易感脑区的早期星形胶质细胞状态。这些星形胶质细胞表现出膨大的突触周围突起,富含p62和糖原,自噬流和钙信号受损,且星形胶质细胞对突触的覆盖减少。膨大星形胶质细胞并未表现出突触吞噬增加,而是显示牛奶脂肪球-表皮生长因子8(MFG-E8)升高,并与局部小胶质细胞突触吞噬增加相关。星形胶质细胞特异性功能获得和缺失实验表明,星形胶质细胞来源的MFG-E8是小胶质细胞突触吞噬所必需的,并通过小胶质细胞β3整合素信号发挥作用。在淀粉样变性模型中,星形胶质细胞Mfge8敲除减少了小胶质细胞吞噬和突触丢失,并与淀粉样病变、胶质增生和认知障碍减轻相关。综上所述,这些发现定义了一种参与早期淀粉样病理期间区域特异性突触易感的星形胶质细胞-小胶质细胞MFG-E8信号轴。
Current therapies for Parkinson's disease (PD) relieve symptoms but do not slow neurodegeneration. Chronic neuroinflammation driven by innate immunity is increasingly implicated in dopaminergic neuron loss, and the cytosolic DNA sensor cGAS and its adaptor STING are candidate mediators. cGAS-STING converts misplaced self- or pathogen-derived double-stranded DNA into type I interferon and NF-κB responses. We summarize the signaling cascade and its structural basis, and review evidence from post-mortem tissue, genetic studies and animal models that mitochondrial DNA leakage, lysosomal dysfunction and α-synuclein pathology activate cGAS-STING in microglia and astrocytes. We propose an Aging-BBB-virus-cGAS-STING hypothesis to explain delayed onset and selective nigral vulnerability. Finally, we evaluate natural compounds, autophagy enhancers and STING inhibitors, and argue that brain penetration and combination approaches will determine whether cGAS-STING inhibition becomes disease-modifying.
中文摘要:当前帕金森病疗法仅能缓解症状,无法延缓神经退行性变。由先天免疫驱动的慢性神经炎症日益被认为与多巴胺能神经元丢失有关,胞质DNA传感器cGAS及其适配蛋白STING是潜在的介导因子。cGAS-STING将错位的自身或病原体来源的双链DNA转化为I型干扰素和NF-κB反应。我们总结了该信号级联反应及其结构基础,并回顾了来自死后组织、遗传学和动物模型的研究证据,表明线粒体DNA泄漏、溶酶体功能障碍和α-突触核蛋白病理激活了小胶质细胞和星形胶质细胞中的cGAS-STING通路。我们提出了衰老-血脑屏障-病毒-cGAS-STING假说,以解释发病延迟和黑质选择性易感性。最后,我们评估了天然化合物、自噬增强剂和STING抑制剂,并认为脑渗透性和联合疗法将决定cGAS-STING抑制是否能成为疾病修饰手段。
Paraquat (PQ) is an environmentally relevant herbicide associated with neurotoxicity and Parkinson's disease (PD) risk, yet the key molecular determinants linking PQ exposure to PD and the cellular states in which these alterations occur remain incompletely understood. We integrated network toxicology, human PD transcriptomics, machine learning, single-cell RNA sequencing, spatial transcriptomics, spatial metabolomics, virtual perturbation, model-inferred protein analysis, molecular docking, and tissue validation to characterize PQ-associated molecular and cellular remodeling. Integrating PQ-associated targets with PD-related genes identified 293 candidates, among which prostaglandin D2 synthase (PTGDS) was consistently prioritized by random forest, XGBoost, and LASSO, with its PD-associated expression pattern reproduced across the discovery and independent validation cohorts. Single-cell analysis localized Ptgds expression predominantly to oligodendrocytes and identified two PTGDS-enriched mature oligodendrocyte (MOL) states with PQ-associated compositional patterns. CytoTRACE placed these PTGDS-enriched populations among relatively mature oligodendrocyte states. Functional analyses revealed distinct state-specific programs, with Ptgds+Mag+ MOL associated with myelin-associated programs, axon ensheathment-related programs, cholesterol metabolism, and lipid transport, whereas Ptgds+Il33+ MOL was linked to neuron-interaction-related programs, synaptic organization, cell adhesion, and neuron-glia communication. Ligand-receptor inference and spatial analyses supported state-specific changes in neuron-glia communication and spatial relationships. Spatial metabolomics showed significantly increased phosphatidylcholine and sphingomyelin signals in regions with higher inferred representation of Ptgds+Mag+ MOL states. Virtual Ptgds perturbation and scTranslator-based protein prediction further suggested state-specific myelin-lipid and neuron-interaction programs, while molecular docking provided preliminary structural predictions regarding a potential PQ-PTGDS interaction. Immunofluorescence further confirmed PTGDS localization in mature oligodendrocytes within the substantia nigra. Collectively, these findings identify PTGDS-enriched mature oligodendrocyte states as cellular contexts associated with PQ-related brain remodeling and extend our understanding of PQ neurotoxicity beyond classical neuron-centered mechanisms. This integrative framework provides mechanistic insight into how an environmental neurotoxicant may reshape myelin-lipid homeostasis and neuron-glia interactions in the context of PD-related brain pathology.
中文摘要:百草枯(PQ)是一种与环境相关的除草剂,与神经毒性和帕金森病(PD)风险相关,但连接PQ暴露与PD的关键分子决定因素及其发生的细胞状态尚不完全清楚。我们整合了网络毒理学、人类PD转录组学、机器学习、单细胞RNA测序、空间转录组学、空间代谢组学、虚拟扰动、模型推断蛋白分析、分子对接和组织验证,以表征PQ相关的分子和细胞重塑。将PQ相关靶点与PD相关基因整合后鉴定出293个候选基因,其中前列腺素D2合酶(PTGDS)被随机森林、XGBoost和LASSO一致优先选择,其PD相关表达模式在发现队列和独立验证队列中均得到复现。单细胞分析将Ptgds表达主要定位于少突胶质细胞,并鉴定出两个具有PQ相关组成模式的PTGDS富集成熟少突胶质细胞(MOL)状态。CytoTRACE将这些PTGDS富集群体置于相对成熟的少突胶质细胞状态中。功能分析揭示了不同的状态特异性程序,其中Ptgds+Mag+ MOL与髓鞘相关程序、轴突包被相关程序、胆固醇代谢和脂质运输相关,而Ptgds+Il33+ MOL与神经元相互作用相关程序、突触组织、细胞粘附和神经胶质细胞通讯相关。配体-受体推断和空间分析支持了神经胶质细胞通讯和空间关系的状态特异性变化。空间代谢组学显示,在推断的Ptgds+Mag+ MOL状态代表较高的区域中,磷脂酰胆碱和鞘磷脂信号显著增加。虚拟Ptgds扰动和基于scTranslator的蛋白预测进一步提示了状态特异性髓鞘脂质和神经元相互作用程序,而分子对接提供了关于潜在PQ-PTGDS相互作用的初步结构预测。免疫荧光进一步证实了黑质中成熟少突胶质细胞内PTGDS的定位。综上所述,这些发现将PTGDS富集成熟少突胶质细胞状态确定为与PQ相关脑重塑相关的细胞背景,并扩展了我们对PQ神经毒性的认识,超越了经典的以神经元为中心的机制。这一整合框架为环境神经毒素如何在PD相关脑病理背景下重塑髓鞘脂质稳态和神经胶质细胞相互作用提供了机制见解。
Hibernation demands rapid brain adaptations, involving cycles of reduced metabolic rate during torpor, followed by brief periods of arousal. Previous studies show hibernation induces a drastic increase in Tau hyperphosphorylation, but a mechanistic connection to disease remains unclear. Using single-nucleus RNA sequencing on hippocampi of golden hamsters, we unveil large transcriptional shifts across the hibernation cycle in all cell types, especially glia. Common transcriptional changes in mitochondrial and ribosomal genes are observed in all different cell types. In addition, hibernation triggers an inflammatory-like response in microglia that in part resembles cell states observed in Alzheimer's disease, but here in the absence of Aβ-accumulation and neurodegeneration. These findings reveal brain transformations that might help preserve vital functions under extreme conditions and they suggest that early cellular changes in AD may be a natural adaptive process.
中文摘要:冬眠要求大脑快速适应,涉及蛰伏期间代谢率降低的循环以及随后短暂的觉醒期。既往研究表明冬眠会导致Tau蛋白过度磷酸化急剧增加,但其与疾病的机制联系尚不明确。通过对金仓鼠海马体进行单核RNA测序,我们揭示了在整个冬眠周期中所有细胞类型尤其是胶质细胞发生的大规模转录变化。在所有不同细胞类型中均观察到线粒体和核糖体基因的共同转录变化。此外,冬眠在少突胶质细胞中触发了类似炎症的反应,这在一定程度上类似于阿尔茨海默病中观察到的细胞状态,但此处不存在Aβ沉积和神经退行性变。这些发现揭示了可能有助于在极端条件下维持重要功能的大脑转变,并提示阿尔茨海默病的早期细胞变化可能是一种自然适应过程。
6多发性硬化与神经免疫 (5篇)
临床研究 (2篇)
To determine the long-term diagnostic transition and temporal pattern of central nervous system (CNS) inflammatory events after a first episode of optic neuritis. Multicenter retrospective cohort study. Six hundred one consecutive patients with first-episode optic neuritis who presented to 11 tertiary referral centers in Japan between January 2016 and December 2023. Patients with MRI-confirmed first-episode optic neuritis were retrospectively enrolled. Clinical characteristics, antibody status, treatments, subsequent events, and final diagnoses were collected from longitudinal follow-up. Transition in the diagnosis of optic neuritis from the time of initial onset to the end of longitudinal follow-up. A total of 601 patients were enrolled and followed for a median of 2 years (interquartile range [IQR], 1-4.5 years). At onset, initial diagnoses were idiopathic in 295 patients (49.1%), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in 134 (22.3%), neuromyelitis optica spectrum disorder (NMOSD) in 120 (20.0%), multiple sclerosis (MS) in 16 (2.7%), and other diagnoses in 36 (6.0%). At last follow-up, final diagnoses were single isolated optic neuritis in 222 patients (36.9%), recurrent isolated optic neuritis in 23 (3.8%), MOGAD in 134 (22.3%), NMOSD in 125 (20.8%), MS in 77 (12.8%), and other diagnoses in 20 (3.3%). Overall, 166 of 601 patients (27.6%) experienced at least one CNS inflammatory event other than the initial optic neuritis. Recurrent optic neuritis was the most frequent event (58.8%), followed by encephalitis (22.9%) and myelitis (18.3%). Among patients with post-onset events, 64 (48.9%) developed an event within 1 year and 97 (74.0%) within 2 years after the initial episode of optic neuritis. Among the 131 patients with post-onset events, more than half (77 patients, 58.8%) developed outside maintenance therapy, including 68 after treatment discontinuation and 9 without maintenance therapy. More than one-quarter of patients with first-episode optic neuritis experienced CNS inflammatory events other than the initial optic neuritis, and only approximately one-third ultimately remained classified as having single isolated optic neuritis. These findings demonstrate that first-episode optic neuritis frequently represents the onset of an underlying CNS inflammatory disease, underscoring the importance of long-term neurological surveillance following the initial episode.
中文摘要:本研究旨在明确首次视神经炎发作后中枢神经系统炎症事件的长期诊断演变及时间模式。这是一项多中心回顾性队列研究,纳入了2016年1月至2023年12月期间日本11家三级转诊中心收治的601例首次发作视神经炎患者。通过纵向随访收集患者的临床特征、抗体状态、治疗方案、后续事件及最终诊断,主要观察指标为从发病到随访结束期间的视神经炎诊断演变情况。结果显示,中位随访时间为2年(四分位距1至4.5年)。在发病初期,295例(49.1%)诊断为特发性,134例(22.3%)为髓鞘少突胶质细胞糖蛋白抗体相关疾病,120例(20.0%)为视神经脊髓炎谱系疾病,16例(2.7%)为多发性硬化,其他诊断36例(6.0%)。在最后一次随访时,最终诊断为孤立性单次视神经炎者222例(36.9%),复发性孤立性视神经炎23例(3.8%),髓鞘少突胶质细胞糖蛋白抗体相关疾病134例(22.3%),视神经脊髓炎谱系疾病125例(20.8%),多发性硬化77例(12.8%),其他诊断20例(3.3%)。总体而言,601例患者中有166例(27.6%)经历了除初始视神经炎外的至少一次中枢神经系统炎症事件。复发性视神经炎是最常见的后续事件(58.8%),其次是脑炎(22.9%)和脊髓炎(18.3%)。在出现后续事件的患者中,48.9%在首次发作后1年内发病,74.0%在2年内发病。在131例有后续事件的患者中,超过半数(58.8%,77例)在维持治疗期间或停药后发病,其中68例在治疗中断后,9例未接受维持治疗。首次发作视神经炎患者中超过四分之一经历了除初始视神经炎外的中枢神经系统炎症事件,仅约三分之一最终被归类为孤立性单次视神经炎。这些发现表明,首次发作视神经炎常代表潜在中枢神经系统炎症疾病的起始,强调了在初始发作后进行长期神经监测的重要性。
Selecting a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) is a preference-sensitive decision where shared decision-making (SDM) is essential. This study aimed to evaluate the perceived quality of the SDM process and identify independent determinants of decisional conflict among patients with early-stage RRMS. This non-interventional, cross-sectional, multicenter study across 16 Spanish neuroimmunology clinics evaluated adults with early RRMS (≤ 3 years disease duration from diagnosis) receiving DMTs. SDM process quality and decisional conflict were assessed using the AGA-25 questionnaire and the SURE tests, respectively. Multivariable logistic regression models were constructed to identify independent determinants of high process satisfaction and decisional conflict. The evaluable population comprised 145 patients (mean age 37.6 years, 69.0% female). Participants evaluated the SDM process favorably (mean total AGA-25 score 67.1 [SD 9.1]). High process satisfaction was reported by 26.2% of patients (n = 38). In multivariable analysis, male sex and a higher total number of relapses since disease onset were associated with significantly lower odds of high process satisfaction, whereas higher decisional certainty was an independent positive determinant. Clinically significant decisional conflict was present in 27.1% of participants (n = 36). In the multivariable model, greater illness-related uncertainty, a more threatening illness perception, and higher fatigue impact independently increased the likelihood of decisional conflict. Although patients with early-stage RRMS generally report a favorable overall perception of collaborative treatment selection, high process satisfaction is attained by only approximately one-quarter of patients. Furthermore, clinically significant decisional conflict affects over 27% of individuals early in their disease course. This decisional distress is driven predominantly by the subjective emotional and perceptual burden of living with MS, rather than objective physical disability.
中文摘要:选择疾病修饰疗法治疗复发型多发性硬化症是一种偏好敏感决策,共享决策至关重要。本研究旨在评估早期复发型多发性硬化症患者对共享决策过程质量的感知,并确定决策冲突的独立决定因素。这项在16家西班牙神经免疫诊所开展的非干预性、横断面、多中心研究纳入了确诊后病程不超过3年的接受疾病修饰疗法的早期复发型多发性硬化症成年患者。使用AGA-25问卷和SURE测试分别评估共享决策过程质量和决策冲突。构建多变量逻辑回归模型以识别高过程满意度和决策冲突的独立决定因素。可评估人群包括145名患者(平均年龄37.6岁,女性占69.0%)。参与者对共享决策过程评价良好(AGA-25总分均值67.1,标准差9.1)。26.2%的患者报告高过程满意度。在多变量分析中,男性性别和自发病以来复发总数较多与高过程满意度的几率显著降低相关,而较高的决策确定性是独立的积极决定因素。27.1%的参与者存在临床显著的决策冲突。在多变量模型中,更高的疾病相关不确定性、更威胁性的疾病感知和更高的疲劳影响独立增加了决策冲突的可能性。尽管早期复发型多发性硬化症患者总体上对协作治疗选择报告了良好的整体感知,但仅有约四分之一的患者获得高过程满意度。此外,临床显著的决策冲突影响了其病程早期超过27%的个体。这种决策困扰主要由患有神经免疫疾病的主观情感和感知负担驱动,而非客观的身体残疾。
基础研究 (3篇)
Clinical progression is strongly linked to gray matter atrophy in multiple sclerosis (MS), detectable early on MRI and progressing nonrandomly across the brain. However, the mechanisms driving its spatiotemporal progression and individual variability remain unclear. Using MRIs from 2187 participants, alongside normative data, we systematically investigated network-based mechanisms underlying MS-related atrophy. Regional atrophy was associated with functional cortical hubness, supporting the nodal stress hypothesis, and was constrained by anatomical and functional connections, consistent with transneuronal degeneration. Lesional disconnection and transcriptomic vulnerability played marginal roles. Patient- and subgroup-level analyses revealed that network-based mechanisms are specifically linked to MS-related neurodegeneration and may operate differently in distinct subtypes or disease phases. Atrophy patterns were anchored to the connectivity profiles of disease epicenters involving the visual, sensorimotor, and temporal cortices, as well as the hippocampi, amygdalae, and thalami. Network-based measures enhanced the explanation of future atrophy progression in people with MS, providing a mechanistic framework to understand neurodegeneration in MS.
中文摘要:临床进展与多发性硬化(MS)中的灰质萎缩密切相关,这种萎缩可早期通过磁共振成像检测到,并在大脑中非随机地进展。然而,驱动其时空进展和个体差异的机制尚不清楚。我们利用2187名参与者的磁共振成像数据及规范数据,系统研究了基于网络的MS相关萎缩机制。区域性萎缩与功能皮层枢纽性相关,支持节点应激假说,并受解剖和功能连接的约束,符合神经元间退行性变的特征。病灶断开和转录组脆弱性作用较小。患者及亚组水平分析显示,基于网络的机制与MS相关的神经退行性变特异性相关,且可能在不同亚型或疾病阶段以不同方式运作。萎缩模式锚定于涉及视觉、感觉运动及颞叶皮层以及海马、杏仁核和丘脑的疾病中心区域的连接特征。基于网络的指标增强了人们对MS患者未来萎缩进展的解释能力,为理解MS中的神经退行性变提供了机制框架。
Several autoantibodies promote inflammation and fibrosis in systemic sclerosis (SSc). Efgartigimod, engineered to block the neonatal fragment crystallisable (Fc) receptor (FcRn) and reduce immunoglobulin G (IgG) autoantibody levels, is approved for autoantibody-driven generalised myasthenia gravis and chronic inflammatory demyelinating neuropathy. FcRn blockade with murinised efgartigimod (mEfgartigimod) and an FcRn-blocking IgG1 Fc fragment was evaluated in the topoisomerase-I (TopoI)-induced mouse model of autoimmunity-driven fibrosis. Effects were assessed by immunoglobulin levels, biochemical and histological fibrosis readouts, Olink analyses, RNA sequencing (RNA-Seq), and imaging mass cytometry (IMC). Both prophylactic and therapeutic mEfgartigimod ameliorated dermal and pulmonary fibrosis in TopoI mice, comparably to nintedanib. Bulk RNA-Seq analysis demonstrated FcRn blockade with mEfgartigimod downregulated inflammatory, autoimmune, and fibrotic signalling pathways, with reduced expression of Ccl chemokines, tumour necrosis factor superfamily cytokines, and type I interferon signalling components. IMC showed reduced accumulation of myofibroblasts, classically activated macrophages, dendritic cells, and T cells upon FcRn blockade. Single‑nucleus RNA-Seq revealed altered fibroblast-macrophage crosstalk, with decreases in myofibroblasts, inflammatory and neutrophil-like macrophages, and T cells with cell-type-specific transcriptional effects associated with reversal of profibrotic/inflammatory transcriptional programs. Consistent with these cellular changes, the circulating levels of Il1β and several chemokines were downregulated upon treatment, whereas antifibrotic mediators, such as Fgf21 and soluble Pd-l2, were upregulated. These findings highlight that FcRn blockers such as efgartigimod may have potential to simultaneously target autoimmune, inflammatory, and fibrotic features of SSc and highlight the potential of autoantibody-reducing therapies as disease-modifying approaches in SSc. A randomised, controlled phase 2 trial with efgartigimod in SSc is currently ongoing.
中文摘要:多种自身抗体促进系统性硬化症(SSc)中的炎症和纤维化。Efgartigimod 经工程改造以阻断新生儿 Fc 受体(FcRn)并降低免疫球蛋白 G(IgG)自身抗体水平,已获批用于自身抗体驱动的全身性重症肌无力及慢性炎性脱髓鞘性多发性神经病。本研究在拓扑异构酶-I(TopoI)诱导的自身免疫驱动纤维化小鼠模型中,评估了鼠源化 efgartigimod(mEfgartigimod)和 FcRn 阻断型 IgG1 Fc 片段的作用。通过免疫球蛋白水平、生化及组织学纤维化指标、Olink 分析、RNA 测序(RNA-Seq)和成像质谱流式细胞术(IMC)评估效果。预防性和治疗性 mEfgartigimod 均能改善 TopoI 小鼠的皮肤和肺部纤维化,效果与尼达尼布相当。批量 RNA-Seq 分析显示,mEfgartigimod 介导的 FcRn 阻断下调了炎症、自身免疫和纤维化信号通路,降低了 Ccl 趋化因子、肿瘤坏死因子超家族细胞因子及 I 型干扰素信号组件的表达。IMC 结果显示,FcRn 阻断后肌成纤维细胞、经典活化巨噬细胞、树突状细胞和 T 细胞的积累减少。单核 RNA-Seq 揭示了成纤维细胞与巨噬细胞相互作用的改变,包括肌成纤维细胞、炎症性和中性粒细胞样巨噬细胞以及 T 细胞的减少,并伴有与逆转促纤维化/炎症转录程序相关的细胞类型特异性转录效应。这些细胞变化与循环中 Il1β 和多种趋化因子水平下调一致,而抗纤维化介质如 Fgf21 和可溶性 Pd-l2 则上调。这些发现表明,efgartigimod 等 FcRn 阻断剂可能同时靶向 SSc 的自身免疫、炎症和纤维化特征,突显了降低自身抗体疗法作为 SSc 疾病修饰策略的潜力。目前正在进行一项关于 efgartigimod 治疗 SSc 的随机对照 II 期临床试验。
Muscle-specific tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG) is a severe autoimmune disease with limited effective treatment options. We designed an mRNA-encoded bispecific T-cell engager (MuSK×CD3 TCE) comprising the human MuSK extracellular domain and an anti-CD3 single-chain variable fragment (scFv), delivered via a lipid nanoparticles (LNPs) to the liver to enable in vivo protein synthesis, which redirects cytotoxic T cells to eliminate B cells expressing anti-MuSK B cell receptors (BCR). In vitro, the MuSK×CD3 TCE mediated dose-dependent cytotoxicity against MuSK+ target cells and induced robust T cell activation. In human PBMC-engrafted NOG mice, mRNA-LNP administration led to dose-dependent and specific inhibition of tumor growth in anti-MuSK BCR-positive tumors, with no significant impact on non-target B cells. Importantly, the TCE retained potent cytotoxic activity in the presence of physiological concentrations of MuSK autoantibodies-a key consideration for clinical translation, as patients with MuSK-MG typically harbor circulating autoantibodies. This "off-the-shelf" mRNA-LNP platform offers a precise, controllable and potent immunotherapy strategy for MuSK-MG and may be broadly applicable for other autoantibody-mediated diseases to eliminate pathogenic BCR+ B cells.
中文摘要:肌特异性酪氨酸激酶抗体阳性重症肌无力(MuSK-MG)是一种严重的自身免疫性疾病,目前缺乏有效的治疗手段。我们设计了一种编码mRNA的双特异性T细胞衔接器(MuSK×CD3 TCE),包含人MuSK胞外结构域和抗CD3单链可变片段(scFv),通过脂质纳米颗粒(LNP)递送至肝脏以实现体内蛋白质合成,从而将细胞毒性T细胞重定向以清除表达抗MuSK B细胞受体(BCR)的B细胞。体外实验显示,MuSK×CD3 TCE对MuSK阳性靶细胞介导了剂量依赖性的细胞毒性并诱导了强烈的T细胞活化。在人PBMC植入的NOG小鼠模型中,mRNA-LNP给药导致抗MuSK BCR阳性肿瘤生长受到剂量依赖性且特异性的抑制,而对非靶向B细胞无显著影响。重要的是,在生理浓度的MuSK自身抗体存在下,该衔接器仍保留了强大的细胞毒性活性,这是临床转化的关键考量因素,因为MuSK-MG患者通常携带循环自身抗体。这种现成的mRNA-LNP平台为MuSK-MG提供了一种精确、可控且强效的免疫治疗策略,并可能广泛适用于其他自身免疫性抗体介导的疾病以清除致病性BCR阳性B细胞。
7帕金森病与运动障碍 (5篇)
临床研究 (1篇)
Evidence for the effect of physical activity on disease progression in Parkinson disease (PD) remains limited. We aimed to examine whether physical activity is associated with the rate of motor and cognitive progression in PD and to identify specific components of physical activity underlying these associations. In this longitudinal cohort study, we analyzed data from individuals with mild-to-moderate PD enrolled in the Cincinnati Cohort Biomarker Program between January 2019 and February 2025. Physical activity was assessed using standardized interviews and quantified as total physical activity time (TPT), total physical activity volume (TPV), and vigorous physical activity time (VPT). Longitudinal associations between physical activity and annual changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale, part III (MDS-UPDRS-III; higher is worse) and Montreal Cognitive Assessment (MoCA; higher is better) scores were assessed using linear mixed-effects models adjusted for demographic and disease-related covariates. We compared predicted severity trajectories across tertiles of TPT and used residualized analyses to evaluate the independent effects of activity intensity and timing. A total of 294 individuals with PD (mean age, 66.4 years; 33.0% female) were included, with up to 5 years of follow-up for MoCA and 7 years for MDS-UPDRS-III. Higher TPT, TPV, and VPT were each associated with slower cognitive decline and motor progression. The annual MoCA change was -0.478, -0.090, and -0.007 points in the low, mid, and high TPT tertiles, respectively, with corresponding annual MDS-UPDRS-III changes of 0.143, -0.225, and -0.783. Compared with the lowest tertile, the highest tertile showed slower cognitive (β = 0.470; 95% CI 0.203-0.737; p < 0.001) and motor (β = -0.926; 95% CI -1.835 to -0.017; p = 0.048) progression. In residualized analyses, recent physical activity remained associated with longitudinal changes in both MoCA and MDS-UPDRS-III scores after accounting for previous 10-year physical activity, whereas vigorous physical activity was no longer associated with outcomes after adjustment for total physical activity time. Higher levels of physical activity were associated with slower cognitive and motor progression in PD. The beneficial associations of moderate-to-vigorous physical activity may be related to activity duration and ongoing engagement. Limitations include the observational design, self-reported physical activity, and potential selection bias.
中文摘要:关于体力活动对帕金森病(PD)疾病进展影响的研究证据仍然有限。本研究旨在探讨体力活动是否与PD的运动和认知进展速率相关,并识别这些关联背后的具体体力活动成分。在这项纵向队列研究中,我们分析了2019年1月至2025年2月期间辛辛那提生物标志物计划项目中轻中度PD患者的数据。通过标准化访谈评估体力活动,并将其量化为总体力活动时间(TPT)、总体力活动量(TPV)和剧烈体力活动时间(VPT)。使用线性混合效应模型评估了体力活动与运动障碍学会统一帕金森病评定量表第三部分(MDS-UPDRS-III;分数越高病情越重)及蒙特利尔认知评估(MoCA;分数越高越好)年度变化之间的纵向关联,并调整了人口统计学和疾病相关协变量。我们比较了不同TPT三分位数的预测严重程度轨迹,并使用残差分析评估活动强度和时间的独立影响。共纳入294名PD患者(平均年龄66.4岁;女性占33.0%),MoCA随访时间最长5年,MDS-UPDRS-III最长7年。较高的TPT、TPV和VPT均与较慢的认知下降和运动进展相关。低、中、高TPT三分位数的年度MoCA变化分别为-0.478、-0.090和-0.007分,对应的年度MDS-UPDRS-III变化分别为0.143、-0.225和-0.783。与最低三分位数相比,最高三分位数显示出更慢的认知(β = 0.470;95% CI 0.203-0.737;p < 0.001)和运动(β = -0.926;95% CI -1.835至-0.017;p = 0.048)进展。在残差分析中,在考虑过去10年的体力活动后,近期体力活动仍与MoCA和MDS-UPDRS-III分数的纵向变化相关,而在调整总体力活动时间后,剧烈体力活动与结果不再相关。较高水平的体力活动与PD较慢的认知和运动进展相关。中等至剧烈体力活动的有益关联可能与活动持续时间和持续参与有关。局限性包括观察性设计、自我报告的体力活动以及潜在的选择偏倚。
基础研究 (4篇)
Precise monitoring of tremor states is critical for guiding medication regimens and optimizing clinical treatment for patients with Parkinson's disease. Inspired by the ampullae of Lorenzini in sharks, we propose a facile wet spinning strategy to construct magnetically conductive core-shell fibers with a hollow core and hierarchical interconnected pore structures (LM-MPU fiber). The unique fiber architecture is formed via the phase separation of thermoplastic polyurethane (TPU) and interfacial interactions between TPU and the surface oxide layer of liquid metal (LM) during spinning. The resultant LM-MPU fibers integrate good flexibility, desirable magnetic responsiveness, and low resistivity (3.9 × 10-5 ± 8.9 × 10-6 Ω m), while exhibiting high strain insensitivity of electrical performance. When woven into flexible textiles, the developed fibrous sensors enable high precision monitoring of hand tremors based on electromagnetic induction, achieving an ultra-short response time of 0.016 s. A specialized data acquisition circuit, a real-time data acquisition application, and a one-dimensional convolutional neural network (1D-CNN) intelligent diagnosis algorithm were developed to accurately record and autonomously classify different hand tremor states. Benefiting from its low cost and superior flexibility, this versatile sensing system holds great promise for evaluating disease progression in Parkinson's patients, providing reliable technical support for efficient clinical diagnosis and personalized medication management.
中文摘要:精确监测震颤状态对于指导帕金森病患者的用药方案和优化临床治疗至关重要。受鲨鱼洛伦兹尼壶腹的启发,我们提出了一种简便的湿法纺丝策略,构建了具有空心核心和层级互连孔隙结构的磁导性核壳纤维(LM-MPU纤维)。这种独特的纤维结构是通过热塑性聚氨酯(TPU)与液态金属(LM)表面氧化层之间的界面相互作用在纺丝过程中发生相分离而形成的。所得的LM-MPU纤维兼具良好的柔韧性、理想的磁响应性和低电阻率(3.9×10-5±8.9×10-6Ωm),同时表现出对电性能的高应变不敏感性。当织入柔性纺织品时,开发的纤维传感器基于电磁感应原理实现了对手部震颤的高精度监测,响应时间极短,仅为0.016秒。我们开发了专用的数据采集电路、实时数据采集应用程序以及一维卷积神经网络(1D-CNN)智能诊断算法,以准确记录并自动分类不同的手部震颤状态。凭借其低成本和卓越的柔韧性,这种多功能传感系统在评估帕金森病患者的疾病进展方面展现出巨大潜力,为高效的临床诊断和个性化用药管理提供了可靠的技术支持。
The gold standard for Parkinson disease (PD) diagnosis is postmortem examination, based on the presence and distribution of pathologic α-synuclein (Lewy pathology) across brain regions. Whether pathologic α-synuclein Braak staging reflects clinical disease progression remains uncertain. We examined the relationship between Braak stage with clinical indices of PD progression in an autopsy-proven cohort. We performed a retrospective clinicopathologic analysis of autopsy-confirmed PD cases from the Parkinson's UK Brain Bank (Imperial College London). Clinical records were systematically reviewed to extract age at symptom onset, disease duration, brain weight, Hoehn and Yahr (H&Y) stage at death, and key clinical features. Normality was assessed using Shapiro-Wilk tests; comparisons across Braak stages used Kruskal-Wallis tests. Correlations with Braak stage were examined using Spearman correlation with 95% CIs. Prevalence of major copathologies was summarized descriptively. Of 119 clinically diagnosed PD cases, we included all 61 with autopsy confirmation and available Braak staging. Mean ± SD age at death was 79.1 ± 7.4 years, disease duration was 13.5 ± 5.8 years, H&Y stage at death was 4.0 ± 0.8, and brain weight was 1,234.2 ± 108 g. Braak stage was not correlated with H&Y at death (ρ = 0.146, 95% CI -0.11 to 0.39, p = 0.262), age at death (ρ = -0.210, 95% CI -0.47 to 0.07, p = 0.104), disease duration (ρ = 0.035, 95% CI -0.23 to 0.29, p = 0.787), or brain weight (ρ = 0.2, 95% CI -0.07 to 0.42, p = 0.139). There were no differences across Braak stages in disease duration (p = 0.925), age at death (p = 0.356), brain weight (p = 0.279), or H&Y stage (p = 0.603). By contrast, brain weight correlated negatively with age at death (ρ = -0.352, 95% CI -0.57 to -0.09, p = 0.005). Copathologies were common, including entorhinal/allocortical tau (B1-B2) in 82%, small vessel disease in 60%, β-amyloid (Thal ≥1) in 58%, and cerebral amyloid angiopathy in 25%. The prevalence of copathologies did not differ across Braak stages. Braak stage was not associated with H&Y at death, disease duration, age at death, or brain weight in autopsy-proven PD patients. These findings provide evidence that pathologic α-synuclein-based staging does not represent a model of clinical progression in PD. The quantification of both monomeric and pathologic α-synuclein may be needed to overcome the clinical limitations of pathology-based staging.
中文摘要:帕金森病的诊断金标准是尸检,基于病理α-突触核蛋白(路易病理)在脑区的存在和分布。病理α-突触核蛋白的Braak分期是否反映临床疾病进展仍不确定。我们在尸检确诊队列中考察了Braak分期与帕金森病临床进展指标之间的关系。我们对帕金森英国脑库(伦敦帝国理工学院)尸检确诊的帕金森病例进行了回顾性临床病理分析。系统审查临床记录以提取症状 onset 年龄、病程、脑重、死亡时的Hoehn和Yahr(H&Y)分期及关键临床特征。使用Shapiro-Wilk检验评估正态性;跨Braak分期的比较使用Kruskal-Wallis检验。使用Spearman相关系数及95%置信区间考察与Braak分期的相关性。以描述性方式总结主要共病的患病率。在119例临床诊断的帕金森病例中,我们纳入了所有61例有尸检确认且具备可用Braak分期的病例。死亡时平均年龄为79.1±7.4岁,病程为13.5±5.8年,死亡时H&Y分期为4.0±0.8,脑重为1,234.2±108g。Braak分期与死亡时的H&Y分期(ρ=0.146, 95%CI -0.11至0.39, p=0.262)、死亡年龄(ρ=-0.210, 95%CI -0.47至0.07, p=0.104)、病程(ρ=0.035, 95%CI -0.23至0.29, p=0.787)或脑重(ρ=0.2, 95%CI -0.07至0.42, p=0.139)均无相关性。不同Braak分期之间在病程(p=0.925)、死亡年龄(p=0.356)、脑重(p=0.279)或H&Y分期(p=0.603)方面无差异。相比之下,脑重与死亡年龄呈负相关(ρ=-0.352, 95%CI -0.57至-0.09, p=0.005)。共病常见,包括82%的颞内/异侧皮质tau蛋白(B1-B2)、60%的小血管病变、58%的β-淀粉样蛋白(Thal≥1)和25%的脑淀粉样血管病。共病的患病率在不同Braak分期间无差异。在尸检确诊的帕金森病患者中,Braak分期与死亡时的H&Y分期、病程、死亡年龄或脑重均无关。这些发现提供证据表明,基于病理α-突触核蛋白的分期并不代表帕金森病的临床进展模型。可能需要量化单体和病理α-突触核蛋白以克服基于病理分期的临床局限性。
Levodopa (LD) is a primary therapeutic agent for Parkinson's disease, and accurately monitoring its concentration in blood is crucial for optimizing treatment regimens. Herein, an electrochemical sensing electrode integrating molecular imprinting with tyrosinase (TYR) catalysis is developed for sensitive and selective LD detection. First, CuCo-ZIF nanosheet arrays are grown in situ on three-dimensional graphene foam (3D GF) and converted into Cu/Co nanoparticle anchored N-doped carbon nanosheet arrays (CuCo@NCNSA/3D GF) by pyrolysis. Subsequently, a molecularly imprinted poly(3,4-ethylenedioxythiophene) (MI-PEDOT) layer is electropolymerized using LD as the template, followed by covalent immobilization of TYR. The electrode integrates the molecular recognition capabilities and electrochemical activity of MI-PEDOT with the enzymatic catalysis of TYR, achieving a sensitivity of 2.059 μA μM-1 and a limit of detection (LOD) of 0.016 μM for LD. In 50-fold and 100-fold diluted serum samples, LODs are 0.31 and 0.10 μM, respectively. For whole blood analysis, a polyacrylamide hydrogel (PAM-H) antifouling layer enables direct whole blood filtration, allowing quantitative LD detection over the range of 0-20 μM with a LOD of 1.0 μM. The PAM-H-assisted electrode maintains a stable response and enables reliable LD quantification in whole blood filtrates, highlighting their potential for the rapid analysis of complex biological samples and for use in point-of-care testing (POCT).
中文摘要:左旋多巴是治疗帕金森病的主要药物,准确监测其血液浓度对于优化治疗方案至关重要。本研究开发了一种将分子印迹与酪氨酸酶催化相结合的电化学传感电极,用于灵敏且选择性地检测左旋多巴。首先,在三维石墨烯泡沫上原位生长CuCo-ZIF纳米片阵列,并通过热解转化为Cu/Co纳米颗粒锚定的氮掺杂碳纳米片阵列。随后,以左旋多巴为模板电聚合分子印迹聚(3,4-乙烯二氧噻酚)层,并共价固定酪氨酸酶。该电极结合了分子印迹层的识别能力与电化学活性以及酶的催化作用,实现了对左旋多巴2.059 μA/μM的灵敏度和0.016 μM的检测限。在稀释50倍和100倍的血清样本中,检测限分别为0.31 μM和0.10 μM。在全血分析中,聚丙烯酰胺水凝胶抗污层实现了直接全血过滤,使左旋多巴定量检测范围达到0-20 μM,检测限为1.0 μM。该辅助电极在整血滤液中保持稳定的响应并实现可靠的定量,凸显了其在复杂生物样本快速分析及即时检测中的应用潜力。
Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) show significant differences in their clinical manifestations, but they all seem to share a common upstream problem: malfunction in the membrane transport controlled by Rab GTPases. This review introduces the concept of Rabopathy, a framework that connects developmental synaptic maturation defects with late-onset protein aggregation. The LRRK2-Rab phosphorylation axis is emerging as a potential common amplifying mechanism across these disorders, with the strongest mechanistic support in PD and growing implications in AD and HD. When Rab substrates are excessively phosphorylated at specific sites, vesicular transport is impaired or arrested, leading to progressive depletion of the reserve pool of synaptic vesicles and the surface pool of receptors, and severe compromise of the autophagy-lysosome flux. The failure of distinct Rab sub-networks also produces disease-specific signatures, including Rab5-driven endosomal congestion in AD, Rab35-mediated α-synuclein secretion in PD, and Rab11/Rab7 trafficking collapse in HD. Restoration of Rab flux may be a therapeutic strategy for neurodegenerative diseases, which can be achieved through calibration of LRRK2 activity, modulation of selective Rab subtypes, and rescue of the trafficking network at the systems level.
中文摘要:阿尔茨海默病、帕金森病和亨廷顿病等神经退行性疾病在临床表现上存在显著差异,但似乎共享一个共同的上游问题:由Rab GTP酶控制的膜运输功能障碍。本综述介绍了Rabopathy的概念,该框架将发育性突触成熟缺陷与迟发性蛋白聚集联系起来。LRRK2-Rab磷酸化轴正成为这些疾病中潜在的共同放大机制,在帕金森病中具有最强的机制支持,并在阿尔茨海默病和亨廷顿病中显示出日益重要的意义。当Rab底物在特定位点被过度磷酸化时,囊泡运输受损或停滞,导致突触囊泡储备池和受体表面池逐渐耗竭,并严重损害自噬溶酶体通量。不同Rab子网络的失败也产生了疾病特异性特征,包括阿尔茨海默病中由Rab5驱动的早期内体拥堵、帕金森病中由Rab35介导的α-突触核蛋白分泌以及亨廷顿病中的Rab11/Rab7运输崩溃。恢复Rab通量可能是治疗神经退行性疾病的一种策略,这可以通过校准LRRK2活性、调节选择性Rab亚型以及在系统水平挽救运输网络来实现。
8神经重症与脑损伤 (3篇)
基础研究 (3篇)
Coagulopathy following traumatic brain injury (TBI) exacerbates secondary neurodegeneration and increases mortality. Neutrophil infiltration and neutrophil extracellular trap (NET) formation are strongly implicated in this post-TBI coagulopathy, suggesting that NET suppression may improve clinical outcome. The immunometabolite itaconate, generated via aconitate decarboxylase 1 (ACOD1), possesses documented anti-inflammatory and cytoprotective properties, but effects on NET formation and coagulopathy post-TBI are largely unexplored. This study examined if the ACOD1-itaconate metabolic pathway serves as an endogenous checkpoint to restrain NET formation, whether ACOD1-itaconate axis dysregulation contributes to coagulopathy and poor outcome following TBI, and if targeting this axis could be a viable therapeutic strategy. A retrospective analysis of the MIMIC-IV database was performed to compare outcomes between TBI patients with and without coagulopathy. Culture and mouse model experiments were conducted to assess the impact of NETs on endothelial cell phenotype and cerebral microcirculation. Single-cell RNA sequencing and pharmacological studies of cultured neutrophils and model mice were employed to investigate the effects of the ACOD1-itaconate axis on NET formation and neurological outcome. Retrospective analysis revealed more severe hypoxia and higher mortality in coagulopathic TBI patients. In coculture and TBI model mice, NETs promoted a procoagulant endothelial phenotype and exacerbated microthrombosis. Hypoxia suppressed the ACOD1-itaconate axis in neutrophils, relieving endogenous inhibition on NET formation. Exogenous 4-OI administration rescued this defect, significantly suppressing NET formation, restoring coagulation function, and mitigating secondary brain injury and neurological deficits in mice. The ACOD1-itaconate pathway is a crucial metabolic checkpoint that restrains NET activity, while suppression post-TBI facilitates pathological NET formation, driving coagulopathy and secondary injury. These findings identify components of the ACOD1-itaconate-NET axis as novel therapeutic targets for treating TBI-induced coagulopathy.
中文摘要:创伤性脑损伤(TBI)后的凝血病会加剧继发性神经退行性变并增加死亡率。中性粒细胞浸润和中性粒细胞胞外陷阱(NETs)形成与此后TBI凝血病密切相关,提示抑制NETs可能改善临床结局。由aconitate脱羧酶1(ACOD1)生成的免疫代谢物衣康酸具有已证实的抗炎和细胞保护作用,但其对TBI后NETs形成和凝血病的影响尚不明确。本研究探讨了ACOD1-衣康酸代谢通路是否作为内源性检查点以限制NETs形成,ACOD1-衣康酸轴失调是否导致TBI后的凝血病和不良预后,以及靶向该轴是否成为可行的治疗策略。通过回顾性分析MIMIC-IV数据库比较有无凝血病的TBI患者结局。开展培养和小鼠模型实验评估NETs对内皮细胞表型和脑微循环的影响。利用单细胞RNA测序和培养中性粒细胞及模型小鼠的药理学研究调查ACOD1-衣康酸轴对NETs形成和神经功能预后的影响。回顾性分析显示,伴有凝血病的TBI患者缺氧更严重且死亡率更高。在共培养和TBI模型小鼠中,NETs促进促凝内皮表型并加重微血栓形成。缺氧抑制中性粒细胞中的ACOD1-衣康酸轴,解除对NETs形成的内源性抑制。外源性给予4-OI挽救了这一缺陷,显著抑制NETs形成,恢复凝血功能,并减轻小鼠的继发性脑损伤和神经功能缺损。ACOD1-衣康酸通路是限制NETs活性的关键代谢检查点,而TBI后的抑制作用促进病理性NETs形成,驱动凝血病和继发性损伤。这些发现将ACOD1-衣康酸-NET轴的成分确定为治疗TBI诱导凝血病的新型治疗靶点。
Aberrant, cranial bone marrow-derived myelopoiesis drives neuroinflammation in chronic traumatic brain injury.
中文摘要:异常的颅骨骨髓来源的髓系造血驱动了慢性创伤性脑损伤中的神经炎症。
The diagnosis of traumatic brain injury (TBI) remains heavily constrained by the limitations of conventional imaging techniques in visualizing the pathological events that determine the disease progression and outcome. To address this clinical challenge, we report a manganese-doped near-infrared quantum dot (QD) to intrinsically integrate the highly sensitive optical imaging with clinical compatible magnetic resonance imaging (MRI). Taking the advantages of optical imaging powered by whole-brain clearing and cellular resolution three-dimensional (3D) panoptic imaging, in combination with the systematic in vitro cell studies on different types of cells involved in TBI, we disclosed the interpretable pathology reflected by TBI imaging through the highly sensitive fluorescence of magnetic QDs, i.e., after systemic administration, the nanoprobes were extravasated through the compromised blood-brain barrier and then selectively phagocytosed by activated microglia, which subsequently migrated into the regions rich in dead neurons and neuronal debris. This microglia-mediated tropism decodes the signal origin of MRI enhanced by the nanometer-sized contrast agent, thereby transforming the MRI from an anatomical tool into a pathological reporter. A biocompatible Fe3O4 nanoparticle of similar size was also compared with the magnetic QD mentioned above for validating the translational merits of nanoparticles in MRI diagnosis of TBI.
中文摘要:创伤性脑损伤(TBI)的诊断仍受限于常规成像技术在可视化决定疾病进展和预后的病理事件方面的不足。为应对这一临床挑战,我们报道了一种掺锰的近红外量子点(QD),旨在将高灵敏度的光学成像与临床兼容的磁共振成像(MRI)内在整合。利用全脑清除技术驱动的光学成像优势及细胞分辨率三维全景成像,结合针对TBI涉及的不同类型细胞的系统体外研究,我们通过磁性QD的高灵敏度荧光揭示了TBI成像所反映的可解释病理机制,即全身给药后,纳米探针通过受损的血脑屏障外渗,随后被激活的小胶质细胞选择性吞噬,这些小胶质细胞随后迁移至富含死亡神经元和神经元碎片的区域。这种小胶质细胞介导的趋向性解码了由纳米级造影剂增强的MRI信号来源,从而将MRI从一种解剖工具转变为病理报告者。我们还比较了尺寸相似的生物相容性Fe3O4纳米粒子与上述磁性QD,以验证纳米粒子在TBI的MRI诊断中的转化优势。
9头痛与疼痛 (2篇)
临床研究 (2篇)
Anxiety and depressive symptoms are common in migraine. Whether calcitonin gene-related peptide (CGRP)-targeted therapies improve these symptoms, and whether improvement is coupled to headache reduction, remains unclear. This was a single-center, retrospective, descriptive pre-post cohort study of adults with migraine and documented anxiety and/or depression initiating a CGRP monoclonal antibody or gepant in the United Arab Emirates (UAE). Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) scores at baseline and 6 months post treatment initiation were compared using the Wilcoxon signed-rank test. Responder rates (≥ 4-point drop in GAD-7 score, ≥ 5-point drop in PHQ-9 score) were computed among patients able to reach each threshold. Between-molecule differences were tested using the Kruskal-Wallis test. Spearman correlation was used to explore the association between change in monthly migraine days (ΔMMD) and mood change. Of the 121 adults who initiated treatment, 113 had paired baseline and 6-month score data (mean [± standard deviation] age 38.9 ± 9.5 years; 83.2% female; 55.8% chronic migraine). At 6 months, the GAD-7 score had fallen from 6.0 ± 4.0 to 2.7 ± 2.9 and the PHQ-9 score had dropped from 9.3 ± 4.9 to 4.3 ± 3.7 (both p < 0.001). MMD fell from 9.1 ± 5.1 to 3.0 ± 2.6 (p < 0.001). Responder rates were 59.8% (49/82) for adults according to GAD-7 scores and 54.8% (51/93) according to PHQ-9 scores. Scores decreased within every CGRP-targeted molecule subgroup, with no detectable between-molecule differences (Kruskal-Wallis p = 0.34 for ΔGAD-7; p = 0.68 for ΔPHQ-9). ΔMMD correlated only weakly with mood change (ρ = 0.04 for ΔGAD-7; ρ = 0.15 for ΔPHQ-9; both non-significant). A worsening PHQ-9 item 9 response (thoughts of death or self-harm) was recorded in one of 113 patients. CGRP-targeted therapies were associated with significant reductions in anxiety and depressive symptoms in this UAE cohort, although the eptinezumab and atogepant subgroups were small. No detectable association was found between changes in migraine days and mood scores. These hypothesis-generating findings warrant confirmation in controlled, prospective studies.
中文摘要:焦虑和抑郁症状在偏头痛患者中很常见。降钙素基因相关肽(CGRP)靶向治疗是否能改善这些症状,以及这种改善是否与头痛减少相关联,目前尚不清楚。本研究是一项来自阿拉伯联合酋长国(UAE)的单中心、回顾性、描述性前后队列研究,对象为伴有记录在案的焦虑和/或抑郁并启动CGRP单克隆抗体或吉泮治疗的成年偏头痛患者。采用Wilcoxon符号秩检验比较基线和治疗开始后6个月的广泛性焦虑障碍量表-7(GAD-7)及患者健康问卷-9(PHQ-9)评分。计算达到各阈值患者的应答率(GAD-7评分下降≥4分,PHQ-9评分下降≥5分)。使用Kruskal-Wallis检验比较不同分子间的差异。采用Spearman相关分析探讨每月偏头痛天数变化(ΔMMD)与情绪变化之间的关联。在启动治疗的121名成年人中,113人拥有基线和6个月的配对评分数据(平均年龄±标准差为38.9±9.5岁;女性占83.2%;慢性偏头痛占55.8%)。治疗6个月后,GAD-7评分从6.0±4.0降至2.7±2.9,PHQ-9评分从9.3±4.9降至4.3±3.7(均p<0.001)。每月偏头痛天数从9.1±5.1天降至3.0±2.6天(p<0.001)。根据GAD-7评分,成年人的应答率为59.8%(49/82);根据PHQ-9评分,应答率为54.8%(51/93)。各CGRP靶向药物亚组内的评分均有所下降,且未检测到分子间差异(ΔGAD-7的Kruskal-Wallis p=0.34;ΔPHQ-9的p=0.68)。每月偏头痛天数变化与情绪变化仅呈弱相关(ΔGAD-7的ρ=0.04;ΔPHQ-9的ρ=0.15;均无统计学意义)。在113名患者中,有1人出现PHQ-9第9项(死亡或自残想法)反应恶化。在该阿联酋队列中,CGRP靶向治疗与焦虑和抑郁症状的显著减少相关,尽管依普奈珠单抗和阿托格潘特亚组样本量较小。未发现偏头痛天数变化与情绪评分之间存在可检测的关联。这些生成假设的发现需要在对照性前瞻性研究中得到证实。
Spontaneous intracranial hypotension (SIH) results from spinal CSF leakage. Epidural blood patch (EBP) is an important first-line treatment. However, pre-EBP, intra-EBP, and post-EBP practice varies widely owing to limited consensus guidance. We aimed to develop expert consensus statements to support clinical decision-making in SIH management, including peri-EBP practices, focusing on patients with spinal longitudinal epidural CSF collection (SLEC) before definitive leak type classification. An international multidisciplinary Delphi process was conducted between January 2024 and July 2025, involving experts in neurology, neurosurgery, radiology, and anesthesiology. Consensus was defined a priori as ≥70% agreement for strong agreement, 60%-69% for partial agreement, and <60% for no consensus, based on a 5-point Likert scale in round 3. Responses were collected anonymously using an online survey platform, with summarized feedback from the previous round provided between rounds. Fourteen experts were invited, with 10, 9, and 9 participants in rounds 1, 2, and 3, respectively. Before EBP, bed rest was recommended for recent-onset SIH with severe orthostatic headache (88.9%); other conservative methods such as abdominal binder and hydration were considered not mandatory (90%). Semitargeted EBP was recommended as initial management for patients with extradural CSF collections (70%). Dynamic CT myelography was preferred for localization (70%). Post-EBP care was variable, particularly in bed rest duration, with most recommendations (70%) exceeding 12 hours. Definitions of clinical remission (80%) and radiologic remission (90%) were established. Radiologic follow-up after clinical remission was recommended (78%). No consensus was reached on follow-up strategies for persistent symptoms, although "doing nothing" was not recommended. No consensus was reached for persistent extradural CSF despite clinical remission, requiring an individualized approach. Light activity after EBP was recommended within a few days (70%). No consensus was reached on the optimal number of EBPs before invasive leak localization or surgical intervention. This Delphi study outlines expert recommendations and uncertainties for SIH management, including peri-EBP practices. This study incorporated the initial management strategy for patients in whom leak-type classification was incomplete. However, the treatment section primarily focused on the SLEC-positive setting and presumed ventral dural tears; lateral dural tears and CSF-venous fistulas warrant future consensus development.
中文摘要:自发性颅内低压(SIH)由脊髓脑脊液漏出引起。硬膜外血贴(EBP)是重要的首选治疗方法,但由于缺乏共识指南,EBP前、中、后的临床实践差异较大。本研究旨在制定专家共识声明以支持SIH的临床决策,重点关注在明确漏出类型分类前的伴有脊髓纵向硬膜外脑脊液积聚(SLEC)患者的围EBP期实践。2024年1月至2025年7月开展了国际多学科德尔菲研究,参与者包括神经病学、神经外科、放射学和麻醉学专家。共识标准预先定义为:基于第3轮5点Likert量表,强同意率≥70%,部分同意率60%-69%,无共识<60%。通过在线调查平台匿名收集回复,并在各轮次间提供上一轮的汇总反馈。共邀请14位专家,第1、2、3轮分别有10、9、9人参与。EBP前,对于近期发作且伴有严重体位性头痛的SIH患者推荐卧床休息(88.9%);其他保守方法如腹部束带和补液被认为非必需(90%)。对于硬膜外脑脊液积聚患者,推荐将半靶向EBP作为初始管理手段(70%)。动态CT脊髓造影被推荐用于定位(70%)。EBP后的护理存在差异,尤其是卧床休息时间,大多数建议(70%)超过12小时。确立了临床缓解(80%)和放射学缓解(90%)的定义。建议在达到临床缓解后进行放射学随访(78%)。对于持续症状的随访策略未达成共识,但不推荐「无所作为」。对于临床缓解后仍存在硬膜外脑脊液积聚的情况未达成共识,需采取个体化方案。EBP后几天内推荐进行轻度活动(70%)。在侵入性漏出定位或手术干预之前,EBP的最佳次数未达成共识。本研究概述了SIH管理的专家建议和不确定性,包括围EB期实践。该研究纳入了漏出类型分类不完整患者的初始管理策略,但治疗部分主要聚焦于SLEC阳性和假设的腹侧硬膜撕裂;侧方硬膜撕裂和脑脊液静脉瘘有待未来共识发展。
10其他 (2篇)
临床研究 (1篇)
This journal club article reviews the strengths and limitations of a 2025 study by Lanman et al., investigating outcomes-particularly overall survival-in patients with isocitrate dehydrogenase mutant (IDHmt) WHO grade 2 and 3 gliomas who received either adjuvant postsurgical radiotherapy (aXRT) or deferred radiotherapy (dXRT). Despite unclear evidence of survival benefit, current standardized guidelines recommend aXRT-after surgery but before progression-as first-line treatment for high-risk patients defined by higher grade, older age, and subtotal resection. This study demonstrated that although aXRT delayed tumor progression in this cohort, it was associated with worse overall survival. This retrospective, dual-institution analysis highlights a discrepancy between current guidelines and real-world clinical outcomes, emphasizing the need for prospective studies evaluating dXRT in patients with IDH-mutant gliomas.
中文摘要:本期刊俱乐部文章回顾了Lanman等人2025年研究的优缺点,该研究探讨了接受辅助术后放疗或延迟放疗的异柠檬酸脱氢酶突变IDHmt世界卫生组织WHO分级2级和3级胶质瘤患者的预后特别是总生存期。尽管生存获益证据尚不明确,但现行标准化指南推荐对由较高分级、高龄和次全切除定义的高危患者采用术后进展前的辅助放疗作为一线治疗。该研究表明,尽管辅助放疗在该队列中延缓了肿瘤进展,但与较差的总生存期相关。这项回顾性双机构分析突显了现行指南与现实世界临床结果之间的差异,强调了评估IDH突变胶质瘤患者延迟放疗的前瞻性研究的必要性。
基础研究 (1篇)
Newcastle disease virus (NDV or AOaV-1) is an avian paramyxovirus that typically causes only mild, self-limiting disease in humans. Here, we report fatal neuroinvasive AOaV-1 infection in a patient with multiple myeloma receiving maintenance therapy with teclistamab, daratumumab, and lenalidomide following frontline teclistamab-based treatment and autologous stem cell transplantation. Following rapidly progressive brainstem-cerebellar encephalitis and negative conventional microbiological testing, unbiased metagenomic RNA sequencing of a cerebellar biopsy identified AOaV-1 at high intraparenchymal abundance. Viral genome analysis revealed striking A-to-G and U-to-C substitutions selectively concentrated in the matrix gene, consistent with ADAR-mediated RNA editing. Long-read sequencing resolved two genetically distinct, independently hypermutated CNS haplotypes. Post-mortem analysis demonstrated widespread dissemination and continued viral diversification in multiple brain regions, whereas a peripheral urine sample contained a minimally mutated putative ancestral lineage. These findings support peripheral infection followed by CNS seeding and compartmentalized within-host evolution. The selective matrix-gene hypermutation closely parallels persistent measles virus infection in subacute sclerosing panencephalitis, revealing a shared mechanism of paramyxovirus adaptation to the CNS. Profound immunotherapy-associated immune dysfunction may thus create niches enabling normally low-pathogenic zoonotic viruses to persist, evolve, and acquire severe neurovirulence.
中文摘要:新城疫病毒(NDV或AOaV-1)是一种禽副黏病毒,通常在人类中仅引起轻微且自限性的疾病。在此,我们报告了一名多发性骨髓瘤患者在接受一线基于teclistamab的治疗和自体干细胞移植后,维持治疗期间使用teclistamab、daratumumab和lenalidomide时发生致命的神经侵袭性AOaV-1感染病例。在患者出现快速进展的脑干小脑脑炎且常规微生物学检测阴性后,对小脑活检样本进行的不偏倚宏基因组RNA测序以高丰度检出AOaV-1。病毒基因组分析显示A-to-G和U-to-C替换显著集中分布于基质基因,这与ADAR介导的RNA编辑一致。长读长测序解析出两个遗传上不同且独立发生超突变的CNS单倍型。死后分析显示病毒在多个脑区广泛扩散并持续进化,而外周尿液样本中含有极少突变的推定祖先谱系。这些发现支持外周感染随后种子进入中枢神经系统并在宿主体内发生区室化进化的观点。基质基因的超突变选择性地与亚急性硬化性全脑炎中持续的麻疹病毒感染相似,揭示了副黏病毒适应CNS的共同机制。因此,深度免疫治疗相关的免疫功能缺陷可能创造了生态位,使通常低致病性的动物源性病毒得以持续存在、进化并获得严重的神经毒力。